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Abstract 
The DNA within a cell is damaged on a continuous basis by both endogenous and 
exogenous agents. One of the most dangerous types of damage a cell can incur are 
DNA Double stranded breaks (DSBs) as failure to repair these types of lesions can 
lead to mutations, cell death and cancer. In order to maintain genome integrity, cells 
have several different mechanisms to repair various types of DNA damage. BRCA1 is 
a tumour suppressor gene commonly mutated in many inherited breast and ovarian 
cancers. BRCA1 is fundamental to the repair to DNA damage especially the faithful 
repair of DSB by homologous recombination (HR) as loss of BRCA1 results in aberrant 
HR, chromosomal translocation and cancer. BRCA1 is almost always found in the 
nucleus bound to BARD1. BARD1 retains BRCA1 in the nucleus and enhances the E3 
ubiquitin ligase function of BRCA1. The importance of BRCA1 in the repair of DNA 
DSBs has been extensively researched, however the role of BARD1 in repair remains 
unknown. 
 Similar to BRCA1, BARD1 contains tandem BRCT domains at its C-terminus 
which are important for binding phosphorylated proteins involved in DNA repair. 
Mutations in the BARD1 BRCT domains have been discovered in a few breast and 
ovarian cancers which suggested that BARD1 is important in the DNA damage 
response (DDR) independent of its function in stabilising BRCA1. Loss of the BARD1 
BRCT domains also results in a decrease in the ability of cells to carry out HR. This 
thesis examines the contribution of the BARD1 BRCT domains to the repair of DNA 
DSBs. Using homologous recombination assays and colony survival assays, Bard1 
DT40 cells reconstituted with BARD1ΔBRCT showed a significant decrease in their 
ability to carry out HR and were also extremely sensitive to PARP inhibitors suggesting 
that the BARD1 BRCT domains do indeed play an important role in HR. Work carried 
out in this thesis suggests that BARD1 contributes to the stabilisation of the BRCA1-C 
complex which is important in the repair of DSBs. The BARD1 BRCT domains also 
showed defects in localisation and delayed recruitment to sites of damage. The defects 
xviii 
 
in HR and localisation seen in the absence of the BARD1 BRCT domains potentially 
implicate a functional role for the BARD1 BRCT domains in DSB repair. Potential 
BARD1 BRCT domain interacting proteins were also identified my Mass spec, which 
may shed some light onto the functional role of BARD1 in DNA repair. 
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Chapter 1 Introduction 
1.1 Maintaining genome integrity and the DNA damage response. 
 Maintaining genome integrity is crucial to the function and survival of the cell. This 
concept refers to the ability of the cell to conserve and protect the information stored in 
its genome and to faithfully pass its genomic content on to daughter cells. DNA 
damage represents a continuous threat to genomic integrity. DNA can be damaged by 
a host of endogenous and exogenous agents such as metabolic by-products, errors in 
replication and toxins. Failure to repair DNA damage correctly can lead to cell death 
and mutations in the DNA which may result in the development of disease and cancer. 
Without an appropriate response to DNA damage, the survival of the cell and organism 
is under great threat.  
 In order to maintain genomic integrity cells carry out an intricate response to 
DNA damage termed the DNA damage response (DDR). The cellular response to DNA 
damage involves collaborative events which allow the repair of damage, cell cycle 
checkpoint control and apoptosis [1-3]. DNA repair pathways are responsible for 
maintaining genome integrity by actively repairing a variety of different types of lesions. 
The regulation of cell cycle progression is equally important in the DDR as inducing an 
arrest in the cell cycle allows the cell time to repair the damage and prevents 
replication of damaged DNA. Apoptosis is required to eliminate cells containing DNA 
damage which are beyond repair. Each of these processes relies on a large number of 
proteins which are involved in several molecular pathways and together they are 
known as the DDR. Defects in the DDR machinery contribute to a variety of diseases 
and cancer which highlights the importance of the DDR in the maintenance of genomic 
integrity [1]. Some of the best characterised diseases associated with DDR defects are 
Fanconi anaemia (FA) and Xeroderma Pigmentosum (XP).      
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1.2 DNA double strand break repair 
DNA double strand breaks (DSBs) are one of the most dangerous types of lesions a 
cell can incur, potentially driving genetic instability leading to cell death or carcinomas. 
Even as little as one unrepaired DSB is sufficient to cause apoptosis [4] and is often 
associated with large chromosomal translocations and rearrangements [5]. DNA DSBs 
are lesions that occur when both strands of a DNA duplex are broken in close proximity 
to each other. Although DSB are commonly associated with normal reactions and 
processes that occur in the cell such as metabolic by products and collapsed 
replication forks [6, 7], they can also be induced by exogenous agents such as ionizing 
radiation and DNA crosslinking reagents. DSBs are also induced by the cell in a 
controlled manner in order to facilitate rearrangement of immunoglobulin loci in B-cell 
and T-cell receptors in process such as V(D)J and class switch recombination (CSR) in 
lymphocytes [8-11]. Moreover, failure to repair DSB is extremely toxic to cells and is 
considered to be a major driver in cancer [1]. 
 In order to repair DSB, cells have evolved several pathways to repair these 
lesions. In eukaryotes, DSBs are repaired by two major pathways, Non-homologous 
end joining (NHEJ) and Homologous recombination (HR). These two repair processes 
are implemented at different stages in the cell cycle. NHEJ repairs the DNA DSB by the 
direct ligation of broken ends back together irrespective of their sequence.  Although 
NHEJ is the more simplistic method of DSB repair, it is also error prone [12]. HR is an 
error free pathway used to repair DNA DSB. During the repair of a DSB a sister 
chromatid is used as a template to repair the damage. NHEJ can repair DSB at all 
stages throughout the cell cycle as it is not restricted by any particular cell cycle stage 
[12]. Although NHEJ is active throughout the cell cycle and favoured in G1, HR is more 
prevalent after DNA replication. HR is however restricted to late S and G2 phases of 
the cell cycle as this mechanism of repair requires the presence of a sister chromatid 
for repair. A schematic representation of the phases of the cell cycle where HR and 
NHEJ are active can be seen in figure 1.1. 
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Figure 1.1 HR and NHEJ activity through the cell cycle 
Representative image reflecting the type of repair carried out at different stages of the cell cycle. 
NHEJ is available for use throughout the cell cycle whereas HR is predominantly used in late S 
and G2 phase due to the requirement of a homologous template for repair, usually in the form of 
a sister chromatid.  
 
1.2.1 DSB repair by NHEJ 
The structure and base pair composition of DNA DSB ends vary depending on the 
method of damage and it is important for the cell to be able to process and repair 
diverse structural DSB ends to maintain genome stability. Unlike the majority of repair 
and recombination pathways, NHEJ evolved in both prokaryotic and eukaryotic cells in 
a manner which allowed mechanistic flexibility and enzyme multifunctionality [13-15]. 
These characteristics attributed to NHEJ repair, enables the repair of a DSB with a 
remarkable degree of structural tolerance to the diverse range of substrate DNA ends 
at DSBs. NHEJ requires a nuclease, to resect the damaged DNA, a polymerase, to 
synthesise nucleotides to bridge the gap at the break and a ligase to anneal the broken 
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strands together. The nucleases, polymerases and ligases which act in DSB repair by 
NHEJ are considered to be the most mechanistically flexible and multifunctional 
enzymes of their kind [15] as they can act in any order and can function independently 
at either side of the DSB.    
 NHEJ is active throughout the cell cycle and is favoured in G1 phase cells. 
NHEJ promotes the direct ligation of DSBs, in an error prone manner often leading to 
small insertions, deletions and chromosomal translocations if DSBs are joined from 
different parts of the genome [12]. As both HR and NHEJ are active during S and G2 
phases of the cell cycle, the mechanisms which determine the choice of repair is still an 
active area of research. NHEJ is however very important in the repair of DSBs as 
NHEJ defective cells are extremely sensitive to IR [16] and exhibit severe combined 
immunodeficiency [17] due to its role in V(D)J and class switch recombination in 
lymphocytes. NHEJ is important for restoring molecular integrity to the cell after DNA 
damage but not sequence information.  
 NHEJ is conserved from bacteria to humans [18] and involves the recognition, 
end processing and ligation of a DSB. Although classical NHEJ is preferentially used 
when available, there is a second, back up, end joining pathway called Microhomology-
mediated end joining (MMEJ) which has been shown to be active when cells are 
defective in both HR and NHEJ [19-21]. Mechanistically the binding of Ku to DSB is 
believed to initiate NHEJ in vertebrates [12]. Ku is predicted to be the initial protein to 
bind DSBs due to its abundance in the cell (estimated at 400,000 molecules/cell). Ku 
has also been shown to have the greatest affinity towards DNA ends in comparison to 
other DNA binding proteins in the cell [22]. Ku forms a toroidal heterodimer consisting 
of the Ku70 and Ku80 proteins which contains a hole large enough to encompass the 
DNA end [23]. deVries et al demonstrated that Ku can only load onto the DNA terminus 
and from there it can migrate to a more internal position on the DNA duplex [24]. The 
Ku heterodimer has no confirmed enzymatic activity and is predicted to provide a 
docking platform for NHEJ proteins, stabilising them and allowing them to carry out 
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their repair functions [25]. Once Ku is bound to the DNA it recruits the catalytic subunit 
of the DNA protein kinase (DNA-PKcs) to form an active DNA-PK holoenzyme [26]. 
This active kinase complex phosphorylates other proteins involved in the repair of DSB 
by NHEJ such as XLF, DNA ligase IV, XRCC4 and RPA2 as well as 
autophosphorlyating the DNA-PKcs [27-30]. The autophosphorylation of DNA-PKcs 
results in a structural change in the holoenzymes which is believed to facilitate DNA 
end processing [25]. In vertebrates, the majority of DNA end processing in NHEJ is 
carried out by Artemis, which forms a complex with the DNA-PKcs [31, 32]. 
Polymerisation or filling in the gap after end processing can be carried out by a variety 
of polymerases such as DNA polymerases X, theta and mu [33]. XRCC4, DNA ligase 
IV and XLF are the ligases responsible for covalently ligating the two DNA ends 
together [34, 35].  
 Recent findings implicated an alternative end joining pathway in the repair of 
DSBs [19, 21], called MMEJ. One of the most distinguishing properties of MMEJ is the 
use of short (5-25 base pairs) microhomologous sequences for aligning the broken 
strands before ligation of a DSB. This mechanism of end joining results in deletions 
around the DSB and has been associated with chromosome abnormalities such as 
translocations and rearrangements [20, 36-38]. Its mutagenic potential has also been 
demonstrated in disease and cancer [20, 39, 40]. Although there is very little 
understanding on the mechanism of MMEJ, it is proposed to involve strand resection 
and end processing to reveal small complimentary sequences followed by pairing of 
the microhomologous regions, flap removal and ligation. It is dependent on Mre11 and 
CtIP for end resection [41, 42], XPF and ERCC1 for cleaving the DNA flaps from the 
annealed intermediated [41, 43, 44]. DNA ligase I and III are involved in the ligation of 
DSBs by MMEJ in humans [45].  Due to the fact that MMEJ is exclusively mutagenic, it 
only occurs in very low frequencies in NHEJ competent cells. Although it is considered 
to be mainly a backup repair pathway there is evidence suggesting that MMEJ is 
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important for the repair of DSBs when HR is not active and the structure of the DSBs 
are not compatible with classical NHEJ [41]. 
 Even with the potential to be error prone, both NHEJ and MMEJ pathways 
serve to protect the integrity of the genome by efficient and quick repair of hazardous 
DSBs. A representative image of the molecular mechanisms of both NHEJ and MMEJ 
can be seen in figure 1.2. 
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Figure 1.2 Mechanism of end-joining repair NHEJ and MMEJ 
Representative illustration of the repair of a DSB by NHEJ and MMEJ. During NHEJ the Ku 
heterodimer binds the DSB and recruits DNA-PKcs. The DNA ends are processed by Artemis 
and DNA Polymerases and then ligated. Sequence is often lost during NHEJ making it an error 
prone process. In MMEJ the DSB ends are resected to reveal microhomologous sequences 
which are joined together. The overhanging DNA flaps are cleaved and the process is 
completed by ligation. MMEJ is exclusively mutagenic as a result.  
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1.2.2. DSB repair by HR 
Homologous recombination is a more accurate DSB repair pathway which uses a 
homologous template to accurately repair damage. As previously mentioned, HR is 
only active during S and G2 phase of the cell cycle as it requires an identical template 
in the form of a sister chromatid to carry out faithful repair [16]. A sister chromatid is 
only available after replication during S and G2 phase. HR is not only vital for the repair 
of DSBs but also for interstrand crosslink repair, repair of DNA gaps, rescue of stalled 
or collapsed replication forks and meiotic chromosome segregation. The ultimate goal 
of HR repair is to retrieve information from an undamaged homologous DNA sequence 
to aid the repair of a DNA molecule which has lost sequence information as a result of 
a break in both strands of the DNA. This process requires the interaction of a damaged 
DNA sequence with a homologous undamaged DNA sequence. It has become evident 
that HR is a major contributor to the maintenance of genome stability as defects in the 
HR machinery can lead to disease, genome instability and cancer [8]. 
 In 1964, Robin Holliday made a major breakthrough in the understanding of HR 
repair. He proposed a model to explain meiotic recombination which introduced the 
concept of the exchange of genetic material between homologous chromosomes 
through the formation of a Holliday junction (HJ) [46, 47]. Although the HJ model 
provided a basic understanding of recombination, it was unable to explain all HR 
scenarios and as a result, new adapted models of HR emerged. Several models have 
been proposed in the repair of DSB by HR: the synthesis dependent strand annealing 
(SDSA) model [48, 49], the Szostak model or more commonly known as the double 
strand break repair (DSBR) model  [50] and the break induced replication (BIR) model 
[51] (figure 1.3). The process of HR can be divided into three main steps: pre-synapsis, 
synapsis and post-synapsis. The initial pre-synaptic phase involves the processing of 
the DNA ends and the loading of RAD51 onto the DNA. During synapsis, homology 
search and strand invasion is carried out resulting in the formation of a D-Loop 
intermediate. Post synapsis involves the synthesis of DNA from the template DNA at 
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the broken ends. All three HR models share the same pre-synaptic and synaptic 
mechanisms and only diverge during post-synapsis resulting in a variety of different 
crossover and non-crossover events.   
Pre-Synapsis 
Our current understanding of HR in higher eukaryotic cells indicates that HR is initiated 
by the formation of a DSB which is first recognised by the MRN complex. The MRN 
complex consists of the core proteins MRE11, RAD50 and NBS1 [52]. The MRN 
complex is involved in the initial processing of DNA DSBs. MRE11 and RAD50 are 
believed to be important for bridging two DNA ends through the coiled coil domain of 
RAD50 [53]. As well as the binding and bridging functions of the MRN complex, it also 
functions as an endonuclease and a 3’-5’ exonuclease at DSBs. This function is 
attributed to the MRE11 protein (reviewed in [52]). The enzymatic activities of MRE11 
have been shown to be stimulated by RAD50 and NBS1 in an ATP dependent manner 
[54]. The MRN complex also plays an important role in recruiting major HR repair 
proteins and signalling factors to sites of damage. In order to resect DNA and generate 
a 3’ overhang which is required for HR, the MRN complex interacts with CtIP [55].  The 
MRN complex and CtIP are responsible for generating long range 5’-3’ end resection 
which results in a 3’ overhang, an essential intermediate in HR. The single stranded 3’ 
overhangs are then coated with RPA (Replication protein A) [56] which initiates the 
next stage in HR called synapsis.  The binding of RPA to ssDNA forms a nucleoprotein 
filament which stabilises and prevents the formation of DNA secondary structures 
which may interfere with the mechanism of HR. 
Synapsis 
During synapsis, the RAD51 protein carries out homology search and DNA strand 
invasion. In order for RAD51 to perform its function, it must first displace RPA from the 
ssDNA. RPA has been shown to have a higher affinity for ssDNA in comparison to 
RAD51 and RAD51 is unable to displace RPA in vitro. In order for HR to proceed, 
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recombination mediators help RAD51 displace RPA from the ssDNA. In yeast, RAD52 
and RAD51 paralogues (RAD55 and RAD57) are recombination mediators which can 
overcome the inhibitory effects of RPA on RAD51 [57-60]. BRCA2 and RAD51 
paralogues have been shown to play a similar recombination mediator role in 
vertebrates [61, 62]. Once RPA is displaced by RAD51, RAD51 forms long helical 
polymers which tightly wrap around the single stranded 3’ overhang referred to as 
RAD51 nucleoprotein filament. This filament is responsible for binding to and invading 
a homologous DNA molecule ultimately forming a heteroduplex DNA (D-loop) 
structure. The ssDNA within the nucleoprotein filament is stretched which greatly 
facilitates fast and efficient homology search [63, 64]. The exact mechanism of 
homology search and strand invasion remains unclear. However when the D-loop is 
formed, a RAD51-dsDNA filament is formed which accommodates both the invading 
and donor DNA strands generating a template in which to repair the broken DNA end. 
DNA synthesis after D-loop formation extends the 3’ annealed end using the 
homologous strand as a template. It is unclear which polymerases are responsible for 
D-loop extension. Post-synapsis will be discussed in relation to the three main 
subgroups of HR. It is important to note that resolution of D-loops forming non-
crossover products is preferential in maintaining genome integrity. 
Synthesis dependent strand annealing (SDSA) model 
During the SDSA HR pathway the invading strand of the DSB is extended by repair 
synthesis. After repair synthesis, the invading strand is displaced from the homologous 
template. The invading strand then anneals to the 3’ end of the original DSB. The 
repaired strand is then used as a further template to repair the second 3’ resected DSB 
end. The process is completed by ligation. As a result, SDSA avoids the formation of 
crossovers products reducing the possibility of genomic rearrangements.  
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DNA Double strand break repair (DSBR) model    
The DSBR branch of HR proceeds after the initial strand invasion by engaging the 
second end of the DSB. This can occur by either second end capture through DNA 
annealing or by invading the homologous template for a second time. Annealing of the 
second end of the DSB to the template DNA involves the protein RAD52 [65]. The 
DSBR model uses a two ended strand invasion mechanism which results in the 
formation of a double Holliday junction (dHJ). The dHJ is a substrate for both crossover 
and non-crossover products by BLM-TOPOIIIα and other structure specific 
endonucleases. Resolvase A activity, which has a similar specificity for HJ as bacterial 
RuvC, has been identified in mammalian cell extracts and appears to be responsible 
for cleaving HJ forming both crossover and non-crossover products [66]. On the other 
hand, the combined action of BLM DNA helicase and TOPOIIIα and their cofactor 
BLAP75/Rmi1 has been shown to process the dissolution of HJ into non-crossover 
products. BLM is believed to migrate the two junctions towards one another where 
TOPOIIIα separates them resulting in non-crossover products [67-69]. This in part 
explains why cells from patients with defective BLM helicase show an increase in sister 
chromatid exchange [67]. 
Break induced replication (BIR) model 
The BIR pathway for HR repair of DSBs is employed when only one end of the DSB 
can engage in recombination. This can be as a direct result of a collapsed replication 
fork resulting in a single ended DSB, or if only one end of the DSB is homologous to 
the template [70, 71]. BIR is thought to be required to initiate replication at stalled and 
collapsed replication forks. As with both other models, BIR involves strand resection, 
invasion and homology search by RAD51, however the main difference is that only one 
strand is extended by DNA synthesis and the other strand is lost due to its absence or 
lack of homology with the template strand. The invading strand is postulated to form a 
replication fork, synthesising DNA until the end of the chromosome is reached [72]. 
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This can often lead to loss of heterozygosity of any genetic information after the 
position of a DSB. Although BIR can involve large scale loss of genetic information, it 
does appear to be important in maintaining genomic integrity by alternative lengthening 
of telomeres and restarting collapsed replication forks. D-loops are resolved into non-
crossover products in the BIR pathway.   
 1.2.3. DSB repair by Single strand annealing (SSA) 
Single strand annealing of DSBs is considered to be an alternative mechanism in 
repairing DSB even though it technically is a form of HR. SSA repair occurs between 
direct repeats initiated by 5’-3’ resection of a DSB end. During SSA the DSB ends are 
resected to expose complimentary repeats on both strands which are then ligated back 
together. Although this process shares similarities with MMEJ processing of DSB, 
resection during SSA can cover a large sequence to expose complimentary repeats. 
RAD52 is believed to be involved in the annealing of the repeats [73, 74]. ERCC1 and 
other SSA enzymes cleave the ssDNA flaps which form as a result of resection and 
annealing [74-76]. SSA results in deletions of sequence surrounding the DSB and is 
considered to be mutagenic in mammalian cells [72, 73]. However there is evidence 
suggesting that SSA is a frequent repair event between repetitive sequences which are 
abundant in the genome [77]. 
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Figure 1.3 HR repair of DNA DSBs by BIR, SSDA and DSBR 
Illustration of the repair of DSBs by different HR repair pathways. DSBs are recognised and 
resected by the MRN complex and CtIP. RPA binds with high affinity to the ssDNA. RAD51 
displaces the RPA and carries out homology search and strand invasion in a homologous 
template leading to the formation of a D-loop. BIR, SSDA and DSBR pathways synthesize new 
DNA and resolve D-loop structures in different ways resulting in either crossover or non-
crossover products after the repair of the DSBs. dHJ (double Holliday Junction), BLM (Blooms). 
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1.2.4 Regulation and DSB repair choice  
The principle pathways to repair DNA DSBs are NHEJ, HR and SSA and the balance 
between them is highly dependent on cell type, species, cell cycle stage and the type 
of DNA damage. Regulation and the choice of DSB repair are fundamental to 
maintaining genome stability. Although NHEJ can lead to chromosomal translocations 
and loss of genomic information, it is important for B and T-cell development by class 
switch recombination and V(D)J recombination. When available, HR is the preferable 
repair pathway for DSB repair as it is considered to be error free. However tight 
regulation of HR is required as recombination can be harmful in certain situations like 
stalled replication forks where translesion synthesis is a safer method of repair. In 
certain genetic backgrounds, HR can generate nucleoprotein intermediates which 
results in a prolonged cell cycle arrest and even cell death [78-80]. It is also important 
to choose the correct type of HR repair in different circumstances and stages of the cell 
cycle. For example, HR repair by SDSA should be preferentially employed during 
mitosis to avoid crossover of genomic information and loss of heterozygosity. 
 One of the most evident types of regulation used in the choice of repair is 
demonstrated by the cell cycle. HR is restricted to the S and G2 phases of the cell 
cycle as a sister chromatid is required for repair and only available during the S and G2 
phase. It has also become evident that transcription of HR genes and CDK mediated 
phosphorylation of HR proteins also restricts the HR process to the S and G2 phases 
of the cell cycle [81, 82]. Resection of DSB is required for the initiation of HR. CtIP is 
required for resection of DSB in mammalian cells and the protein levels of CtIP is 
reduced in G1 cells and greatly increased in S and G2 phases of the cell cycle which in 
turn regulates the amount of HR during the cell cycle [83].   
 Resection of a DNA DSB is fundamental to the commitment of repair by HR. 
DSB resection is highly regulated and low in G1 which favours NHEJ over HR repair at 
this stage in the cell cycle [84]. A major restriction point in the choice of repair in S and 
G2 phases of the cell cycle is the competition between end protection and resection 
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[85]. As previously mentioned the Ku heterodimer binds DNA ends with high affinity 
promoting NHEJ [12]. The combined action of the MRN complex and CtIP in humans 
and yeast is required for resection which promotes HR. DSB must be resected 
appropriately in the S and G2 stages of the cell cycle and cell cycle regulation of CtIP is 
paramount to the resection of DSB and initiation of HR. As well as CtIP protein 
degradation in G1, CDK phosphorylation of CtIP, which is required for MRN-CtIP 
complex formation, occurs in S/G2 phase [86, 87]. Resection is also negatively 
regulated by acetylation of CtIP [88, 89]. After DNA damage, CtIP is deactylated by 
SIRT6 as a means to promote HR [89]. The molecular mechanism by which MRN-CtIP 
displaces Ku from the DNA DSB end remains unclear. However recent studies of 
meiotic DSB repair in budding yeast has provided several insights into this process 
[90]. During meiotic recombination in yeast, Spo11 induces programmed DSB and 
remains covalently attached to the DSB. In order for 5’-3’ resection to occur, Spo11 
must be removed from the DSB end. Mre11 has been proposed to introduce an 
asymmetric endonucleolytic nick adjacent to Spo11 on the 5’ DNA ends [90, 91] which 
is suggested to promote Exo1 dependent 5’-3’ resection. Mre11 is responsible for 3’-5’ 
degradation of the nicked strand to the DNA DSB end removing Spo11 [92]. It is 
possible that the same process is required in vertebrates using MRE11 and CtIP, 
however further evidence and study is required to investigate this possibility. 
 Regulation of RAD51 is another important factor in the control and choice of 
DSB repair. Regulation of RAD51 not only determines the type of repair used but it also 
prevents the use of HR when the effects may be detrimental to the cell as discussed 
earlier. Evidence from yeast suggests that Srs2 can counteract the function of RAD51 
which is vital to the repair of DSB by HR. Biochemical studies revealed that Srs2 
efficiently removes RAD51 filaments from DSB during pre-synapsis [93, 94]. The 
removal of RAD51 requires its interaction with Srs2 and is greatly enhanced in the 
presence of RPA preventing re-association of RAD51 with the DSB [93-97]. The 
interaction of Srs2 with RAD51 triggers the ATP hydrolysis of RAD51 which 
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destabilises the RAD51-DNA interaction [98]. To counteract this process and promote 
RAD51 filament formation on DSB ends, mediators of recombination, such as 
RAD55/RAD57, can suppress the action of Srs2 [99] and promote HR. There are no 
known human homologues of Srs2, however there are several human helicases 
predicted to have acquired a similar function. BLM and FANCJ have both been 
reported to contribute to the removal of RAD51 from DSBs [100, 101]. 
 As discussed previously, BLM is important for resolving dHJ structures to 
prevent crossover events [67] during HR, maintaining genome integrity. The drosophila 
melanogaster BLM homologue, MUS-309, has also been shown to free the invading 
ssDNA tail from the D-loop promoting SDSA [102, 103]. In order to suppress 
crossovers in mitotic cells it is preferential to use SDSA over DSBR as SDSA results in 
non-crossover events. As well as BLM, FANCM in human cells has also been 
proposed to regulate HR by promoting SDSA [104]. 
 RPA poses a major restriction to the implementation of HR as efficient 
displacement of RPA from ssDNA is required for RAD51 to bind and initiate strand 
invasion and homology search. RPA is an extra method of regulation of HR as it has a 
greater affinity for ssDNA than RAD51 and RAD51 can only displace RPA with the aid 
of recombination mediators triggered by DNA damage. It is also important to note that 
although regulation of DSB occurs through various mechanisms, signalling events 
which incorporate a vast amount of post-translational modifications such as 
phosphorylation, methylation and ubiquitylation, are responsible for the recruitment of 
key repair proteins at DSB. These PTM are reversible and are arguably the most 
important form of overall regulation of repair, not only contributing to the recruitment of 
repair proteins but also to the choice of repair of DSB. The involvement of signalling at 
DNA DSB will be discussed later in this chapter. 
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1.3 Signalling at DSBs 
The eukaryotic cell employs a plethora of proteins involved in the detection and repair 
of DNA damage through a highly coordinated and complex signalling cascade. This 
signalling cascade, also known as the DDR, orchestrates a variety of processes 
including DNA repair, cell cycle checkpoint activation and transcriptional regulation in 
response to DNA damage. One of the main functions of the signalling cascade at DSBs 
is to recruit major repair proteins to the site of damage as well as regulating the type of 
repair carried out. The recruitment of repair protein involves an intricate cascade of 
posttranslational modifications including phosphorylation, ubiquitylation, actylation and 
sumoylation which actively recruit repair proteins and remodel the chromatin around a 
break to facilitate repair (figure 1.4). Signalling at DSB employs a variety of DDR 
proteins and various post-translational modifications which form sub nuclear foci at the 
DSB site known as ionizing radiation induced foci (IRIF) [105]. The IRIF arise due to 
extensive chromatin remodelling and accumulation of DDR proteins, which are 
paramount for mediating not only the signalling and repair of damaged DNA but also to 
activate cell cycle checkpoints or apoptosis. The importance of the proteins involved in 
signalling at DSB are highlighted in various disease phenotypes associated with 
defective DDR proteins such as developmental defects, immunodeficiency and 
neurodegenerative disorders [106-108]. 
 The phosphorylation of histone variant H2A, H2AX, by ATM is one of the initial 
signals which allows the recruitment of other DDR proteins to accumulate at sites of 
DSBs [109, 110]. ATM is recruited and activated by the MRN complex which 
recognises DSB ends. ATM directly binds to the C-terminus of NSB1 [111, 112] and 
phosphorylates H2AX, on a conserved serine, within seconds of the induction of DSBs 
[113]. Phosphorylation of H2AX is an extremely important step early on in the signalling 
response to DSBs as it provides a docking platform for other DDR proteins. Many 
mediator and repair proteins fail to translocate to the nuclear foci when the ATM 
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phosphorylation site of H2AX is mutated [110, 114]. To further prove the importance of 
H2AX, knockdown of H2AX in cells promotes genomic instability [110].  
 Mediator of DNA damage checkpoint 1 (MDC1) has been shown to bind the C-
terminal phosphopeptide ofH2AX via its BRCT domains [115, 116]. MDC1 is recruited 
within seconds of a DNA DSB and appears to have several functions. Studies have 
shown that MDC1 may protect the C-terminus of H2AX from premature 
dephosphorylation therefore allowing completion of DNA repair [116, 117]. It has also 
been proposed that MDC1 serves to amplify the DNA damage signal [115, 118] by 
interacting with ATM through its FHA domains causing further accumulation of ATM 
which leads to the propagation of H2AX.  
 MDC1 also acts as an adaptor protein which leads to the recruitment of RNF8 
through its FHA domain after phosphorylation by ATM. RNF8 is an E3 ubiquitin ligase 
which functions with UBC13, an E2 ubiquitin-conjugating enzyme, previously believed 
to mediate mono-ubiquitylation of histones H2A and H2AX at DSBs [119-122]. 
However recent studies have suggested that although RNF8 is recruited to DSBs 
before RNF168, RNF168 and not RNF8 is responsible for the initial monoubiquitylation 
of H2A [123]. Mattiroli et al. discovered that RNF8 is inactive towards H2A whereas 
RNF168 catalyses the monoubiquitylation of H2A at position K13/15 and RNF8 is more 
likely to extend the ubiquitin chain [123]. RNF168, another E3 ubiquitin ligase is 
recruited to DSBs in a RNF8 dependent manner which relies not only on the FHA 
domain of RNF8 but also its RING domain [124-126]. As a means to explain the 
requirement of the E3 ubiquitin ligase function of RNF8 in the recruitment of RNF168, 
Mattiroli et al. suggested that RNF8 ubiquitylates non-histone proteins which recruit 
RNF168 to the site of damage [123]. The recruitment of RNF8 and RNF168 is believed 
to further amplify the DSB signals by increasing K63-linked poly-ubiquitination on H2AX 
and H2A [124-126]. Cells lacking RNF8 and RNF168 have defective DSB repair [127] 
highlighting their importance in signalling at DSBs.  
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 BRCA1, the tumour suppressor protein, is recruited to DSBs via the formation 
of the BRCA1-A complex. RAP80, an integral component of the BRCA1-A complex 
binds to K63 linked polyubiquitin chains on H2A catalysed by RNF8 and RNF168 [128]. 
This in turn tethers BRCA1 to the DSB via its interaction with Abraxas. RAP80 contains 
tandem ubiquitin binding motifs (UIMs) which recognise the ubiqitylated proteins at 
DSBs and facilitates BRCA1 localisation. RAP80 forms a complex with Abraxas, a 
scaffold protein, and three additional proteins, BRE, MERIT40 and a deubiquitylation 
protein called BRCC36 [128-133]. Phosphorylated Abraxas is recognised by the BRCT 
domains of BRCA1. BRCA1 is phosphorylated on serine 1386 and 1423 by ATM and 
phosphorylation at these sites are important for both S-phase and G2/M checkpoints 
after IR [134, 135]. The exact function of BRCA1 at DSB sites remains unclear. 
 P53 binding protein 1 (53BP1) is another checkpoint mediator protein recruited 
to DSBs.  53BP1 has been shown to interact with methylated histones H3 and H4. Foci 
formation of both BRCA1 and 53BP1 has been shown to be dependent on MDC1 and 
the RNF8 ubiquitin ligase [136] however the mechanism of recruitment of 53BP1 is still 
unknown as is the mechanism by which ubiquitin affects the interactions between the 
53BP1 tudour domains and methylated histones. 53BP1 is a known activator of p53 
[137] and is important in checkpoint signalling. 
 As mentioned earlier, repair of DSB by NHEJ may leave the cell subject to 
mutations. To date, the exact mechanism that allows preferential repair by HR has not 
yet been identified. Recently an interesting discovery was made in relation to 53BP1 
and BRCA1 at DSBs. It is important to note that homozygous deletion of BRCA1 
appears to be lethal during human and mouse development, primary cultured cell, 
MEFs and stem cells [138]. BRCA1 null mice can be rescued by the deletion of one 
allele of p53 however these mice exhibit an increase in spontaneous tumour formation 
[139]. BRCA1 deficient cells show a decrease in DSB repair by HR in the presence of 
53BP1, however cells lacking both BRCA1 and 53BP1 have a partially restored HR 
20 
 
pathway [140]. This new discovery leads us to believe that there may be a more 
complicated interplay between BRCA1 and 53BP1 at DSB sites. 
 The recruitment of a vast number of repair and signalling proteins to the site of 
damage is further complicated by the fact that repair does not take place on naked 
DNA, but instead on chromatin. Chromatin is the complex structure of DNA wrapped 
tightly around histone proteins which can be packed in a very tight complex known as 
heterochromatin or a more loosely packed euchromatin. Euchromatin is normally 
associated with a more open structure which is transcriptionally active as the DNA is 
easier to access whereas heterochromatin is considered to be transcriptionally silent 
due to the tight compaction of the DNA [141]. As a result the different packing of 
chromatin serves as an extra method of regulating key cellular process such as 
transcription, replication and repair due to the limitations imposed on proteins to access 
the DNA in heterochromatin [142, 143]. As a result, the modification of chromatin by 
chromatin remodelling factor plays an important role in the response to DSBs and 
many such factors have been shown to be recruited to sites of damage during the 
signalling cascade at DSBs [144].  
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Figure 1.4 Signalling at DNA DSBs 
Illustration of the signalling cascade after the induction of a DSB. The MRN (Mre11-RAD50-
NBS1) complex recognises the DSB and activates and recruits ATM. ATM then phosphorylates 
the histone variant H2AX which initiates a complex signalling pathway involving several proteins 
important for repair. MDC1 binds γ-H2AX and recruits the ubiquitin ligase RNF8. RNF8 then 
recruits RNF168 which mono-ubiquitylates H2A and H2AX and together the concerted action of 
RNF8 and RNF168 extends the polyubiquitin chain. Poly-ubiquitin conjugated H2A/H2AX 
provides a docking platform for RAP80 which recruits BRCA1 through the BRCA1-A complex. 
As a result of the signalling cascade, repair proteins BRCA1 and 53BP1 are recruited to sites of 
damage. 
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1.3.1 Ubiquitin and signalling at DSBs 
Although phosphorylation has long been known as a crucial post-translational 
modification in orchestrating several protein-protein interactions at DSBs, ubiquitylation 
has recently emerged as another key protein modification at sites of damage to ensure 
genome stability in response to damage. The ubiquitylation system is best 
characterised for its role in protein degradation however it is the non-degradative 
aspects of ubiquitylation known as the non-conventional signalling functions of 
ubiquitylation that appear to play the predominant role in the DDR.  The signalling 
aspect of ubiquitin acts as a reversible post-translational modifier for proteins involved 
in the response to DNA damage. Shortly after its discovery, ubiquitylation and 
subsequent polyubiquitylation of proteins was found to target proteins for degradation 
in an ATP dependent manner by the 26S proteasome [145, 146]. Since then, ubiquitin 
modification has been associated with numerous non-degradative roles and is 
considered to be a signal similar to many other post-translational modifications.  
 Ubiquitylation of a substrate protein can occur by covalently attaching a single 
ubiquitin moiety onto a target protein known as mono-ubiquitylation or by extending the 
mono-ubiquitin chain forming a poly-ubiquitin chain. The mono-ubiquitylation of a 
protein can have several functional consequences such as intracellular vesicle 
transport, chromatin structure regulation, transcription and processing of DNA damage. 
However the intrinsic complexity of ubiquitin signalling arises from its ability to form 
poly-ubiquitin chains on its substrate. Ubiquitin is conjugated to a lysine residue on its 
substrate protein. Ubiquitin is a small 76 amino acid protein around 8.5 kDa and it 
contains seven lysine residues on the surface of the protein which can all be used for 
further ubiquitylation to form a ubiquitin chain [147]. Ubiquitin chains of different 
linkages can be formed on lysine’s on the surface of ubiquitin which are associated 
with different functional outcomes [148]. For example, K48 linked poly-ubiquitin chains 
target the substrate protein for degradation, whereas K63 linked chains are more 
commonly associated with non-proteosomal signalling functions known to be involved 
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in endocytosis and the DDR [149]. The modification of a protein by the conjugation of 
ubiquitin is believed to create an additional interaction site on the substrate. Over 
twelve ubiquitin binding motifs have been identified in a variety of proteins such as the 
UIM in RAP80. Although most of these ubiquitin binding motifs are not selective for the 
type of ubiquitin modification, some are extremely selective and can distinguish 
between K63 linked ubiquitin chains and linear chains [150-152].  
 In response to DNA damage, especially DNA DSBs, a series of ubiquitin 
enzymes are recruited to sites of damage where they are involved in mediating a 
response to DNA damage serving to amplify the DNA damage signal and recruit major 
repair proteins. DNA checkpoint activation and repair relies on the recruitment of 
several E3 ubiquitin ligases. As a result many different E3 ligases are found at DNA 
DSBs including BRCA1, RNF8, RNF168, HERC2 and RNF2 among others. Although 
many questions about the regulation of ubiquitylation, substrates and functional 
relevance of ubiquitin chains remain unanswered, the importance of ubiquitin in the 
signalling at DNA DSBs is evident as loss of ubiquitylation abrogates the repair of 
DSBs.  
1.3.2 Mechanism of protein ubiquitylation  
Ubiquitin was first discovered by Ciechanover et al in the 1970s while studying the 
ATP-dependent degradation of the tyrosine aminotransferase enzyme. This group 
isolated a protein called ATP-dependent proteolysis factor 1 (APF-1) [145] which is 
now known as ubiquitin (ub). Since its discovery, the extensive research of several 
groups lead to the discovery of the process of ubiquitylation [153] (figure 1.5). 
Ubiquitylation involves the attachment of a ubiquitin moiety onto a substrate protein via 
the formation of an isopeptide bond between an amino group on a substrate protein 
and the c-terminus of the ubiquitin. Ubiquitylation is an ATP dependent process which 
involves the sequential action of three ubiquitin enzymes, the E1 activating enzyme, 
the E2 conjugating enzyme and the E3 ubiquitin ligase enzyme.  
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 The initial step of ubiquitylation involves the activation of ubiquitin by the E1 
enzyme. The E1 enzyme activates ubiquitin by displacing pyrophosphate from ATP 
generating a ubiquitin-adenylate intermediate [154-156]. As a result, a thioester bond 
forms between the thiol group of the cysteine in the active site of the E1 enzyme and a 
carboxyl group of a glycine in the C-terminus of ubiquitin. This process leads to the 
release of AMP. The active ubiquitin is then transferred to a cysteine in the active site 
of the E2 enzyme which is catalysed by a thioester transacylation process [157]. The 
final step on ubiquitylation involves the E3 ubiquitin ligase enzyme which catalyses the 
conjugation of the ubiquitin onto a lysine residue of the substrate protein via the 
formation of an isopeptide bond.  
 There are two main classes of E3 ubiquitin ligases which are categorised 
depending on the presence of either a HECT or RING domain and over 600 such 
proteins have been identified in mammalian cells [158]. RING domain containing E3 
enzymes act as scaffolds to facilitate the conjugation of the ubiquitin on the E2 enzyme 
onto the substrate bringing the E2, ubiquitin and substrate in close proximity to each 
other. On the other hand, HECT domain containing proteins have direct catalytic 
activity forming an extra thioester bond between the catalytic cysteine residue and the 
ubiquitin [159]. In humans there are only two known E1 enzymes, Ube1 and Uba6. 
There are around 40 E2 enzymes in humans all containing a conserved catalytic 
conjugating domain [160]. The E3 enzymes have been shown to possess substrate 
specificity from structural studies [161-163] and it is believed that the combination of E2 
and E3 enzymes ultimately determines not only the target substrate but also the type of 
ubiquitylation. 
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Figure 1.5 Mechanism of Ubiquitylation 
Diagram of the process of conjugating ubiquitin onto a substrate protein. Ubiquitin is first 
activated by an E1 enzyme in a process requiring ATP. The active ubiquitin is then attached 
onto the E1 enzyme via a thioester bond. The ubiquitin is then transferred onto the conjugating 
E2 enzyme catalysed by a thioester transacylation process. The final stage of ubiquitylatiuon 
requires an E3 enzyme to transfer the ubiquitin to a lysine residue on the substrate protein 
forming an isopeptide bond. After mono-ubiquitylating the protein further ubiquitylation can 
occur to create a poly-ubiquitin chain. 
 
1.3.3 Ubiquitin ligases and their role in the DDR 
Ubiquitylation of proteins involved in the DDR is fundamental for efficient DSB repair 
and signalling at sites of damage [164, 165]. As a result, several E3 ubiquitin ligases 
are recruited to sites of DNA damage such as BRCA1/BARD1, RNF8, RNF168, 
HERC2, RAD18 and RNF4 and loss of these proteins results in impaired DSB repair 
,signalling and an increase in sensitivity to DNA damaging agents [119-122, 124, 126, 
166-168]. Although the BRCA1 BARD1 heterodimer is a well characterised ubiquitin 
ligase, the relevance of the E3 activity of these proteins in the repair of DNA damage 
remains unclear. Several breast cancers contain mutations in the BRCA1 RING 
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domain which abrogates its E3 ubiquitin ligase activity [169-171]. This suggested that 
the E3 ligase activity of BRCA1 is required for tumour suppression, however most of 
the breast cancer BRCA1 RING mutations not only abrogated its E3 ligase activity but 
also disrupted the BRCA1 BARD1 interaction suggesting that the phenotypes observed 
with these mutations were as a result of a complete loss of BRCA1 function in the 
absence of BARD1 rather than a requirement for the ubiquitin ligase activity of BRCA1. 
The hypothesis that the BRCA1 E3 ligase activity is not fundamental to the DDR was 
further strengthened when Reid et al, observed that the RING domain of BRCA1 was 
not required for DSB repair or cell viability [172]. The group introduced a point mutation 
(I26A) into the BRCA1 RING domain which abrogated the ubiquitin ligase activity of 
BRCA1 whilst still enabling its interaction with BARD1. The BRCA1I26A mutant was 
HR competent and showed no increased sensitivity to DNA damaging agents 
suggesting that the BRCA1 RING domain is not required for HR.  
RNF8 is a 485 amino acid E3 ubiquitin ligase enzyme first discovered in 1998 
by Seki et al [173]. RNF8 contains an N-terminal forkhead-associated (FHA) domain 
which is responsible for binding to phospho-threonine residues and also a C-terminal 
RING domain which attributes its E3 ubiquitin ligase function [174, 175]. Research over 
the past few years have highlighted the importance of RNF8 in response to DNA 
damage. Loss of RNF8 in cells has been shown to lead to defective HR especially in 
heterochromatin [176]. Recently Oestergaard et al. demonstrated that Rnf8 DT40 cells 
were sensitive to DNA damaging agents and required for ubiquitylation at DNA DSBs 
to facilitate the recruitment of BRCA1 and 53BP1 to sites of damage [177]. The 
analysis of Rnf8 deficient mice revealed a mild phenotype. These Rnf8 mice were 
sensitive to IR and also exhibited subtle defects in V(D)J recombination and CSR [178-
180]. 
 Following DNA damage, RNF8 is recruited to sites of damage by interacting 
with the phosphorylated MDC1 through its FHA domain [119-121]. RNF8 has been 
elucidated as an important factor in the recruitment of both BRCA1 and 53BP1 to sites 
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of damage which is dependent on its E3 ligase function [119-122] . RNF8 is also 
responsible for the recruitment of another E3 ubiquitin ligase, RNF168, to sites of 
damage [124, 126]. This recruitment is dependent on both the FHA and RING domain 
of RNF8. Interestingly the ubiquitin ligase activity of RNF8 is not sufficient to retain 
BRCA1 and 53BP1 at sites of damage and the concerted action of RNF8 and RNF168 
has been shown to be required for this stabilisation. Due to the recruitment order of 
RNF8 and RNF168, it was originally predicted that RNF8 mono-ubiquitylated H2A and 
RNF168 extended the ubiquitin chain in the form of K63-linked poly ubiquitin chains, 
however recent evidence has demonstrated that although RNF8 can ubiquitylate free 
H2A in vitro it does not have any activity towards H2A in the context of chromatin. 
Instead it was shown that RNF168 mono-ubiquitylated H2A and together RNF8 and 
RNF168 extended the poly-ubiquitin chains [123]. Given that RNF8 acts on H2A after 
RNF168 yet the ubiquitin ligase function is required to recruit RNF168, it has been 
suggested that RNF8 ubiquitylates non-histone proteins which may lead to the 
recruitment of RNF168 [123]. However these potential RNF8 substrates have not yet 
been identified. 
RNF168 is another E3 ubiquitin ligase enzyme important in mediating the 
response to DNA damage and recruiting repair proteins to DNA damage sites. RNF168 
contains an N-terminal RING domain and two UIMs (ubiquitin interacting motif). Similar 
to RNF8, RNF168 has been implicated in HR, as loss of the protein leads to defective 
HR and sensitises cells to DNA damaging agents [176, 177]. Mutations in RNF168 are 
also associated with the human RIDDLE syndrome which is characterised by 
radiosensitivity and immunodeficiency among other clinical features [126]. RNF168 is 
recruited to DNA damage via its UIM domains in a manner dependent on RNF8 and is 
responsible for the mono-ubiquitylation of H2A, ultimately leading to the recruitment of 
BRCA1 and 53BP1 [123]. K63, non-degrading, ubiquitin chains are essential for the 
recruitment of repair proteins BRCA1 and 53BP1 to DSBs [2, 181, 182], Both RNF8 
and RNF168 are required for ubiquitylation at sites of damage and loss of either 
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proteins severely impedes the recruitment of BRCA1 and 53BP1 to DSBs [122, 124, 
126, 177]. 
 RNF8 and RNF168 are important in the recruitment of BRCA1 and 53BP1 to 
DSBs, however these two proteins are predicted to have contrasting functions in terms 
of repair. BRCA1 is thought to stimulate repair of DSBs via HR in a faithful manner 
whereas 53BP1 promotes the more error prone pathway on repair, NHEJ. It has 
become evident over the last few years that signalling at DSBs mediates and regulates 
the decision to repair DSB either by HR or by NHEJ and much further work is needed 
to address the function of RNF8 and RNF168 in the decision of repair. The exact 
function and biological relevance of these two ubiquitin ligases in relation to the repair 
of DSB remains unclear.  
 
1.4 BRCA1 and BARD1  
1.4.1 Introduction to the tumour suppressor gene BRCA1 
A tumour suppressor gene is defined as a genetic factor in which loss of heterozygosity 
can lead to the development of a tumour. Breast cancer is one of the most common 
cancer affecting 1in 9/12 women throughout their life time. Although there are many 
factors that contribute to the development of breast cancer including hormonal 
imbalance and obesity, the most prominent factor is family history. The genetic basis 
underlying common forms of inherited breast and ovarian cancers was discovered to 
be due to germ line mutations in the Breast cancer type 1 susceptibility protein 
(BRCA1) and BRCA2 [183, 184]. BRCA1 and BRCA2 are the most commonly mutated 
genes in hereditary breast and ovarian cancer [185] Although germ line mutations of 
BRCA1 are only associated with a small percentage of total breast and ovarian 
cancers, it is estimated that around 10% of hereditary breast and ovarian cancer arise 
due to germ line BRCA1 mutations [186]. There has also been some recent evidence 
that BRCA1 is responsible for the development of some sporadic breast cancers [187]. 
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BRCA1 mutation carriers inherit one mutated copy of the BRCA1 gene and loss of 
heterozygosity of the Wild type gene is commonly associated with tumours. Although 
patients do not display any apparent phenotypic abnormalities, they have an increased 
risk of 80% in developing either breast or ovarian tumours throughout their life time 
[188]. BRCA1 is involved in many important cellular processes including cell cycle 
checkpoint control, repair and chromatin remodelling. However its role in the repair of 
DSB by HR is considered to be its most important function in tumour suppression. 
1.4.2 The BRCA1 gene 
The BRCA1 gene was identified in 1990 and subsequently cloned in 1994 [184, 189]. 
BRCA1 is a relatively large gene of 1863 amino acids encoded in 24 exons. 
Orthologues of BRCA1 can be found in many vertebrates including mice, chicken and 
zebra fish. BRCA1 homologues and several BRCA1 complex members have also been 
discovered in plants [190-192] however, to date there is no clear BRCA1 homologue in 
either Saccharomyces cerevisea or Schizosaccharomyces pombe. Many functions of 
BRCA1 can be attributed to functional domains encoded in the gene. BRCA1 contains 
a really interesting new gene (RING) domain at its N-terminus which contributes to the 
E3 ubiquitin ligase function of the protein [193, 194]. The C-terminus of the protein 
contains a tandem BRCA1 C-terminal (BRCT) repeat which is known to bind 
phosphorylated proteins important for repair [193]. BRCA1 also harbours a nuclear 
export signal (NES) at its C-terminus and two central Nuclear localisation signals (NLS) 
[193, 195]. BRCA1 interacts with a variety of proteins attributing several functional roles 
for BRCA1 in DNA repair, cell cycle regulation and transcriptional regulation [196, 197] 
(figure 1.6) 
1.4.3 The BARD1 gene 
BRCA1 associated RING domain protein 1 (BARD1) was identified in a yeast two 
hybrid screen of BRCA1 RING domain interactors [194]. BARD1 is encoded by 777 
amino acids [194] and shares many structural similarities with BRCA1 (figure1.6). 
30 
 
BARD1 has a RING domain in its N-terminus which has been shown to interact with 
the BRCA1 RING domain forming a stable heterodimer both in vitro and in vivo [170, 
198]. Similar to BRCA1, BARD1 also contains tandem BRCT domains at its C-
terminus. Furthermore BARD1 also has three tandem ankyrin repeats [199] not present 
in BRCA1. It has been suggested that all three functional domains of BARD1 (RING, 
BRCT and ankyrin repeats) are essential for its role in the DDR.  
 
 
 
 
 
 
 
 
 
 
Figure 1.6 BRCA1 and BARD1 functional domains and BRCA1 interacting proteins 
Representative image of the BRCA1 and BARD1 genes illustrating common functional domains, 
the RING and BRCT domains. BRCA1 also contains NES and NLS motifs and BARD1 harbours 
ankyrin repeats. The proteins above BRCA1 represent BRCA1 interacting proteins and their 
position corresponds to the region of BRCA1 with which they interact.  
 
1.4.4 The role of BRCA1/BARD1 in the DNA damage response 
In order to maintain genome stability the cell must implement an efficient response to 
DNA damage. BRCA1 has been shown to be important in the response to DNA 
damage as defects or loss of BRCA1 in cells results in gross genome instability. This 
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phenotype is strikingly evident in the karyotyping of BRCA1 null cells as they 
demonstrate extensive chromosomal translocations, aberrant fusion events and 
duplications [200-202]. The genome instability phenotype associated with loss of 
BRCA1 is associated with several diseases such as Fanconi anaemia, Blooms 
syndrome and cancer [203, 204]. BRCA1 is associated with numerous complexes [184, 
196, 205] resulting in a variety of distinct functions. These BRCA1 complexes have 
several functions in DNA repair, cell cycle checkpoint activation and transcriptional 
regulation [196, 197]. 
 BRCA1 is found almost exclusively in the nucleus bound to its interacting 
protein BARD1 [194]. The BRCA1-BARD1 heterodimer is formed by the interaction of 
four alpha helices flanking their RING domains [198, 206]. The interaction of BRCA1 
with BARD1 is paramount to the DDR functions of BRCA1 and is heavily supported by 
both in vivo and in vitro evidence. Abolishing the BRCA1 BARD1 interaction results in 
defective HR and point mutations preventing the BRCA1 BARD1 interaction are often 
seen in breast cancers [172, 207]. Binding of BARD1 masks the nuclear export signal 
of BRCA1 allowing its retention in the nucleus where it has its function. 
Heterodimerization of BRCA1 and BARD1 has also been shown to greatly increase the 
ubiquitin ligase activity of BRCA1 and it considered to be important for the stabilisation 
of both proteins [170, 208, 209]. Both Bard1 and Brca1 knockout mice are embryonic 
lethal and almost phenotypically indistinguishable. The loss or mutation of either 
proteins in cells has been demonstrated to severely increase sensitivity to DNA 
damaging agents indicating that both BRCA1 and BARD1 share similar function in 
response to DNA damage [201, 207, 210]. The importance of the BRCA1 BARD1 
interaction in genome stability is further demonstrated by BRCA1 mutations found in  
cancers which abrogate its binding to BARD1[211]. The frequency of BARD1 mutations 
found in cancers is very low in comparison to those found in BRCA1, however a 
number of BARD1 mutations in cancers have been discovered [212-214]. 
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 As previously mentioned, BRCA1 interacts with a variety of proteins attributing 
several unique functions to BRCA1 in response to DNA damage (figure 1.6). The 
importance of these interactions will be discussed in relation to three major functions of 
BRCA1 in DNA repair, cell cycle checkpoint activation and regulation and 
transcriptional regulation. Unless otherwise stated, all these interactions and functions 
of BRCA1 are dependent on the formation of the BRCA1 BARD1 heterodimer. 
The role of BRCA1 in DNA repair 
Initial clues that BRCA1 is important for the repair of DSBs via HR came from a study 
carried out by Scully et al in 1997 demonstrating that BRCA1 colocalised with RAD51 
at sites of damage [215]. Since then a vast number of studies have implicated BRCA1 
in the repair of DSB via HR. Loss of BRCA1 or partial loss of BRCA1 function has been 
shown to decrease HR [201, 202, 216, 217] in cells and sensitises the cell to various 
DNA damaging agents [218]. BRCA1 null cells have also been shown to be extremely 
sensitive to PARP inhibitors [219]. The recruitment of BRCA1 to DSBs remains to be 
one of the most convincing pieces of evidence suggesting a role for BRCA1 in HR. 
Upon DNA damage, BRCA1 is activated and recruited to DSBs. This recruitment is 
initiated by the MRN complex which recognises the break and recruits ATM. The key 
role of ATM is to recruit repair proteins by phosphorylating histone H2AX [113, 220]. 
BRCA1 localises to DSBs through its interaction with Abraxas, which forms a stable 
complex at sites of damage. The relevance and importance of this interaction will be 
discussed later on in this chapter. 
Although the exact molecular mechanism by which BRCA1 contributes to the repair of 
DSB via HR remains unknown, the interaction of BRCA1 with certain repair proteins 
has provided potential mechanisms of action. Evidence suggests that BRCA1 interacts 
with the MRN complex through its interaction with CtIP forming the BRCA1-C complex 
[221]. The MRN complex, which is fundamental to the recruitment of repair proteins to 
sites of damage and also in the initiation of HR, is thought to directly recruit BRCA1-
CtIP by binding phosphorylated CtIP [221]. The MRN-CtIP-BRCA1 complex mediates 
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extensive resection at DSBs generating ssDNA, a prerequisite for HR [55, 222]. 53BP1 
is believed to inhibit DSB resection promoted by CtIP and BRCA1 is required to 
overcome this inhibition [223]. Although both CtIP and the MRN complex are required 
for resection and HR, the direct interaction between CtIP and BRCA1 appears to be 
less important [166, 224, 225] suggesting that BRCA1 may be more important in 
preventing the inhibition of resection by 53BP1and therefore promoting HR. 
 DNA strand invasion and homology search during HR is carried out by the 
recombinase protein RAD51 [226]. After DNA end resection by MRN-CtIP, RAD51 
displaces RPA from the ssDNA with the help of recombination mediators. BRCA2 has 
been shown to be important in the formation of the RAD51 filament [227]. BRCA1 is 
essential for the retention of both RAD51 and BRCA2 at sites of damage [228]. It is 
believed that this is one of BRCA1s fundamental roles in DSB repair by HR. Whether 
BRCA1 interacts with RAD51 in a direct or indirect manner remains unclear. BRCA1 
has been suggested to recruit BRCA2 to DSBs via PALB2 which acts as a linker 
protein between BRCA1 and BRCA2 [229, 230]. Indirectly, BRCA1 is considered to be 
vital for the recruitment of the RAD51 to DSBs through the recruitment of BRCA2 via 
PALB2. In confirmation of this functional role of BRCA1, BRCA1 is known to colocalise 
with RAD51 at sites of damage and loss of BRCA1 results in a reduction of BRCA2, 
PALB2 and RAD51 foci formation after DNA damage and abrogates HR [229, 230].  
 Over the last few years a novel role for BRCA1 in DNA repair has emerged. 
Recent evidence suggests that BRCA1 plays an important role in the regulation and 
choice of repair at DSBs. BRCA1 localises to DSBs via its interaction with Abraxas, 
however the recruitment of BRCA1 to DSBs can also be facilitated by the DNA 
damaged induced interaction of BRCA1 N-terminus with the NHEJ protein Ku80 [231]. 
Rather than promoting NHEJ, the recruitment of BRCA1 to DSB by Ku80 is predicted 
to facilitate HR by removal of NHEJ repair proteins such as 53BP1 from the DSB [223]. 
This function is suggested to prevent aberrant end joining and to regulate the choice of 
NHEJ and HR. Contrary to expectations, the depletion of RAP80 and Abraxas, which 
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are responsible for recruiting BRCA1 to DSBs, resulted in an increase in DNA end 
resection and HR [224, 232](unpublished results). Loss of RAP80 also correlates with 
an increase of RAD51 and CtIP at DSB resulting in excessive resection at DSB and 
gross chromosomal rearrangements [224]. This suggests that BRCA1 plays an 
important role in regulating the amount of HR that occurs at a DSB preventing genome 
instability. 
 All the known interactors of BRCA1 which are important in DNA repair, such as 
Abraxas, CtIP, PALB2 and RAD51, interact with the C-terminal BRCT domains of 
BRCA1 or in the case of RAD51, it is predicted to bind to a more central region of 
BRCA1. Although the RING domain of BRCA1 is important in DNA repair as it interacts 
with BARD1, the ubiquitin ligase function of BRCA1 appears to be dispensable for HR. 
As previously mentioned, the introduction of an I26A point mutation into the RING 
domain of BRCA1, which disrupts its E3 ubiquitin ligase function, had no effect on HR 
efficiency [172]. Although the ubiquitylation targets of BRCA1 BARD1 remain elusive, it 
has been suggested that H2A is a target. Chen et al. demonstrated that the N-terminus 
of BRCA1 containing its RING domain is required for the ubiquitylation of H2A and 
several groups have reported that loss of BRCA1 results in a decrease in ubiquitylated 
H2A [233-235]. CtIP has also been shown to be ubiquitylated by BRCA1 BARD1 both 
in vivo and in vitro and suggested that ubiquitylation of CtIP was required for its 
retention at DSB [236]. Earlier reports also demonstrated that the loss of BRCA1 
resulted in a reduction in ubiquitylation at DSB, suggesting a role for the BRCA1 
ubiquitin ligase function in the signalling cascade at sites of damage [121]. It would 
appear that although BRCA1s ubiquitin ligase function may contribute to ubiquitylation 
events at DSBs, its function is not vital to the repair process as defects in HR are not 
seen in the absence of BRCA1 ubiquitin ligase activity [172] and the majority of BRCA1 
function in HR can be attributed to its BRCT domains. 
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The role of BRCA1 in cell cycle checkpoint activation and regulation. 
In order to ensure that the cell proceeds through the cell cycle  without any DNA 
lesions or mutations, cell cycle checkpoints are used to monitor the chromatin and DNA 
status during various stages during the cell cycle [237]. After DNA damage it is 
important for the cell to activate cell cycle checkpoints to allow the cell time to repair 
the damage and also to prevent unrepaired damage being replicated resulting in the 
loss of genomic information or mutations in daughter cells [238]. Defects in cell cycle 
checkpoint proteins often results in developmental abnormalities, genome instability 
and cancer [239]. Cell cycle checkpoints can be classified as G1/S, S and G2/M 
checkpoints and BRCA1 is suggested to play a role in all checkpoints to maintain 
genome integrity in response to DNA damage. 
 Following DNA damage cells are arrested at the G1/S boundary by the G1/S 
checkpoint. This checkpoint prevents damaged DNA progressing into S phase and 
subsequent replication of damaged DNA. Fabbro et al demonstrated the importance of 
BRCA1 in the G1/S checkpoint as the loss of BRCA1 failed to arrest cells in on the 
G1/S phase boundary after DNA damage [240]. In this study it was demonstrated that 
in response to IR damage, BRCA1 was required for the phosphorylation of p53 by ATM 
which in turn lead to the G1/S checkpoint activation via p21 [240]. The tumour 
suppressor protein p53 plays a vital role in the G1/S checkpoint by regulating the 
transcription of p21, a cyclin inhibitor [241-243]. Shortly after the cloning of BRCA1, it 
was discovered that inhibition of BRCA1 resulted in the acceleration of growth in both 
WT and malignant cells [244]. It was believed that this was as a result of cell cycle 
control via BRCA1 and it was later established that the interaction between RB and 
BRCA1 was required to induce a G1/S arrest [245]. Aprelikova et al. demonstrated that 
BRCA1 BRCT domains interact with hypophosphorylated RB and that 
hypophosphorylated RB interacts with E2F inhibiting cell proliferation [245]. They 
suggested that the binding of BRCA1 to RB maintained RB in a hypophosphorylated 
state allowing it to interact with E2F.  
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 The S phase checkpoint is another cell cycle checkpoint which prevents S 
phase progression and replication directly in response to DNA damage [246]. Xu et al 
highlighted the involvement of BRCA1 in the S phase checkpoint after IR induced DNA 
damage. They showed that the S phase checkpoint was defective in the BRCA1 
mutant cell line HCC1937, and the introduction of functional BRCA1 restored the S 
phase checkpoint defect [134]. Defects in the S phase checkpoint are a common 
characteristic associated with defects in many DDR proteins such as ATM, ATR, Chk1 
and Chk2 [247-250]. After DNA damage, ATM and ATR are activated and are involved 
in regulating Chk1 and Chk2 activity which in turn leads to the regulation of cyclins and 
cyclin-dependent kinases (CDKs) [251]. Cyclins and CDKs are essential in the 
regulation of cell cycle progression.  Although the exact mechanism of BRCA1 function 
in S phase checkpoint is not clear, it has been suggested that BRCA1 regulates the 
Chk1 kinase activity and that BRCA1 phosphorylation by ATM /ATR is required for this 
function [252]. Phosphorylation of Ser1387 on BRCA1 by ATM is required for the S 
phase checkpoint [134] 
 The final checkpoint is the G2/M checkpoint which serves as a barrier to 
prevent damaged cells from entering mitosis and passing their damage on to a 
daughter cell. Late S and G2 phases of the cell cycle are also responsible for the most 
accurate type of DSB repair during the cell cycle. Arresting the cell in G2 phase allows 
the cell time to faithfully repair its damage before cell cycle progression. As with the 
G1/S and S phase checkpoints, the G2/M checkpoint is also activated in response to 
IR damage. Loss of functional BRCA1 has also been shown to abrogate the G2/M 
checkpoint [202]. As previously mentioned Chk1 and Chk2 are activated by ATM and 
ATR in response to damage which leads to the activation of the G2/M checkpoint by 
suppressing cyclin B and Cdc2 activity [253-256]. Similarly to S phase, BRCA1 
regulates the activity of Chk1 during the G2/M checkpoint [86]. In contrast to S phase 
checkpoint control, the ATM mediated phosphorylation of Ser1423 on BRCA1 is 
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required for G2/M checkpoint activation [86] suggesting that phosphorylation on 
different sites of BRCA1 may be key to the activation of different cell cycle checkpoints. 
The role of BRCA1 in transcriptional activation. 
Monteiro et al. discovered that BRCA1 could activate transcription in both yeast and 
mammalian cells [257]. They showed that the transcriptional activity of BRCA1 
depended on a region in its C-terminus (BRCT domains) which, when bound to a GAL4 
DNA binding domain, activated transcription. It was also demonstrated that the 
transcriptional role of BRCA1 was a key aspect of its tumour suppressor function as a 
point mutation associated with the BRCT domains of BRCA1, was commonly found in 
patients with early onset breast and ovarian cancer and were deficient in transcriptional 
activation [257]. Further evidence of the importance of BRCA1 transcriptional 
regulation in the prevention of cancer came from a study demonstrating that cancer 
prone point mutations in the BRCT domains of BRCA1 were often defective for both 
transcriptional regulation and growth control whereas neutral BRCA1 polymorphisms 
did not show the same defects [258]. 
 It is believed that the transcriptional role of BRCA1 is mainly due to its 
interaction with RNA polymerase II (RNA polII). BRCA1 was found to co-
immunoprecipitate with RNA polII holoenzyme complex via its association with RNA 
helicase A [259]. Cancer associated point mutation of BRCA1 were found to prevent 
the BRCA1-RNA polII interaction strengthening the belief that this interaction is 
important for tumour suppression [260]. As well as BRCA1s interaction with RNA polII, 
it has been demonstrated that BRCA1 regulates the phosphorylation of RNA polII by 
negatively regulating the phosphorylation of Cdk-activating kinase [261]. This function 
is believed to regulate cell cycle progression in response to DNA damage. Although 
BRCA1 has been shown to interact with RNA polII, it is not required for basal 
transcriptional function and it also doesn’t appear to be an essential component in the 
RNA polII holoenzyme complex. The biological relevance of BRCA1 and transcriptional 
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regulation remains unclear, however it is possible that it is only required in response to 
DNA damage. 
 As previously mentioned, BRCA1 interacts with the growth suppressor RB [262] 
under non-damaging conditions preventing the activation of p21. It is thought that in the 
presence of DNA damage, this interaction is abrogated which in turn allows the 
transactivation of p21mediated by BRCA1 [262]. p21 plays an important role in the 
arrest  of cells during the cell cycle in response to DNA damage allowing the cell time 
to repair its damage. As well as its interaction with RNA polII and RB, BRCA1 has also 
been shown to interact with a variety of transcription factors such as estrogen receptor 
α, p53 and STATI [263-265]. Through these interactions, BRCA1 is predicted to 
modulate transcription activation in response to DNA damage. 
The role of BARD1 in the DDR. 
Very little is known about the role of BARD1 in response to DNA damage apart from its 
functional role in stabilising BRCA1 in the nucleus and enhancing the E3 ubiquitin 
function of BRCA1. It is believed that all the tumour suppressor and DDR functions of 
BRCA1 depend on its interaction with BARD1. However there is evidence that BARD1 
may play a functional role in DNA repair independent of its role in stabilising BRCA1 as 
mutations in BARD1 independent of BRCA1 mutations have been discovered in a few 
breast and ovarian cancers [213, 214, 266]. Furthermore, another mechanism by which 
BARD1 is suggested to contribute to the tumour suppressor function of BRCA1 is 
through its interaction with the cleavage stimulation factor (CstF) [267]. It was 
discovered that CstF is required for 3’-terminal endonucleolytic cleavage of pre-mRNA 
a process fundamental to transcription [268]. BARD1 interacts with CstF via its ankyrin 
repeats and it has been speculated that this interaction is involved in DNA repair by 
preventing mRNA processing[267]. 
 Although there are no known proteins which interact with the BARD1 BRCT 
domains, studies revealed that the BRCT domains of BARD1 are important for the 
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repair of DNA DSBs via HR [266, 269] as the loss of the BARD1 BRCT domains 
resulted in defects in HR efficiency. It is evident that BARD1 contributes to genome 
stability and has a functional role in HR, however more research is needed to 
understand its contribution to the DDR and repair of DNA DSBs independent of its role 
in stabilising BRCA1. 
1.4.5 The role of PARP and PARP inhibitors in the repair of DSBs. 
The clinical relevance of PARP and PARP inhibitors in relation to BRCA1 and BRCA2 
defective breast and ovarian cancers came from the discovery that PARP inhibitors 
were selectively lethal to cells harbouring mutations or loss of BRCA1 and BRCA2 due 
to synthetic lethality [219, 270-272]. The potential of PARP inhibitors to kill BRCA1 and 
BRCA2 deficient cells arose from the rationale that cells with a defective HR repair 
pathway rely on single stranded break repair pathway to repair single stranded breaks 
which is dependent on PARP. However with the inhibition of PARP, single stranded 
breaks are not repaired and can lead to DSB through replication. Cells which are 
defective in HR and treated with PARP inhibitors are unable to repair damage 
efficiently resulting in cell death [270, 273]. As a result of this phenomenon, PARP 
inhibitors are commonly used as a research tool to assess the ability of a cell to carry 
out efficient HR. 
 Research over the past decade has illustrated the importance of Poly(ADP-
ribosyl)ation catalysed by the PARP1 enzyme as a fundamental post translational 
modification involved in the signalling, detection and repair of ssDNA breaks as well as 
DSBs. PARP1 catalyses the covalent attachment of PAR polymers onto histones, 
repair proteins and chromatin modulators as well as auto Poly(ADP-ribosyl)ation [274, 
275]. Parylation is a rapidly reversible process catalysed by PARG [276]. PARP1 plays 
an important role in DNA repair and binds to damaged DNA under conditions of 
genotoxic stress [274]. The main role of PARP1 in response to DNA damage is in the 
repair of single stranded breaks via both the base excision repair (BER) and single 
stranded break repair (SSBR) pathways after oxidative stress. PARP1 catalyses the 
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formation of long branched PAR chains on repair proteins involved in ssDNA breaks 
and these negatively charged polymers form a scaffold recruiting other critical repair 
proteins such as XRCC1 to sites of damage [277, 278]. 
 Although PARP1 is historically considered to be involved in the SSBR and BER 
repair pathways of ssDNA breaks, evidence is continuing to emerge on the importance 
of PARP1 in the repair of DSBs. PARP1 has since been shown to interact and 
cooperate with several key DSB repair proteins, namely ATM, DNA-Pkcs, Ku80 and 
the MRN complex [279-282]. Studied have revealed that loss of PARP1 results in a 
hyper-recombination phenotype leading to an increase in spontaneous sister chromatid 
exchange suggesting a regulational role for PARP1 in DSB repair [283, 284]. Bryant et 
al. have also contributed to the understanding of the role of PARP1 in DSB repair 
suggesting that PARP1 plays an important role in HR at HU induced collapsed 
replication forks [285]. Although the function of PARP and PARylation in DSBs is 
unclear, recent crystal structure analysis of PARP1 suggests that PARP1 can 
recognise and potentially bind DSBs [286]. Li et al proposed that PARylation at DSBs is 
required for the early recruitment of BRCA1 via the BARD1 BRCT domains to sites of 
damage [287] however the biological relevance of this observation is not known as 
BRCA1 still recruits to DSB independent of PARP1 later on in a γH2AX dependent 
manner [287]. Interestingly, PARP1 has also been recently shown to be involved in 
recruiting several chromatin remodelling proteins, such as CHD4 and MTA1 involved in 
DSB repair, to sites of damage [288]. 
 The collective evidence of the function of PARP1 clearly demonstrates that it 
plays many important roles in the repair of DNA damage, especially DSB repair, 
however more research is required to elucidate its mechanism and function in DSB 
repair. 
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1.5 The role of BRCT domains in DSB repair 
The BRCT domain was originally identified in BRCA1 and mutations in the BRCA1 
BRCT domains are associated with many breast and ovarian cancers [183, 184, 193]. 
Since their discovery, BRCT domains have been discovered in over 50 proteins, the 
majority of which are associated with DNA damage repair [289, 290]. Mutations in the 
BRCT domains of several other proteins apart from BRCA1, such as NBS1, NBN and 
MCPH1 have been found in cancer [291-293] which further highlight the importance of 
the BRCT domains in the DDR. BRCT domains are conserved and found in species 
ranging from bacteria to humans [289, 290]. Although they don’t have any intrinsic 
enzymatic activity, BRCT domains play a pivotal role in mediating phosphorylation 
dependent  protein-protein interactions essential for DNA repair and cell cycle 
checkpoint activation [291, 294-297].  
 The BRCT domains of BRCA1 and BARD1 appear to play an important role in 
HR. Loss of either the BARD1 or BRCA1 BRCT domains has been shown to abrogate 
HR indicating that [269, 298], at least for these two proteins, the BRCT domains are 
extremely important for faithfully repairing DSB. 
1.5.1 The structure and function of BRCT domains. 
The BRCT domains were first identified as a structural domain in the C-terminus of 
BRCA1 and the structural fold of a BRCT domain was revealed from crystallography 
studies carried out in XRCC1 [299]. The BRCT domain is relatively small containing 
between 90 and 100 amino acids [193]. BRCT domains are present in many scaffold 
proteins involved in DNA repair and cell cycle checkpoint control. BRCT domains are 
found as both single units and multiple units in proteins and the ability of BRCT 
domains to bind phosphorylated proteins has been shown in both single and tandem 
BRCT domains [300, 301]. For example, the tandem BRCT domains in BRCA1 
recognise the phosphorylated peptide motif pS-P-T-F found in three BRCA1 interacting 
proteins; Abraxas, FANCJ and CtIP [86, 133, 300-303]. It is believed that BRCA1s 
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ability to recognise and interact with different proteins involved in the DDR is 
fundamental to its function in DNA repair and is responsible for BRCA1 recruitment to 
sites of damage. The relevance and function of BRCA1 BRCT interacting proteins will 
be further discussed latter on in this chapter. 
 Although the main attribute of BRCT domains is their ability to bind 
phosphorylated proteins, it has recently become evident that their function is not 
exclusive to phospho-binding. BRCT domains have been shown to interact with 
proteins in a phospho-independent manner, bind DNA and also interact with PAR 
[304]. This highlights the diverse function and specificity of BRCT domains. The 
structure of a BRCT domain is a globular α/β fold. The fold contains a central 4-
stranded β-sheet flanked by a single α-helix on one side and 2 α-helices on the 
opposite side. This fold is conserved amongst the majority of BRCT domains and 
deviations in sequence and structure mainly occur in the connecting loops and linkers 
between BRCT domains. The most highly conserved regions within BRCT domains are 
found within regions responsible for binding a phospho-peptide and a hydrophobic core 
[291, 305].  
 Although the core structure of BRCT domains are well conserved between 
proteins, the domain architecture can be very varied. As well as the identification of 
single and tandem BRCTs in proteins, BRCT domains have also been shown to 
interact with other functional domains increasing their functional capacity and 
specificity. Single or isolated BRCT domains have been discovered in proteins such as 
PARP1 and DNA ligase III which contain only one BRCT domain. XRCC1 also contains 
single BRCT domains as the two BRCT domains in XRCC1 are separated by a long 
stretch of amino acids making both BRCT domains isolated from each other [299]. The 
ability of tandem BRCT domains to bind to phosphorylated proteins has been well 
established in terms of both structure and function however the phospho-binding ability 
of single BRCT domains remains unclear. Initial evidence that single BRCT domains 
can interact with phosphorylated peptides came from an in vitro study by Yu et al. 
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demonstrating that the single BRCT domains of yeast REV1 and Lig3 preferentially 
interacted with a phospho ligand library in comparison to a non-phosphorylated 
counterparts [301]. Crystal structure evidence from TopBP1 BRCT6 protein containing 
single BRCT domains, revealed that it lacked a functional phospho-binding pocket and 
therefore it was suggested that it could not bind phospho-peptides on its own [306]. 
Given the smaller surface area available for binding on a single BRCT compared to 
that of a tandem BRCT domain it is highly plausible that tandem BRCT domains are 
more efficient in their capacity to bind phosphorylated proteins. 
 The canonical structure and packing of  tandem BRCT domains was revealed 
through the crystallisation of the BRCA1 BRCT domains [307]. This study revealed that 
the packing of the tandem BRCT domain occurred through a hydrophobic interface 
involving the α2 helix from the N-terminal BRCT domain and the α1’ and α3’ helices 
located in the C-terminal BRCT domain. Since then, the conserved configuration of 
BRCT-BRCT domains has been observed in many other tandem BRCT containing 
proteins such as BARD1, MDC1 and the 7/8th BRCT domains in TopBP1 [308-311]. 
Their role in phospho-binding has been well established in comparison to single BRCT 
domains.  Interestingly, variations within tandem BRCT domains also exist as in the 
tandem BRCT domains of DNA ligase IV which do not fold together as the linker arm 
between the BRCT domains is distinctively longer than normal tandem BRCT domains. 
However it is due to this variation in structure that DNA ligase IV is able to bind its 
partner XRCC4 [297, 312]. In the case of NBS1, its tandem BRCT domains are 
coupled to its FHA domain which is suggested to attribute a higher level of complexity 
and specificity to the protein [221, 313]. 
 The crystal structure of tandem BRCT containing proteins such as BRCA1 and 
MDC1 bound to their phospho-ligands uncovered a bipartite recognition method 
conserved within the tandem BRCT domains required for phospho-ligand binding. The 
two regions responsible for binding were described as a pSer/pThr binding pocket in 
the N-terminal BRCT domain and a hydrophobic binding pocket in the interface of the 
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two BRCT domains (figure 1.7). The pSer pocket is believed to bind the 
phosphorylated Ser/Thr residue on the ligand whereas the hydrophobic pocket is 
expected to bind the peptide at the +3 position in respect to the pSer [116, 291, 310, 
314, 315]. The minimal requirement for recognition of a peptide by tandem BRCT 
domains is a pS/pT-X-X-X motif whereby the amino acid in position +3 dictates the 
majority of the binding specificity [316]. 
 As well as binding phospho-ligands, the tandem BRCT domains of BRCA1 and 
TopBP1 have been shown to bind DNA strand breaks and ends in vitro [317, 318]. The 
implication that proteins involved in the repair of DNA damage containing BRCT 
domains may be able to directly bind DNA ends offers the possibility that BRCT domain 
proteins may act as damage sensors as well as signal transduces.  
 
 
 
 
 
 
 
 
 
 
Figure 1.7 BRCT domain phospho-binding pockets 
Representative image of the two areas within the BRCA1 tandem BRCT domains which 
recognise a phosphorylated peptide. The phospho-serine binding pocket binds the pSer 
whereas the hydrophobic groove is responsible for binding the amino acid residue at position +3 
in relation to the pSer. Figure adapted from Williams et al 2004. 
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1.5.2 The BRCA1 BRCT domains. 
Truncations and missense mutations in the BRCT domains of BRCA1 are commonly 
associated with both breast and ovarian cancers highlighting their importance in the 
tumour suppressor function of BRCA1 [183, 184]. BRCA1 contains tandem BRCT 
domains in the C-terminus of the protein. As in most BRCT domains, the structure of 
the BRCA1 BRCT repeats consist of a central four stranded β-sheet flanked by three α-
helices [307, 319]. The two BRCA1 BRCT domains pack together in a head to tail 
manner to form one domain involving the α1 and α3 of the C-terminal BRCT domain 
and α2 of the N-terminal BRCT domain [307, 320]. Only the tandem BRCT domains of 
BRCA1 can bind phosphorylated peptides but not the singly isolated BRCT domains 
suggesting that the packing of the two BRCT domains is extremely important for 
binding. The hydrophobic interface between the two tandem BRCT domains is highly 
conserved in tandem BRCT domain containing proteins and has been shown to be 
extremely important in binding phospho-ligands. In agreement with this, several breast 
and ovarian cancers have been identified which contain the M1775R point mutation in 
the hydrobhobic interface of the tandem BRCT domains of BRCA1 [183, 184]. The 
phospho-binding pocket of BRCA1 is selective for pSer and is believed to interact with 
two side chains; S1655 and K1702 in the BRCA1 BRCT domains. The BRCA1 BRCT 
domains have been shown to selectively bind phosphorylated peptides containing a 
pS-P-T-F motif. BRCA1 interacts with pS-P-T-F motifs within Abraxas, CtIP and FANCJ 
and it is thought that the ability of BRCA1 to recognise and bind several different 
proteins involved in the DDR contributes to BRCA1 function in DNA damage and repair 
[86, 133, 300, 301, 303]. The M1775 residue within the hydrophobic binding pocket at 
the interface of the two BRCT domains of BRCA1 is believed to bind the 
phosphorylated peptide at position +3 in relation to the pSer.  
 BRCA1 BRCT domains interact with Abraxas, FANCJ and CtIP which are 
known to be important in the signalling and repair of DSBs. The interaction of BRCA1 
as part of the BRCA1 BARD1 heterodimer forms three mutually exclusive complexes 
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with these proteins called the BRCA1-A,-B and –C complex and the disruption of these 
complexes has been shown to increase sensitivity to IR and cause genome instability 
[321] (figure 1.8). Mutations in the BRCT domains of BRCA1, which are known to 
disrupt phospho-peptide interactions, have been shown to result in both hyper-
recombination by Dever et al. [321] and defects in HR by Shakya et al. [298]. Although 
the interaction between the BRCA1 BRCT domains and Abraxas, CtIP and FANCJ 
appear to be fundamental to the repair of DSBs and BRCA1 functions in the DDR and 
tumour suppression it remains unclear how these complexes function in the DDR. The 
BRCA1 complexes will now be discussed in terms of their potential function in the DDR 
and DSB repair. 
 
Figure 1.8 The BRCA1 -A, -B and –C complexes 
Graphic representation of the different components of the BRCA1 complexes. The BRCA1 
BARD1 heterodimer forms the integral core of all three complexes. Abraxas is the main protein 
to interact with BRCA1 in the BRCA1-A complex whereas FANCJ and CtIP interact with BRCA1 
to form the BRCA1-B and –C complexes. 
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The BRCA1-Abraxas interaction in the DDR.   
The BRCA1-A complex is known to contain at least five proteins including RAP80, 
Abraxas, MERIT40, BRE and BRCC36 [128-130, 132, 133, 302, 303]. Abraxas has 
been shown to interact with the BRCA1 BRCT domains through a phospho-Serine 
group in its C-terminus. The residue in Abraxas responsible for binding to BRCA1 is 
S406 [302]. Abraxas functions as an adapter protein which mediates the interaction of 
BRCA1 with the BRCA1-A complex and participates in recruiting BRCA1 to sites of 
damage. It appears that most of the BRCA1 complex members are important for 
maintaining BRCA1 at DSBs as a decrease in MERIT40 or BRE leads to a reduction in 
many BRCA1-A complex members and severely reduces the number of BRCA1 foci at 
sites of damage [322]. BRCA1 is recruited to sites of damage through the BRCA1-A 
complex as RAP80 recognises K63 ubiquitin chains covalently attached to histone 
H2AX [2, 323]. It is believed that one of the main functions of the interaction of BRCA1 
and Abraxas is to recruit BRCA1 to DSBs. It has been suggested that the function of 
the BRCA1-A complex at DSB is to regulate the amount of HR at sites of damage as 
loss of RAP80 and Abraxas results in aberrant hyper-recombination [224, 232]. 
 Ubiquitylation is a key regulatory mechanism in many cellular processes 
including the DDR [324, 325]. Ubiquitylation is a reversible process and de-
ubiquitylation at DNA DSBs is crucial to the regulation of signalling in the DDR. [326-
329]. Deubiquitinating enzymes (DUBs) catalyse the removal of ubiquitin from modified 
proteins. BRCC36 is a DUB found in the BRCA1-A complex and it has deubiquitylating 
activity specifically towards K63 linked chains [128, 330]. It is important to note that four 
members of the BRCA1-A complex have ubiquitin binding motifs. Although RAP80 is 
the only UIM containing protein in this complex with the ability to bind K63 ubiquitin 
chains, Abraxas, BRCC36 and BRE also contain MPN and UBC domains which can 
bind long poly ubiquitin chains [132]. Hence it is likely that the BRCA1-A complex is 
structured in a way which facilitates the DUB activity of BRCC36 attributing a possible 
regulatory role for the BRCA1-A complex in the repair of DSBs.  
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The BRCA1-FANCJ interaction in the DDR.   
FANCJ is a DNA helicase which interacts with the BRCA1 BRCT domains in a cell 
cycle dependent manner. During S-phase the C-terminal region of FANCJ, Ser990, 
becomes phosphorylated and interacts with BRCA1 [294, 301, 331]. It has previously 
been demonstrated that FANCJ is required for progression through S-phase and for 
the checkpoint accumulation of cells in G2 in response to DNA damage [86, 301, 332]. 
FANCJ is involved in the replication stress induced checkpoint via its interaction with 
TopBP1 [333]. As well as interacting with BRCA1, FANCJ has also been shown to be a 
member of the Fanconi anaemia complex. Loss of any of the Fanconi anaemia proteins 
results in the genetic disorder Fanconi anaemia which is associated with several 
developmental defects and an increased risk of malignancies due to an increased 
sensitivity to crosslinking agents [331, 334-338]. 
 In vitro studies have shown that FANCJ is an ATP dependent helicase which 
preferentially unwinds DNA in a 5’-3’ direction. FANCJ binds and unwinds DNA 
substrates that share great similarities with an intermediate step during HR [339, 340]. 
FANCJ has been shown to be required for HR in human cells as loss of FANCJ results 
in defective HR and chromosome instability after damage by intercrosslinking agents 
[331]. DT40 cells lacking FANCJ are extremely sensitive to intercrosslinking agent and 
show genome instability after damage, however they do not exhibit the same HR 
defects seen in human cells with the loss of FANCJ [331, 341]. This may be partially 
due to the fact that avian FANCJ lacks the Ser990 residue which interacts with BRCA1 
hence in DT40 cells, BRCA1 and FANCJ do not interact (Sequence alignment in 
PubMed). Although the exact function and mechanism remains unclear, it is believed 
that BRCA1-FANCJ are essential for DNA repair especially during replication repair, 
checkpoint activation and tumour suppression [301, 342, 343]. 
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The BRCA1-CtIP interaction in the DDR.   
The BRCA1-C complex contains the MRN complex as well as CtIP. The formation of 
this complex is cell cycle dependent and interacts during S and G2 phase where the 
BRCT domains of BRCA1 interact with the phosphorylated Ser327 residue on CtIP [86, 
87]. As previously discussed, CtIP plays a crucial role in the end resection at DSBs, an 
early requirement for HR [55, 222]. By interacting and stimulating the nuclease activity 
of the MRN complex, CtIP promotes HR by end resection. The requirement of BRCA1 
to interact with CtIP for efficient repair of DSBs by HR remains controversial. Work 
carried out by Yun et al, in DT40 cells harbouring a CtIP mutant unable to interact with 
BRCA1 suggested that this interaction was necessary for HR [344]. However further 
studies carried out by Reczek et al, and Nakamura et al, suggests that this interaction 
is not required for HR repair [225, 345]. Much further research is required to investigate 
the functional relevance of the BRCA1-CtIP interaction.   
 The biological and functional relevance of the BRCA1 complexes remains 
somewhat unclear in relation to the function of BRCA1 in the repair of DSBs via HR. 
However, the fact that many breast and ovarian cancers contain point mutations in the 
BRCA1 BRCT domains preventing phospho-protein binding clearly highlights the 
importance of these interactions as there are no other proteins known to interact with 
the BRCA1 BRCT domains. Evidence suggesting that loss or point mutations in the 
BRCT domains of BRCA1 show defects in HR augments the importance of the BRCA1 
BRCT domains in DSB repair. 
1.5.3 The BARD1 BRCT domains. 
The crystal structure of BARD1 BRCT domains were elucidated by Birrane et al. in 
2007 [311]. The BRCA1 and BARD1 BRCT domains are structurally very similar. 
BARD1 also contains tandem BRCT domains at the C-terminus of the protein which 
are predicted to bind phospho-peptides. The crystal structure of BARD1 BRCT 
domains revealed a very similar fold with those of BRCA1 and MDC1 with a central 
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four stranded β-sheet flanked by three α-helix. As in the tandem BRCA1 BRCT 
domains the two BRCT domains are linked by a central α-helix [311].  It is of note that 
no phosphorylated peptides are known to interact with the BARD1 BRCT domains 
however, using a synthetic peptide library it was predicted that the BARD1 BRCT 
domains recognise ligands with the following motif; pSer-D/E-D/E-E [346] which is 
different to that of BRCA1. The two BRCT domains are closely packed revealing a 
potential phospho-protein interacting pocket and a hydrophobic pocket suggested to 
bind a ligand at the +3 position. The phospho-binding pocket is formed from Ser575, 
Gly576, Thr617 and Lys619 residues which structurally conform to the standard 
binding pocket in BRCA1. The hydrophobic pocket at the interface of the two BARD1 
BRCT domains is lined with Ser616, Met621, His685, His686, and Ile764 residues. 
His686 in the BARD1 BRCT domains corresponds with Met1775 in the BRCA1 BRCT 
domains and is predicted to be responsible for interacting with the ligand at the +3 
position in relation to the pSer. Interestingly the hydrophobic pocket has a negative 
electrostatical potential at neutral pH and requires a more acidic environment to 
protonate His686 and positively charge the hydrophobic pocket. This suggests that the 
potential of BARD1 BRCT domains to bind a ligand may be greatly influenced by local 
changes in pH [311]. 
 Although the BARD1 BRCT domains have not been shown to interact with any 
proteins to date, the importance of the BARD1 BRCT domains is highlighted in several 
breast and ovarian cancers which carry mutations and truncations  in the BARD1 
BRCT domains [213, 214, 266]. Further evidence of the importance of the BARD1 
BRCT domains in the DDR was evident from studies carried out by Westermark et al. 
and Laufer et al. which demonstrated that in the absence of the BARD1 BRCT domains 
HR was severely compromised [266, 269]. Interestingly Li et al have very recently 
shown that the BARD1 BRCT domains are important for the very early recruitment of 
BRCA1 and BARD1 to DSBs initiated by the interaction of the BARD1 BRCT domains 
with PAR [287]. This work suggests a functional role for the BARD1 BRCT domains in 
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recruitment at DSBs. However, the functional relevance of this process remains to be 
determined.   Very little is known about the BARD1 BRCT domains or their function in 
the DDR however this evidence strongly implicates a role for the BARD1 BRCT 
domains in the faithful repair of DSBs via HR. 
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1.6 Aims 
The aim of this thesis is to investigate the contribution of the BARD1 BRCT domains in 
the DDR. Using Bard1 DT40 cell lines reconstituted with BARD1ΔBRCT, the first aim is 
to confirm their role in HR using Homologous recombination assays and assess their 
sensitivity to DNA damaging agents. As BARD1 is bound to BRCA1 in the BRCA1 
complexes, the contribution of the BARD1 BRCT domains in the formation of the 
BRCA1 complexes will be investigated. Recent evidence suggests that the BARD1 
BRCT domains are important for the early recruitment of BRCA1 to DNA damage sites, 
this suggests that the BARD1 BRCT domains may be important for localisation to 
DSBs. The function of the BARD1 BRCT domains in relation to localisation to DSBs 
within the cell will be studied using both live microscopy recruitment to sites of damage 
and fixed cell microscopy. BRCT domains serve as phospho-interacting domains, 
however there are no known proteins which interact with the BARD1 BRCT domains. 
This thesis will also attempt to elucidate any potential BARD1 BRCT domain interacting 
proteins which could implicate a functional role for BARD1 in response to DNA 
damage. 
 In the final results chapter of this thesis the functional role of the ubiquitin 
ligases RNF8 and RNF168 in the signalling at DNA DSBs will be investigated. This will 
be carried out by identifying point mutations in the RING domains of RNF8 and 
RNF168, which render the proteins ubiquitin ligase dead, and assessing the 
contribution of the ubiquitin ligase activity of both proteins to the DDR. 
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Chapter 2 Materials and Methods  
Materials 
2.1 General reagents and Buffers 
2.1.1 General Reagents 
Company Catalogue # Product 
VWR UK A1493.0010 Kanamycin [10g] 
Melford A0104 Ampicillin [25g] 
SIGMA C0378-25G Chloramphenicol [25g] 
In house Core reagent Lysogeny broth (LB) 
UK VWR 28029.260 di-Sodium hydrogen phosphate 2.H2O  
UK VWR 103156X Tris Base  
UK VWR 27810.295 Sodium Chloride  
UK VWR 443852A Dithiothreitol (DTT) 
UK VWR 436992S Magnesium Chloride  
UK VWR 24387.292 Glycerol  
UK VWR 20302.260 EDTA disodium salt 2.H2O  
Melford Labs E1102 EGTA  
UK VWR 28829.296 Tween 20  
UK VWR 28244.262 Sodium Hydroxide Pellets  
UK VWR 20821.330 ethanol 
UK VWR 20104.334 Acetic acid (glacial) 100% (17.4M)  
SIGMA 09830-500G Ammonium hydrogen carbonate  
UK VWR 22317.26 Calcium Chloride 2.H2O  
UK VWR 22711.244 Chloroform 
Melford Labs B2001 HEPES  
UK VWR 20254.401 Hydrochloric acid 32 % (10.2M)  
Sigma Aldrich I8896-100ML Igepal CA630 (NP40) 
Melford Labs B2004 PIPES  
UK VWR 26764.260 Potassium Chloride  
UK VWR 20842.330 2-Propanol (iso-propanol) 
UK VWR 27727.231 di-Sodium tetraborate decahydrate  
UK VWR 27778.260 Sodium Bicarbonate  
UK VWR 441514A Tris Hydrochloride  
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UK VWR 28817.295 Triton X 100 
SIGMA B5002-100MG BrdU 
Qiagen 19101 RNase A (100mg/ml)  
Melford Labs Y1333 Yeast Extract [500g] 
Melford Labs T1332 Tryptone 
Roche Applied 
Science 
05892970001 c0mplete ULTRA, mini, EASYpack [30 
tablets] 
Roche Applied 
Science 
04906837001 PhosStop [20 tablets] 
Fisher PN87785 Halt Protease Inhibitor Cocktail, 
EDTA-Free (100X)  [1ml] 
Fisher PN78420 Halt Phosphatase Inhibitor Cocktail 
(100X) [1ml] 
UK VWR 70746-3 Benzonase [10K Units] 
Fisher PN88701 Universal Nuclease for Cell Lysis  
SIGMA T1895 Thymidine 
 
2.1.2 General Buffers 
Binding Buffer 40mM Imidazole, 20mM HNa2PO4, 500mM NaCl. 
Elution buffer 500mM Imidazole, 20mM HNa2PO4, 500mM NaCl 
Dialysis Buffer 500mM NaCl, 50mM Tris-CL, 2mM DTT 
MOPS Buffer 50 mM MOPS, 50 mM Tris Base, 0.1% SDS, 1 mM EDTA, pH 7.7 
Transfer Buffer 1x NuPAGE® Transfer Buffer, 10-20% Methanol, 1x Antioxidant  
TEA ubiquitin 
ligase buffer 
Triethanolamine 
50X TAE buffer 2M Tris-Base, 1M Acetic acid, 50mM EDTA 
SOC 0.5% Yeast Extract, 2% Tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM 
MgCl2, 10 mM MgSO4, 20 mM Glucose 
Lysis Buffer 20mM Tris-Base (pH 7.5), 0.14M NaCl, 10% v/v glycerol, 0.01% v/v 
NP40, 2mM MgCl2, 1X protease and phosphotases, Benzonase 
50U/ml 
Wash Buffer 50mM Tris-Base (pH 7.5), 0.5M NaCl, 20mM EGTA, 1% v/v Triton X, 
1X protease and phosphotases. 
Isotonic lysis 
buffer 
10 mM Tris HCl pH7.5, 2 mM MgCl2, 3 mM CaCl2, 320 mM sucrose, 
1 mM DTT, 1x protease inhibitor cocktail 
Extraction 20 mM HEPES pH 7.7, 1.5 mM MgCl2, 420 mM NaCl , 0.2 mM EDTA, 
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buffer 25% glycerol, 1 mM DTT, 1x protease inhibitor cocktail 
Ce buffer 10mM HEPES, 60mM KCl, 1mM EDTA, 0.075% NP40, 1mM DTT, 1X 
protease and phosphotases 
NE buffer 20mM Tris-Base, 420mM NaCl, 1.5mM MgCl2, 0.2mM EDTA, 25% v/v 
glycerol, 1X protease and phosphotases 
Blocking Buffer 0.5% v/v Tween, 1% w/v BSA in PBS 
CSK Buffer 0.1M NaCl, 0.3M Sucrose, 10mM PIPES (pH7), 3mM MgCl2, 1mM 
EGTA 
 
 
2.2 Molecular Biology Methods 
2.2.1 DNA extraction and purification 
UK VWR VWRID6943-02 E.Z.N.A. Plasmid Miniprep Kit I (V-Spin) 
UK VWR VWRID6942-02 E.Z.N.A. Plasmid Miniprep Kit I (Q-Spin) 
UK VWR VWRID6905-03 E.Z.N.A. Fastfilter Plasmid Midiprep Kit 
UK VWR VWRID6915-03 E.Z.N.A. Fastfilter Endo-free Midiprep Kit  
UK VWR VWRID6924-03 E.Z.N.A. Fastfilter Plasmid Maxiprep Kit  
UK VWR VWRID5032-03 EZNA SQ Blood DNA Purification Kit 
UK VWR VWRID2500-01 EZNA Gel Extraction Kit (V-Spin)  
UK VWR VWRID6294-01 EZNA MicroElute Gel Extraction Kit (V-Spin)  
UK VWR VWRID6492-01 EZNA Cycle Pure Kit (V-Spin)  
UK VWR VWRID6293-01 EZNA MicroElute Cycle Pure Kit (V-Spin) 
UK VWR VWRID6296-01 EZNA MciroElute DNA Clean-up Kit (V-Spin) 
Qiagen 12163 QIAGEN Plasmid Maxi Kit 
 
2.2.2 Restriction endonuclease digests. 
DNA digestions were carried out using either New England Biolabs digestion enzymes 
or Fermentas Fast digest enzymes.  
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2.2.3 DNA Ligations 
Fisher FQ-K1422 Rapid DNA Ligation Kit   
 
2.2.4 Bacterial Transformations 
Invitrogen 18265-017 Subcloning Efficiency DH5α Competent Cells 
   
2.2.5 Plasmids and primers used 
Plasmids 
Plasmid name Source 
pcDNA5 FRT TO N GFP John Rouse 
pcDNA5 FRT TO delBRCT hBARD N GFP John Rouse 
pcDNA5 FRT TO hBARD N GFP John Rouse 
pOG44 John Rouse 
pSV2-Fok1mCherryLacI Rodger Greenberg 
pSV2-Fok1D450AmCherryLacI Rodger Greenberg 
pEYFP C1-ggRNF168 Vibe Oestergaard 
pEGFP C1-hsRNF8 Vibe Oestergaard 
PcB/His BARD1 K619M Created in Lab 
PcB/His BARD1 S575F Created in Lab 
PcB/His BARD1 S575F/K619M/H686R Created in Lab 
PcB/His BARD1 del BRCT Created in Lab 
PcB/His BARD1 FL Created in Lab 
PcB/His BRCA1 M1775R Created in Lab 
PcB/His BRCA1 K1702M Created in Lab 
PcB/His BRCA1 S1655F Created in Lab 
PcB/His BRCA1 del BRCT Created in Lab 
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PcB/His BRCA1 FL Created in Lab 
PcB/His BARD1 H686R Created in Lab 
pcDNA5 FRT TO hBARDS575F/K619M/H686R N GFP Created in Lab 
pcDNA5 FRT TO hBARDS575F N GFP Created in Lab 
pcDNA5 FRT TO hBARDK619M N GFP Created in Lab 
pcDNA5 FRT TO hBARDH686R N GFP Created in Lab 
pcDNA5 FRT TO hBARDS575F/H686R N GFP Created in Lab 
pcDNA5 FRT TO hBARDS575F/K619M N GFP Created in Lab 
pcDNA5 FRT TO hBARDK619M/H686R N GFP Created in Lab 
pcDNA5 FRT TO hBARDL107P N GFP Created in Lab 
pM3Not hBARDdeltaBRCT Created in Lab 
pM3Not hBARDS575F/K619M/H686R Created in Lab 
pM3Not hBARDS575F Created in Lab 
pM3Not hBARDK619M Created in Lab 
pM3Not hBARDH686R Created in Lab 
pM3Not hBARDL107P Created in Lab 
pM3Not hBRCA1S1655F/K1702M/M1775R Created in Lab 
pM3Not hBRCA1S1655F Created in Lab 
pM3Not hBRCA1K1702M Created in Lab 
pM3Not hBRCA1M1775R Created in Lab 
pM3Not hBRCA1S1655F/M1775R Created in Lab 
pM3Not hBRCA1K1702M/M1775R Created in Lab 
pM3Not hBRCA1S1655F/K1702M Created in Lab 
pVP16 Abraxas Created in Lab 
pVP16 Abraxass406a Created in Lab 
eGFP-hsRNF8i405a Created in Lab 
eYFP-ggRNF168i18a Created in Lab 
POPTH RNF8 Created in Lab 
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POPTH RNF8i405a Created in Lab 
POPTH RNF168 Created in Lab 
POPTH RNF168i18a Created in Lab 
pM3 Not Clontech 
pVP16 Clontech  
pM3Not - hs BARD1 Created in Lab 
pM3Not - hs BRCA1 BRCT (4585-5589) Created in Lab 
pM3Not - hs BARD1 (aa 1-119) Created in Lab 
pVP16- Y3Not - hs BRCA1 (aa 1-109) Created in Lab 
pVP16-Y3Not - hs BACH1 aa 888- 1249 Created in Lab 
pVP16-Y3Not - hs BRCA1 big RING (aa 1- 250) Created in Lab 
pM3Not - hs BARD1 big RING (aa 14- 186) Created in Lab 
pVP16-Y3Not - hs FANCJ S990D Created in Lab 
pVP16 -Y3 - hs CtIP Created in Lab 
pVP16- Y3 - A hs CtIP S327A Created in Lab 
pVP16-Y3Not - hs FANCJ Created in Lab 
p- ISce I expression vector Created in Lab 
Table 2.1 Plasmids generated and used. 
 
Primers 
EcoRI miBrca1 R TACAGAATTCAGCCTTTTCTACATTCATTCTG 
BRCA2R EcoRV GATCGATATCTTAGAGCTCCTCTTGAGATGGGTAGTT 
BRCA1R EcoRV GATCGATATCTCAGTAGTGGCTGTGGGGGAT 
BRCA1F Acc651 GATCGGTACCGCCACCATGGATTTATCTGCTCTTCG 
BRCA1F BsiWI GATCCGTACGGCCACCATGGATTTATCTGCTCTTCG 
BARD1 Kpn1 1R ATAGGTACCTCAGCTGTCAAGAGGAAGCAACTC 
BARD1delpm3f ATCTGTCGACCATGCCGGATAATCGGCAGCCG 
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BARD1delpm4R ATCTCTAGAATCAATCCCTACGCTGCCCAGTGTTC 
delta BARD1 1R ATACCCGGGTCAATCCCTACGCTGCCCAGTGTT 
ggBARD1 1R CTGGCAATTGGGTTACTACCAGGG 
ggBARD 1F GGTGCAAGACATGCAGATAAACCG 
hsBARD1 1R TTCACAGCCATATTGGGCAACAG 
hs BARD1 1F TGTGGTTTAGCCCTCGAAGTAAGAA 
BRCA1 S1655F AAAGAATGTCCATGGTGGTGTTTGGCCTGACCC 
BRCA1 M1775R GCTATGGGCCCTTCACCAACAGGCCCACAGATC 
BRCA1 K1702M TGTGTGTGAACGGACACTGATGTATTTTCTAGGAATTGCGGG 
BARD1 H686R GGGAACCTTCAAACACCGTCCAAAGGACAACCTTA 
BARD1 S575F GACCTCTTGTACTTATAGGCTTTGGGCTGTCTTCAGAACAAC 
BARD1 K619M GCAGTTCAAAGTACCTTGATGTGTATGCTTGGGATTCTC 
BARD1L107P R CAAATTTCGAAGCTTACTACAAGGTTGAATCATGCTGTCCAGTTG 
BARD1L107P F CAACTGGACAGCATGATTCAACCTTGTAGTAAGCTTCGAAATTTG 
VO233 TTAGGCATTGCTCTGCTGAGGTTTTGC 
VO230 CCTCTTTTTCCCACGTTCCTGTCTCC 
VO231 GAATTACAGATGGTATGGTTGCACGGC 
VO232 ACACGCTCTCTGGTGCTGGATAACTGC 
ggRNF168 cD 1R CAAGAACCTTTCCGACCCTTGTGG 
ggRNF168 cD 2F GAGGTCTTTGTGGAGCCCGTGAC 
RNF8 2R cD GCAATTGTCCAGAACCAAAGAGTACGT 
RNF8 cD 1F TCTGCCCCCTGATGATTTCTCGA 
mutIggRNF168 1R AGGAATCTACTGACGGAGACGGTTCGAACGTACCTCCAG 
mutIggRNF168 1F TCCTTAGATGACTGCCTCTGCCAAGCTTGCATGGAGGTC 
ABRAs406a 1R CCGCTCAAAATGTAGGAGCCCGTGAATATTCACCAAA 
ABRAs406a 1F TTTGGTGAATATTCACGGGCTCCTACATTTTGAGCGG 
hRNF8 1F CATAGATCTGGGGAGCCCGGCTTCTTCG 
hRNF8 1R GATGGTACCCGGTCTTCAGAACAATCTCTTTGC 
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hRNF8dI-1R(mut) TGAAGTATTCTGAACAAGCAATACATTGGAGCTCATTCTCTAGCACATCAT 
hRNF8dI-1F(mut) ATGATGTGCTAGAGAATGAGCTCCAATGTATTGCTTGTTCAGAATACTTCA 
Table 2.2 List of Primers used 
 
2.2.6 RNA and cDNA preparation and amplification 
AMS Bio CS-104B RNA Bee [100ml] 
UK VWR VWRIPR032 DEPC Treated Water (RNase free)  
Fermentas K1631 RevertAidTM H Minus First Strand cDNA 
Syntheis Kit 
Fermentas K1651 Maxima H Minus First Strand cDNA Synthesis 
Kit  
UK VWR 22711.244 Chloroform  
 
2.2.7 Polymerase Chain reaction (PCR) 
Fermentas R0192 dNTP Mix, 10mM each  
Fermentas EP0702 DreamTaqTM DNA Polymerase (5u/μl) 
Fermentas EP0712 DreamTaqTM Green DNA Polymerase (5u/μl)  
Fermentas F-530S Phusion® High Fidelity DNA Polymerase  
Star Lab UK A1402-3700 8 Strip PCR Tube (0.2ml) 
 
2.2.8 Site directed mutagenesis 
Agilent 
(Stratagene) 
210518 QuikChange Lightening Mutagenesis Kit  
Agilent 
(Stratagene) 
210515 QuikChange Lightening Multi Mutagenesis Kit 
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2.2.9 DNA Agarose gels electrophoresis 
UK VWR 730-2961 GelGreen Nucleic Acid Stain in water (10,000x)  
Fermentas SM0242 GeneRulerTM 100bp DNA Ladder   
Fermentas SM0311 GeneRulerTM 1kb DNA Ladder   
Melford  MB1200 Agarose  
 
 
2.3 Protein methods and Biochemical Materials 
2.3.1 Protein quantification by Bradford assay 
Perbio 
Science 
23200 Coomassie (Bradford) Protein Assay Kit 
VWR UK 634-2501 1.5-3.0 ml Semi Micro Cuvettes (PS) - 340-900 nm  
 
 
2.3.2 Polyacrylamide gel electrophoresis (PAGE) 
Invitrogen NP0335BOX NuPAGE® Novex® 4-12% Bis-Tris Gel 1.5 
mm, 10 well 
Invitrogen NP0004 NuPAGE® Sample Reducing Agent (10X) 
Invitrogen NP00061 NuPAGE® Transfer Buffer (20X) 
Invitrogen NP0005 NuPAGE® Antioxidant 
Invitrogen NP0008 NuPAGE® LDS 4X LDS Sample Buffer 
Fisher Scientific PN26634 SpectraTM Multicolor Broad Range Protein 
Ladder   
Perbio Science 26625 SpectraTM Multicolor High Range Protein 
Ladder   
Perbio Science 26628 SpectraTM Multicolor Low Range Protein 
Ladder   
Fermentas R0571 PageBlueTM Protein Staining Solution   
Perbio Science 26616 PageRulerTM Prestained Protein Ladder   
Perbio Science 26614 PageRulerTM Unstained Protein Ladder   
UK VWR 0670-500G MOPS  
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2.3.3 PAGE staining 
Perbio Science 24612 GelCode SilverSNAP Stain Kit II  
Thermo  24620 PageBlue Protein Staining Solution 
 
 
2.3.4 Western Blotting 
SevernBiotech 40-2010-01 10% Sodium Azide  
Perbio Science 23228 BCA Protein Assay Reagent A  
Perbio Science 23224 BCA Protein Assay Reagent B  
Perbio Science 32106 Pierce ECL Western Blotting Substrate   
Konica Minolta A9KN A Plus Medical Film - 18x24cm  
UK VWR 730-3230 Kodak Biomax MS-1 X ray Film  
UK VWR 730-3241 Kodak BioMax MR-1 X ray film  
Labtech  Ltd. CAXOSGK01824 Type B X ray Cassette - 18 x 24 cm 
Labtech  Ltd.  1212604 Pure Nitrocellulose Supported - 0.45µm 
Millipore IPFL00010 Immobilon-FL PVDF Transfer Membrane 
Insight 
Biotechnology 
sc-2955 Chicken anti-rabbit IgG-HRP  
Insight 
Biotechnology 
sc-2371 Bovine anti-mouse IgG-HRP 
Insight 
Biotechnology 
sc-2313 Donkey anti-Rabbit IgG-HRP  
Insight 
Biotechnology 
sc-2005 Goat anti-Mouse IgG-HRP  
Insight 
Biotechnology 
sc-2020 Donkey anti-goat IgG-HRP  
Insight 
Biotechnology 
sc-2064 Goat anti-mouse IgM-HRP  
LI-COR 926-68071 IRDye 680RD Goat anti-Rabbit IgG 
LI-COR 926-32210 IRDye 800CW Goat anti-Mouse IgG  
LI-COR 926-68074 IRDye® 680RD Donkey anti-Goat IgG  
 
63 
 
Anitodies for Western blot and microscopy 
Antibody Dilution Source 
CHD4 (Mouse) 1:1000 Abcam (ab54603) 
HUWEI (Rabbit) 1:1000 Bethyl (A300-486A) 
Abraxas (Rabbit) 1:500 Bethyl (A302-180A) 
RbBP7 (Rabbit) 1:1000 Bethyl (A300-959A) 
MTA2 (Rabbit) 1:1000 Bethyl (A300-395A) 
UBC9 (Rabbit) 1:200-500 Abgent (AP1064a) 
LSD1 (Rabbit) 1:1000 Abcam (ab17721) 
ARF1 (Rabbit) 1:1000 Abcam (ab32524) 
GAPDH (Mouse) 1:2000 Gene Tex (GTX627408) 
CtIP (Goat) 1:500 Santa Cruz (sc-5970) 
CtIP (Rabbit) 1:500 Bethyl (A300-488A) 
FLAG® M2 (Mouse) 1:1000 Sigma (F1804-1MG) 
Fancj (Mouse) 1:1000 R&D systems (MAB6496) 
BRCA1 (Rabbit) 1:500 Santa Cruz (sc-642) 
BRCA1 (Mouse) 1:200 Calbiochem (OP92-100UG) 
BARD1 (Rabbit) 1:500 Santa Cruz (sc-11438) 
GFP (Mouse) 1:1000 Santa Cruz (sc-53882) 
Histone H2A (Rabbit) 1:1000 Abcam (ab13923) 
P84 (Mouse) 1:1000 GeneTex (GTX70220) 
His-probe (Rabbit) 1:1000 Santa Cruz (sc-803) 
RAD51 (Ab-1) (Rabbit) 1:300 Calbiochem (PC130) 
RPA (Ab-2) (Mouse) 1:300 Calbiochem (NA18) 
Phospho H2AX (Mouse) 1:500 Millipore (05-636) 
Phospho H2AX (Rabbit) 1:500 Millipore (07-164) 
Table 2.3 List of Antibodies  
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2.3.5 Protein Purification 
GE Healthcare 17-5286-01 HisTrap FF crude column 5mls 
Life 
Technologies 
C6000-03 BL21(DE3) Chemically Competent E. coli 
Fermentas R0391 IPTG [1g] 
UK VWR 286874D Imidazole  
Fisher PN87785 Halt Protease Inhibitor Cocktail, EDTA-Free  
Perbio Science 87731 Slide-A-Lyzer G2 Dialysis Cassettes, 10K 
MWCO, 15mL 
 
2.3.6 Ubiquitin ligase activity assay 
Perkin Elmer NEX404010UC I-125 Ubiquitin [10μCi/100μl] 
GE Healthcare 27-1006-01 ATP 
Sigma U5507-1MG Ubiquitin 
New England 
Biolabs 
M2502S Histone H2A Human (1mg/ml) 
New England 
Biolabs 
M2505S Histone H2B Human (1mg/ml) 
New England 
Biolabs 
M2503S Histone H3.1 Human (1mg/ml) 
New England 
Biolabs 
M2504S Histone H4 Human (1mg/ml) 
Boston Biochem U-100H Human Recombinant Ubiquitin 
Boston Biochem E-305 Ubiquitin Activating Enzyme (UBE1) 
Boston Biochem E2-616 UbcH5a/UBE2D1 
 
2.3.7 Mammalian two hybrid analysis 
Dual-Luciferase® Reporter Assay System 
Promega E1910 Dual-Luciferase® Reporter Assay System 
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2.3.8 GFP Pull down 
Thermo 
scientific 
22585 DSP(Dithiobis[succinimidyl propionate]) 
Chromotek gta-20 GFP-Trap® coupled to agarose beads 
Cambio CA-1713-2105 Agarose beads 2% cross-linked 
SIGMA T7660-5G Tetracycline HCl [5g] 
 
2.4 Cell Culture Materials 
2.4.1 Tissue Culture 
SIGMA C5405-500ML Chicken Serum  
BIOSERA S07859S180T/500 FBS, Tet Free, EU Approved  
BIOSERA FBS-6911-
BRI10700 
FBS, EU Approved  
BIOSERA FBS-8033-
BRI10700 
FBS, EU Approved  
SIGMA D2650-100ML DMSO - Tissue Culture Grade  
SIGMA T4049-500ML 1 x Trypsin-EDTA  
Invitrogen 15070063 Penicillin-Streptomycin, liquid 
(5000U/ml) 
Invitrogen 31985047 Opti-MEM® I Reduced Serum Medium 
Invitrogen  41966029 DMEM media 
Invitrogen 21875034 RPMI 
UK VWR 479-3200 Mr Frosty  [1/box] 
Roche Diagnostics 05651786001 CASY Clean [3 x 500ml] 
UK VWR HECH1102/1 Medicine Cup - 30ml Clear [800] 
UK VWR HECH1102/15 Medicine Cup Lid [1000] 
Roche Diagnostics 05651808001 Casyton [10l] 
UK VWR 391-8845 10 Cryovials [200/box] 
SOURCE 
BIOSCIENCE 
ant-gn-1 G418 (Neo) [10mls (100mg/ml)] 
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2.4.2 DT40 Transient transfection 
LONZA VCA-1002 Amaxa Nucleofection Kit T (DT40) [25 rxn] 
Equipment; Lonza; Nucleofector™ 2b Device 
2.4.3 DT40 Stable transfection 
UK VWR 732-2269 Electroporation Cuvette - 4mm [50] 
Equipment; Bio-rad; Gene Pulser® II 
2.4.4 Transient and stable transfection of adherent cells (human) 
Roche Applied 
Science 
06366236001 X-tremeGENE HP Transfection Reagent  
Roche Applied 
Science 
06365779001 X-tremeGENE 9 Transfection Reagent  
SIGMA C7983-50EA Cloning Cylinder - 4.5mm  
SIGMA Z273554-1EA Dow Corning® high-vacuum silicone grease  
SIGMA Z374458-100EA Cloning Discs - 5mm [100/pkt] 
SOURCE 
BIOSCIENCE 
ant-hg-1 Hygromycin B (☠) [10mls (100mg/ml)] 
 
2.4.5 Colony survival assay 
Invitrogen 32500043 DMEM/F-12 Powder with Glutamine  
SIGMA M0512-500G Methylcellulose 4000cP  
Life Technologies 25080060 Sodium Bicarbonate 7.5% solution 
Axon Medchem Axon 1464 Olaparib  
UK VWR 400046-5 Hydroxyurea  
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2.4.6 siRNA knockdown in human cells 
Thermo Scientific T-2001-02 DharmaFECT 1 Transfection Reagent 
Thermo Scientific  L-003461-00-0005 ON-TARGETplus Human BRCA1 (672) 
siRNA - SMARTpool 
 
2.5 Flow cytometry methods 
2.5.1 Flow cytometry and FACS 
BD 
Pharmingen 
555627 Anti-BrdU (Mouse) antibody 
BD 
Pharmingen 
554001 Goat anti-mouse FITC antibody 
UK VWR 734-0000 5ml round bottom tubes (FACS) (BD 352008) 
[1000/box] 
Sigma P4170-
10MG 
Propidium Iodide [10MG] 
 
2.6 Microscopy methods 
2.6.1 Immunocytochemistry 
VWR UK 631-1580 Round Coverslip - 18mm ∅ [10 x 100] 
VWR UK 631-1582 Round Coverslip - 22mm ∅ [10 x 100] 
VWR UK 631-0107 Polysine Slide [72] 
VWR UK 631-1578 Round Coverslip - 13mm ∅ [10 x 100] 
Science Services 
Gmbh 
157-8-100 8% Paraformaldehyde [100mls] 
Invitrogen D3571 DAPI dilactate [10mg] 
Invitrogen  P36930 ProLong® Gold antifade reagent [10mls] 
UK VWR 631-1507 Microscope Slide Box for 25 slides  
Invitrogen A-11001 Alexa Fluor® 488 Goat Anti-Mouse IgG  
Invitrogen  A-21042 Alexa Fluor® 488 Goat anti-Mouse IgM  
Invitrogen A-11008 Alexa Fluor® 488 Goat Anti-Rabbit IgG  
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Invitrogen A-11078 Alexa Fluor® 488 Rabbit Anti-Goat IgG  
Invitrogen A-11004 Alexa Fluor® 568 Goat Anti-Mouse IgG  
Invitrogen A-11079 Alexa Fluor® 568 Rabbit Anti-Goat IgG  
Invitrogen A-11011 Alexa Fluor® 568 Goat Anti-Rabbit IgG  
Invitrogen A-11012 Alexa Fluor® 594 Goat Anti-Rabbit IgG  
Invitrogen  A-21238 Alexa Fluor® 647 Goat anti-Mouse IgM  
Invitrogen  A-21244 Alexa Fluor® 647 Goat Anti-Rabbit IgG  
Invitrogen  A-21235 Alexa Fluor® 647 Goat Anti-Mouse IgG  
Grace Biolabs  664204 Silicone isolators 
Ibidi  81166 Micro 35mm dish Grid 500 
Invitrogen  21063-029 DMEM, HEPES, no phenol red 
Invitrogen C10388 Click-iT® EdU Alexa Fluor® 555 Imaging Kit 
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Methods 
2.7 Molecular Biology Methods 
2.7.1 DNA extraction and purification 
All purification of circular plasmids was performed using E.Z.N.A. Miniprep kit, Midiprep 
kit and Maxiprep kit. The Qiagen Plasmid Maxi kit was used solely in the purification of 
the ISce1 plasmid as the ISce1 plasmid could not be purified using E.Z.N.A Maxiprep 
kit. Linearised plasmid DNA was purified using either E.Z.N.A PCR purification or gel 
extraction kits. 
Genomic DNA from DT40 cells purified using EZNA SQ BLOOD DNA PURIFICATION 
KIT, 3-5x106 cells were pelleted by centrifugation at 300g for 5mins and the medium 
was aspirated leaving behind 30μl. The pelleted cells were resuspended in the residual 
liquid. 600μl of WTL buffer was added to the cell suspension and mixed by pipetting. 
3μl of RNAse A was added to the mix and inverted 20 times, then incubated at 37° 
for10mins. Once the lysate cooled to RT 200μl of PCP buffer was added, vortexed for 
30sec and incubated on ice for 5mins. The lysate was then centrifuged at 14000g for 
3mins. The supernatant was transferred to a new 1.5ml eppendorf and 600μl of 
isopropanol was added and mixed by inverting. The lysate was then centrifuged at 
14,000g for 1min, the supernatant was aspirated and the DNA pellet was washed twice 
with 70% ethanol. After the wash step the DNA pellet was allowed to dry before 
resuspension with 30-50μl 8mM Sodium Hydroxide to aid the solubility of the DNA.  
2.7.2 Restriction endonuclease digests  
Restriction endonuclease digests were carried out using either New England Biolab 
endonucleases or Fast digest Fermentas endonucleases. Digestions were carried out 
according to manufacturer’s protocols. Generally reactions were carried out in a final 
volume of 30µl. For diagnostic digestions 1µl of miniprep DNA was digested for 1hr at 
37°C. For cloning purposes, 5-7µg of DNA was digested o/n at 37°C. 1 unit of alkaline 
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phosphatase per 1μg of DNA was added to vectors for the same duration as the 
endonuclease digestion.  
2.7.3 DNA Ligations 
DNA ligations were performed using Rapid DNA Ligation Kit from Fisher, according to 
manufactures guidelines. Generally 50ng of vector DNA and sufficient insert DNA to 
give a 3:1 molar ratio of insert to vector were used per reaction. Reactions were 
incubated at room temperature for 30mins. 
2.7.4 Bacterial Transformations 
Bacterial transformations were performed using Subcloning Efficiency DH5α 
Competent Cells (Invitrogen) as follows; 100µl of ice cold chemically competent 
Escherischia coli suspension was mixed in a 1.5 ml eppendorf with 10-20µl ligation 
reaction or 300ng uncut plasmid DNA, incubated on ice for 20 min, incubated at 42°C 
for 45 s to heat-shock and transferred immediately to ice. After 1min, 700µl SOC media 
(2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, and 20 mM glucose) was added to the transformation and it was incubated at 
37°C for 1 h with shaking at 220 rpm. 200-700µl was then plated on LB agar plus 
antibiotic selection plates and incubated overnight at 37°C. 
2.7.5 DNA Sequencing and sequence analysis 
Plasmid DNA was sequenced by the DNA sequencing services in the MRC department 
of the University of Dundee. For a single reaction, 600ng of DNA in 30μl of elution 
buffer (from Miniprep kit) was sent to the sequencing services. Primers provided by the 
sequencing services were used, or own primers at a concentration of 3.2μM were also 
sent with the plasmid DNA. 
 Sequence files were received as a “.zip” file and analysed using vector NTI 
software. Sequences were compared to reference sequences obtained from Pubmed. 
DNA constructs and oligonucleotide were all designed using Vector NTI software. 
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2.7.6 RNA and cDNA preparation and amplification 
RNA was extracted from cells using RNA-Bee from Amsbio. For adherent human cells, 
a confluent 10cm plate was trypsinised and the cells were pelleted (300g 5mins), for 
DT40 cells, roughly 6x106 cells were pelleted. The cell pellets were washed in PBS and 
resuspended in 50µl of PBS. 1ml of RNA-Bee and 200µl of chloroform was added to 
the cells and shaken vigorously for 30sec, then incubated on ice for 5mins. The lysates 
were spun down at 12,000g for 15mins at 4°C. The upper aqueous phase was 
transferred to a new eppendorf and 500µl of isopropanol was added and left for 5-
10mins at RT. The sample was centrifuged at 12,000g for 5mins at 4°C. The 
supernatant was carefully removed and the RNA pellet was washed x2 in 70% ethanol 
and centrifuged at 7,500g for 5mins. After allowing the pellet to dry, it was resuspended 
in 200µl RNase-free water and the concentration of the RNA was measured using a 
spectrometer. 
 Reverse transcription PCR (RT-PCR) was carried out using either RevertAid H 
Minus First Strand cDNA Synthesis Kit or Maxima H Minus Reverse Transcriptase 
according to manufacturer’s guidelines (see below). cDNA was diluted to 2µg in 100µl 
of Millipore Water (MPW). 
Reaction (RevertAid)  
RNA 2µg 
Oligo(dt)18 primer 1µl 
Random hexamer primer 1µl 
5x reaction buffer 5µl 
Ribolock RNase inhibitor 1µl 
10mM dNTP mix 2µl 
RevertAid H reverse transcriptase 1µl 
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Reaction (Maxima)  
RNA 2µg 
Oligo(dt)18 / Random hexamer primer 1µl 
5x reaction buffer 4µl 
10mM dNTP mix 1µl 
Maxima H Minus Enzyme Mix 1µl 
 
Table 2.4 RevertAid and Maxima RT-PCR reactions. 
 
2.7.7 Polymerase Chain reaction (PCR) 
PCRs were carried out as follows for the different PCR enzymes 
Phusion high fidelity DNA polymerase 
Reaction  
5X Phusion HF or GC Buffer 10μl 
10 mM dNTPs 1μl 
Forward Primer (10μM) 2μl (0.4μM) 
Reverse Primer (10μM) 2μl (0.4μM) 
Template DNA 20ng 
Phusion DNA Polymerase 0.5μl 
MPW Up to 50μl 
 
Cycle 
Temperature Time Cycles 
98°C 3mins 1 
98°C 20sec  
35 Annealing temp 30sec 
72°C 15-30 seconds/kb of DNA 
72°C 10 mins 1 
4°C ∞ 1 
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Dream Taq Green DNA polymerase 
10X DreamTaqGreen Buffer 5μl 
10 mM dNTPs 1μl 
Forward Primer (10μM) 2μl (0.4μM) 
Reverse Primer (10μM) 2μl (0.4μM) 
Template DNA 20ng 
DreamTaq DNA Polymerase 0.5μl 
MPW Up to 50μl 
 
Cycle 
Temperature Time Cycles 
95°C 3mins 1 
95°C 30sec  
35 Annealing temp -5°C 30sec 
72°C 1min/kb of DNA 
72°C 10 mins 1 
4°C ∞ 1 
 
Table 2.5 PCR reactions and PCR cycle for Phusion and Dream Taq polymerases. 
 
2.7.8 Site directed mutagenesis 
Site directed mutagenesis was performed using QuikChange Lightening Mutagenesis 
Kit from Agilent. Primers were designed using the Quick change primer design tool on 
the Agilent website to mutate a single amino acid. Mutagenesis of plasmid DNA was 
confirmed by sequencing. The reaction was carried out as follows; 
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Plasmid DNA 50ng 
10× QuikChange Lightning Buffer 5μl (1x) 
Forward primer 125ng 
Reverse Primer 125ng 
dNTPs (10mM) 1μl 
Quick solution 1.5μl 
QuikChange Lightning Enzyme 1μl 
MPW Top up to a final volume of 50μl 
 
PCR cycle; 
Temperature Time Cycles 
95°C 2mins 1 
95°C 20sec  
18  60°C 10sec 
68°C 30 seconds/kb of plasmid DNA 
68°C 5 mins 1 
4°C ∞ 1 
Table 2.6 PCR reactions and PCR cycle for Site directed mutagenesis. 
 
Directly after the PCR, 2μl of DpnI restriction enzyme was added to the reaction and 
incubated for 30mins at 37°C to digest the parental non-mutated DNA. The mutated 
plasmids were then transformed using XL10-Gold ultracompetent cells according to 
manufacturer’s guidelines. 
Multi-Site directed mutagenesis was performed using QuikChange Lightening Multi 
Mutagenesis Kit from Agilent. Primers were designed using the Quick change primer 
design tool on the Agilent website to mutate a single amino acid. In order to mutate 3 
amino acids, three separate forward primers were generated. No reverse primers are 
needed for this reaction. The reaction was carried out as follows; 
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Plasmid DNA 300ng 
10× QuikChange Multi Lightning Buffer 5μl (1x) 
Forward primer 175ng in total (see below) 
dNTPs (mM) 2μl 
Quick solution 0.5μl 
QuikChange Lightning Enzyme 2μl 
MPW Top up to a final volume of 50μl 
 
Primers  
Primers 1 2 3 
Reaction 1 100ng 50ng 25ng 
Reaction 2 25ng 100ng 50ng 
Reaction 3 50ng 25ng 100ng 
 
This primer mix was used to increase the likelihood of obtaining all the different 
mutation combinations possible. 
PCR cycle 
Temperature Time Cycles 
95°C 2mins 1 
95°C 20sec  
30 55°C 30sec 
65°C 30 seconds/kb of plasmid DNA 
65°C 5 mins 1 
4°C ∞ 1 
Table 2.7 PCR reaction, primers and PCR cycle for multi-Site directed mutagenesis. 
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2.7.9 Ethanol precipitation of DNA 
1/10 Volumes of 3M Sodium acetate (pH 5.2) was added to the DNA to be precipitated. 
2 volumes of 100% ethanol was added to the mix and inverted a few times to insure 
mixing. The mixture was incubated at -20°C for at least 1hr and then the DNA was 
pelleted by centrifugation at 20000 x g for 20mins. The DNA pellet was then washed 
twice with 70% ethanol and spun down at 15000 x g for 5mins between washes. The 
DNA pellet was allowed to air dry before resuspension in an appropriate buffer. 
2.7.10 DNA Agarose gel electrophoresis 
DNA was run on Agarose gels ranging from a 0.5-1.5%. Agarose gels were made by 
dissolving agarose in 1x TAE buffer. Once the TAE buffer was added to the agarose 
powder the solution was weighed and then microwaved to dissolve the agarose. The 
solution was weighed again after boiling and the volume of the solution was 
compensated for by adding MPW to bring it back to its original volume. Ethidium 
bromide or gel green (concentration according to manufacturing protocol) was added to 
the melted agarose once it had cooled down to around 60°C and poured into a casting 
tray with a suitable comb. Once the gel had set, DNA plus loading buffer was added to 
the wells and run at 110Volts for around 1hr in 1xTAE buffer. The DNA was imaged 
using an Alpha Innotech FluorChem® Imaging system. 
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2.8 Protein methods and Biochemical techniques 
2.8.1 Preparation of whole cell extracts  
1.5 x107 DT40 cells, or a confluent 10cm dish of human adherent cells were pelleted at 
300g for 5mins and washed twice in 10mls of PBS. The cell pellet was resuspended in 
200μl lysis buffer and incubated at RT for 10mins to allow the nuclease to work. 
Lysates were then incubated on ice for 20-30mins. The lysates were then centrifuged 
at 20000 x g for 20mins at 4°C to pellet debris and insoluable protein and the soluble 
protein was transferred to a fresh 1.5ml eppendorf. Protein concentration was 
measured by Bradford assay (as described in section 2.2.5) and stored at -80°C. 
2.8.2 DT40 cellular fractionation 
Cellular fractionation was performed essentially according to (Wang and Caldwell, 
2006). All buffers were ice cold and all incubation steps were performed on ice. Briefly, 
1.5 x 108 DT40 cells were pelleted, washed 2x in 100ml ice-cold PBS, resuspended 
gently in 5x the packed cell volume (PCV) of isotonic lysis buffer. The PCV was taken 
as being 1 µl per 1x106 cells, i.e. for 2.0 x108 cells the PCV was 200 µl. The 
resuspended cells were transferred to a 1.5ml eppendorf on ice and incubated for 15 
min. 10% NP-40 was added to a final concentration of 0.3% and the cell suspensions 
mixed gently by inversion then immediately centrifuged for 30 sec at 3000 x g. The 
supernatant (cytoplasmic fraction) was transferred to a fresh tube. The pellet was 
resuspended in 5x PCV isotonic lysis buffer, mixed gently and pelleted at 1500 rpm for 
5min. The supernatant was removed and the pellet resuspended in 3x PCV extraction 
buffer. Tubes were vortexed at medium speed for 15 min followed by vortexing at high 
speed for 15 min. Insoluble material was pelleted by centrifugation at 20000 x g for 15 
min and the supernatant was moved into a fresh tube (soluble nuclear fraction). 
Samples were either used for PAGE Western blot or stored at -20°C. 
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2.8.3 Human adherent cellular fractionation 
Confluent 15cm plates of HEK cells were washed twice with cold PBS, scraped off and 
spun down. Supernatant was aspirated off and the pellet was resuspended in 5PV Ce 
buffer and incubated on ice for 3mins. The lysate was centrifuged at 1,300 x g for 
10mins and the supernatant was collected (cytoplasmic fraction). The nuclear pellet 
was washed in Ce buffer minus NP40. Nuclear pellet was then resuspended in 1 pellet 
volume NE buffer and the salt concentration was adjusted to 400mM using 5M NaCl. 
An additional pellet volume of NE buffer was added to the pellet and mixed. Incubate 
on ice for 10mins, vortexing the sample from time to time. Spin down the nuclear and 
cytoplasmic lysates at 14000 x g for 15mins. 
2.8.4 Acid histone extraction 
1.5 x 107 DT40 cells were harvested and washed twice with PBS. The cells were then 
lysed in isotonic lysis buffer as described in 2.2.2. The nuclei were pelleted and the 
supernatant was discarded (cytoplasmic fraction). The nuclei were washed in isotonic 
lysis buffer before adding 60µl of 0.2M HCL solution. The suspension was gently mixed 
and incubated o/n at 4°C. The debris was then pelleted at 10,000 x g and the 
supernatant histone fraction was transferred to a clean tube and neutralised (pH 7) with 
0.2 M NaOH before Western blot analysis.  
2.8.5 Protein quantification by Bradford assay 
1-10μL of the protein solution to be assayed was added to a cuvette and lysis buffer 
was added to a final volume of 10μL. Bradford reagent was diluted 1:1 with MPW and 
1ml dispensed into the cuvette. Absorbance at 595 nm was measured and protein 
concentrations were calculated by comparison to a standard curve of 595 nm 
absorbance’s made using a range of known concentrations of bovine serum albumin in 
the Bradford assay. 
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2.8.6 Polyacrylamide gel electrophoresis (PAGE) 
Polyacrylamide gel electrophoresis (PAGE) was carried out using 4-12% pre-cast Bis-
tris mini-gels. 50mg of protein in 1xLDS sample buffer and 50mM DTT were boiled for 
5mins prior to gel loading. 10μL of protein marker was used, unless otherwise stated. 
Gels were run at 180V for 1hr with 1X Mops buffer using Novex gel electrophoresis 
tanks.  
2.8.7 PAGE staining 
After PAGE, gels were either coomasie or silver stained using PAGE-blue or Pierce 
silver staining. Both staining were carried out according to manufacturer’s guidelines. 
2.8.8 Western Blotting 
Western blotting was performed using the Xcell IIBlot module in the Novex minigel 
tanks. Either Nitrocellulose or PVDF membranes were used for transfer. Nitrocellulose 
membrane was used for all conventional Western blots and PVDF membranes were 
used for Licor Western blot analysis. PVDF membrane was pre-treated with methanol 
for 1min, water for 2mins and then 1xTransfer buffer for a further 2-5mins. 
Nitrocellulose membrane was briefly incubated in 1xTransfer buffer prior to transfer. 
The transfer buffer was composed of 1x transfer buffer, 10% (nitrocellulose membrane) 
or 20% (PVDF membrane) methanol and 1x antioxidant. Transfer was set up according 
to manufacturer’s protocol. Samples were transferred for 1hr 30mins – 2hrs at room 
temperature at 35Volts.  
 Post transfer, membranes were rinsed in PBS-T (PBS with 1% Tween 20) and 
blocked for 1hr in PBS-T with 5% marvel. The membrane was incubated with the 
primary antibody in PBS-T marvel o/n at 4°C shaking. The membrane was washed 3x 
5mins in PBS-T. The membrane was then incubated with the secondary antibody in 
PBS-T with 5% marvel for 1hr at RT, washed 3x 5mins in PBS-T and incubated with 
ECL (1;1 detection regent1;2) for 3mins before exposure to x-ray film and developed.  
80 
 
 For quantification of relative protein levels, the Licor system was employed. Low 
background immunofluorescence PVDF membrane was used for transfer. Membrane 
was treated the same as aforementioned. Fluorescent secondary antibodies were used 
to detect the protein of interest. After the secondary antibody was washed off with PBS-
T x3, the membrane was incubated in water and then imaged using the Licor. 
2.8.9 Protein Purification 
Full length RNF8, RNF168 and point mutants RNF8, RNF168 were purified via a His-
trap column. His-tagged proteins were expressed in BL21(LysE3) E-coli cells. 
Culture growth and protein expression 
A single colony was inoculated into 10mls of LB plus ampicillin (100µg/ml) and 
chloramphenicol (37µg/ml). The cultures were incubated o/n at 37°C. 7mls of culture 
was then inoculated into 400mls of LB plus ampicillin (100µg/ml) and incubated at 37°C 
until the O.D. reached 0.6. 0.4mM IPTG was then added to the culture to induce 
protein expression. RNF8 and mutant RNF8 were incubated for 2hrs at 37°C before 
harvesting. RNF168 and mutant RNF168 were incubated at 18°C o/n before 
harvesting. Cultures were spun down and pellets were either frozen until needed or 
lysed. 
Cell lysis 
10mls of binding buffer was added per gram of bacterial pellet and resuspended. The 
following was added to the resuspended pellets and allowed to rock at RT for 30mins; 
 1mM MgCl2 
 1mMPMSF 
 0.2mg/ml lysozyme 
 5mM DTT 
 Protease inhibitor cocktail 
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Samples were freeze-thawed (incubation at -80°C then thawed at RT) 2-3 times to 
ensure lysis. Lysates were sonicated at 60% output for 5mins until they were no longer 
viscous. Lysates were centrifuged at 38,000g for 20mins. Supernatant was filtered 
through a 0.22μM PES membrane. 
Loading lysate onto column 
The His-trap crude FF 5ml columns were washed with 5-10 column volumes of MPW 
and then with 10 column volumes of binding buffer. Lysate was loaded on to the 
column in a loop manner using an electrical pump o/n at 4°C. 
Column purification and dialysis  
Proteins were purified using the Akta explorer. His columns were washed with 75mls 
binding buffer and then eluted in 1.5ml fractions using the elution buffer. Samples were 
collected according to the elution peak.  
 Slida lyzers were incubated in dialysis buffer before sample was applied. 15ml 
slida lyzers were used in the dialysis process. Protein sample was injected into the 
cassette. The buffer was changed twice throughout the day and once more before 
leaving o/n. The dialysis process occurred at RT and gentle stirring via a magnetic 
stirrer. With every buffer change, the NaCl content was reduced by 100mM. The final 
concentration of NaCl was 300mM. The dialysed samples were aliquoted into 1ml 
volumes and the insoluble fractions were pelleted. A Bradford assay was carried out to 
check the protein concentration of the samples. The protein samples were then frozen 
down with 10% glycerol at -80°C. 
Note 
All proteins apart from mutant RNF168 were eluted from the column in a one-step 
elution process by adding 500mM imidazole buffer. Mutant RNF168 was eluted using a 
gradient elution buffer from 50mM up to 500mM imidazole. This was carried out to 
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clean up the elution process, however no difference was observed between the one-
step and gradient elution process 
 
2.8.10 Ubiquitin ligase activity assay 
Ubiquitin ligase activity assays were carried out as follows, first by pre-incubating the 
enzymes with cold ubiquitin before adding 125I labelled ubiquitin to the mix. 
10x buffer 1µl 
ATP (20mM) 1µl 
E1 enzyme 1µl 
E2 enzyme 1µl 
E3 enzyme 2µl 
Ubiquitin (1mg/ml) 1µl 
Top up to 10µl of MPW - 
 
The reaction was incubated for 1hr at 37°C, the following was then added to the mix 
10x buffer 1µl 
ATP (20mM) 1µl 
125I labelled ubiquitin 1µl 
Histones 2µl 
Top up to 10µl of MPW - 
Table 2.8 Ubiquitin ligase activity assay reaction 
 
The reaction was incubated for a further 1hr at 37°C before samples were run on 4-
12% gradient Bis-Tris gel. The gel was then dried and exposed to either X-ray film 
imaged via a phosphoimager, from 1hr to 24hr at -80°C before developing. 
2.8.11 Mammalian two hybrid analysis 
Genes of interest were cloned into the pM3-Not and pVP3-Not plasmids resulting in 
their fusion to either the GAL4 DNA binding or activation domains respectively (pM3-
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Not expresses the bait, pVP3-Not expresses the prey). Hek-293 or HeLa cells were 
seeded in 24 well plates and transfected with xtremegene 9 when 70-90% confluent. 
Cells were transfected with 125ng of each vector, 125ng of pG5-Luc (GAL4 driven 
firefly luciferase vector) and 12.5ng of an internal control vector (pRL-CMV, expressing 
renilla luciferase). 24hrs after transfection cells were washed x2 with PBS and lysed 
using 100µl 1xPLB buffer by rocking at RT for 20-30mins. 20µl of lysate was loaded 
onto a 96 well plate and a dual luciferase assay was used to calculate the ratios of 
firefly/renilla luciferase activity for each sample according to manufacturer’s guidelines. 
The fold induction is the ratio for a given interacting pair of proteins divided by the 
same ratio for the empty vectors. 
2.8.12 GFP Pull down 
GFP tagged proteins were pulled down using chromotek GFP-trap beads. HEK 293 
cells were grown in 15cm plates and induced with 2.5ng/ml (GFP, GFP- BARD1) or 
7.5ng/ml (GFP -BARD1ΔBRCT) tetracycline o/n before lysis. Cells were washed x2 
PBS and scraped from their dishes. The cells were pelleted at 300g for 5mins and 
resuspended in 500µl lysis buffer/15 cm dish and incubated at RT for 10mins 
(Nuclease enzyme activity) and then on ice for a further 20mins. The crosslinker in the 
lysis buffer was then quenched by adding 200mM TRIS-HCL to the mix and allowed to 
incubate on ice for a further 30mins. The insoluble fraction and debris was then 
pelleted by centrifugation at 20000 x g at 4°C for 20mins. Protein concentration was 
measured using the Bradford assay. 
 GFP trap beads and the agarose beads were washed twice with PBS followed 
by a single wash with lysis buffer before suspension in a 50% slurry with lysis buffer. 
For pull downs with less than 5mg of protein, 20µl of GFP-trap slurry was used, 
otherwise for every 1mg of protein 4µl of GFP-trap slurry was used. 10 times the 
volume of agarose beads were used in comparison to GFP-trap per pull down. 
Pelleting of beads was carried out at 4°C for 2mins at 3,200 x g. 
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Following protein quantification, equal amounts of comparative GFP-proteins were 
added to agarose beads to remove any unspecific protein binding to the beads. The 
lysates were gently mixed on a rotating wheel at 4°C for 1hr 30mins. The beads were 
then pelleted and the lysate was then transferred to a new tube and incubated with the 
GFP-trap beads. The lysates were gently mixed again on a rotating wheel at 4°C for 
1hr 30mins. The GFP and agarose beads were pelleted and washed x3 with wash 
buffer. After adding the wash buffer, the beads were gently mixed by inverting the 
tubes 10 times before pelleting. After the washing step, beads were resuspended in 2x 
Sample buffer containing 50mM DTT (roughly 40µl/2mg of protein used in the pull 
down) and boiled for 20-30mins. Boiling in sample buffer removed the crosslinks and 
also striped the protein from the beads. The beads were pelleted and 40µl of sample 
was loaded per gel for western blotting. 50µg of input was used for western blotting. 
Concentration of input was determined as in section 2.2.5. 
2.8.13 Mass spectrometry 
Tandem Mass spectrometry (MS/MS) was performed by the Mass spectrometry facility 
at the college of life sciences Dundee according to standard protocols. Samples were 
processed as part of the service. Proteins were digested with trypsin. An Orbitrap Velos 
machine was used to carry out the Mass Spec. Data was used to search the IPI human 
database using Mascot (Matrix Science, UK). Mascot output was validated using 
Scaffold 3 (Proteome Software, USA). Peptide identifications were accepted if they 
could be established at greater than 85.0% probability as specified by the Peptide 
Prophet algorithm (Keller et al., 2002). Protein identifications were accepted if they 
could be established at greater than 99.0% probability and contained at least 2 
identified peptides. Protein probabilities were assigned by the Protein Prophet 
algorithm (Nesvizhskii et al., 2003). Proteins that contained similar peptides and could 
not be differentiated based on MS/MS analysis alone were grouped to satisfy the 
principles of parsimony.  
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 Mass Spectrometry of a second set of samples (no crosslinker) were carried out 
in the Ninewells Mass spectrometry facility using an orbitrap machine. Data was 
analysed by PEAKs software adhering to the same stringency factors as mentioned 
above. The sample preparation was carried out in house as follows; Samples were run 
around 1cm into a 4-12% Bis-Tris gel via PAGE. After the initial running of the samples 
in a gel, all further preparation and processing was carried in in a laminar flow hood. 
The protein bands were cut from the gel into very small pieces. 100µl of 100mM 
ammonium bicarbonate in a 50% acetonitrile solution was added to the gel pieces and 
incubated at RT for 30mins. 500µl of acetonitrile was then added to the samples and 
incubated at RT until the gel slices were visibly white and shrunken. Samples were 
then spun down and liquid was removed from the samples. After destaining the gel 
slices, the samples were reduced and alkylated. 50µl of 10mM DTT in 100mM 
ammonium bicarbonate was added to the samples and incubated at 56°C for 30mins 
and then allowed to cool. 500µl acetonitrite was then added to the samples for 10mins 
before removing. 50µl of a 55mM iodacetamide solution in 100mM ammonium 
bicarbonate was added to the sample and incubated in the dark for 20mins. The gel 
slices were finally shrunk with the addition of 500µl acetonitrile which was removed 
after dehydrating the samples. The next stage of processing the samples for Mass 
spectrometry involved the trypsin digestion of the peptides within the gel slices. The 
samples were covered with trypsin (13ng/µl trypsin in 10mM ammonium bicarbonate 
containing 10% v/v acetonitrile) and sonicated for 1hr at 37°C before incubation o/n at 
37°C. Extraction of the digested peptides was then employed by the addition of 100µl 
extraction buffer (1:2 v/v 5% formic acid/acetonitrile) for 15mins at 37°C. The liquid was 
then removed and the samples were dried using a speedy-vacuum and stored at -20°C 
until Mass spectrometry analysis. 
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2.9 Cell Culture Methods 
2.9.1 Culture of DT40 
DT40 cells were grown in  suspension at concentrations ranging between 3x104 cell/ml 
and 1x106 cells/ml. Cells were grown in RPMI medium supplemented with 10% FBS, 
3% CS and 5mls Penn/strp at 37°C with 5% CO2. CS was heat inactivated for 30mins 
at 56°C prior to addition to RPMI medium. Complete medium was preheated at 37°C 
before use.  DT40 cells were generally split every second day to 1x105 cells/ml. the day 
before the use of DT40 cells in an experiment, the cells were split to 2x105 cells/ml to 
ensure logarithmic growth. 
2.9.2 Culture of human adherent cell lines 
Adherent HeLa, Hek 293 and U2OS cells were grown in DMEM medium supplemented 
with 10% FBS at 37°C with 5% CO2. Tetracycline inducible cell lines were grown in 
tetracycline free medium. To Split adherent cells, plates with adherent cells were 
washed twice with PBS-EDTA and incubated with TE for 3-5mins at 37°C until the cells 
detached from the plate. They were then seeded in new plates with fresh medium at a 
lower density. Cells were generally split 1 in 4 every second day. 
2.9.3 Freezing and storage of cells 
For freezing, 3x106 DT40 cells were pelleted at 300g for 5mins and frozen in aliquots of 
500µL freezing media. Confluent 10cm plates containing human cell lines were 
trysinised and pelleted then frozen in aliquots of 500µL freezing media. All cells were 
frozen in cryovials and stored in Mr. Frosties at -80°C for the first 24hrs. The cells were 
then transferred to liquid nitrogen for long term storage. 
2.9.4 DT40 Transient transfection 
Transient transfection of DT40 cells was performed using the Amaxa Nucleofector II 
and the Nucleofector T kit (Lonza). For each transfection, 3x106 cells were pelleted at 
300g for 5mins and resuspended in 82μl of room temperature nucleofector plus 18μl 
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supplement. 30μg of plasmid DNA dissolved in 1-10 μl of TE buffer was added and the 
suspension thoroughly mixed by gentle pipetting. This was transferred to the supplied 2 
mm electroporation cuvette and electroporated in the Amaxa Nucleofector II using 
program B-023. The transfected cells were then transferred to 5ml of media in a 
labelled 6-well plate and cultured for 24 hours at 37°C and 5% CO2 in complete RPMI 
in a humidified environment. 
2.9.5 DT40 Stable transfection 
50μg of plasmid DNA containing genes of interest was linearized o/n using suitable 
restriction enzyme. After linearization, the DNA was then ethanol precipitated and 
resuspended in 50μl sterile PBS. 1x107 subconfluent DT40 cells were pelleted, washed 
in 25ml ice-cold PBS, resuspended in 600 μl ice-cold PBS and gently mixed with DNA. 
The cell/DNA mixture was transferred to 4mm electroporation cuvettes and incubated 
on ice for 20 min. The cell/DNA mixture was again gently mixed before electroporation. 
Electroporation was performed using a Gene Pulsar II (Bio-rad) and the following 
settings: 250V (volts), 950μF (capacitance). 
Cells were placed on ice for 5 min to recover, then added to 50 ml complete RPMI in a 
125 cm2 flask. The cells were then incubated at 37°C at 5% CO2. 24hrs after 
transfection 50 ml 2x selection media was made up by adding antibiotics to 50 ml 
complete RPMI. 2x selective media was added to the transfected cells and mixed well 
(total volume 100mls). Cells in selective media were plated out into flat-bottomed 96-
well plates in 200μl aliquots, and were incubated at 37°C/5% CO2 for 7-10 days until 
clones were apparent. G418 was used as a selective agent at a concentration of 
2mg/ml. 
2.9.6 Transient transfection of adherent cells (human) 
HeLa and HEK-293 cells were transfected with X-tremeGENE 9 transfection reagent 
and U2OS cells were transfected with X-tremeGENE HP transfection reagent. Cells 
were seeded the day before transfection so that they were 70-90% confluent on day of 
88 
 
transfection. On the day of transfection, Optimem was added to a sterile tube, the 
transfection reagent was then added to the tube as well as the DNA. The mix was 
vortexed briefly and then spun down and incubated at RT for 15-20mins. The mixture 
was added to the cells in a drop wise manner and incubated for 24hrs at 37°C, 5% CO2 
before analysis. 
X-tremeGENE 9 
 Total volume for 
transfection (μl) 
DNA (μg) XtremeGENE 
reagent 3:1 (μl) 
24 well plate(1 well) 25 0.25 0.75 
12 well plate(1 well) 50 0.5 1.5 
6 well plate (1 well) 100 1 3 
10cm plate 500 5 15 
 
X-tremeGENE HP 
 Total volume for 
transfection (μl) 
DNA (μg) XtremeGENE 
reagent 1:1 (μl) 
24 well plate(1 well) 50 0.5 0.5 
12 well plate(1 well) 100 1 1 
6 well plate (1 well) 200 2 2 
10cm plate 1000 10 10 
Table 2.9 X-tremeGENE 9/HP transfection reaction 
 
2.9.7 Stable transfection of Human Adherent cells 
HEK-FRT-Flp-In cells were stably transfected using Invitrogens Flp-In system. This 
DNA recombination system uses a recombinase (Flp) and site-specific recombination 
to facilitate integration of the gene of interest into a specific site in the genome of 
mammalian cells. In summary, a Flp Recombination Target (FRT) site is first integrated 
into your cell line. The FRT plasmid also confers zeocin resistance allowing positive 
cells to be selected for. Once the FRT site is stably integrated into a locus in the 
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genome, pcDNA5 (an expression plasmid containing an FRT site linked to a 
hygromycin resistant gene) containing your gene of interest is then transfected into the 
zeocin resistence cells. A Flp recombinase expression plasmid, pOG44, for expression 
of the Flp recombinase under the control of the human CMV promoter is cotransfected 
with pcDNA5. Upon co-transfection, the Flp recombinase expressed from pOG44 
mediates a homologous recombination event between the FRT sites (integrated into 
the genome and on pcDNATM5/FRT) such that the pcDNA5/FRT construct is inserted 
into the genome at the integrated FRT site. 
The HEK and U2OS cells used were already stably transfected with pFRT/lacZeo. 
HEK-FRT-Flp-In cells were transfected with xtremegene 9 and U2OS-FRT-Flp-In cells 
were transfected with xtremegene HP according to manufacturer’s guidelines.  
Transfections were as follows in 10cm plates; 
 Total volume 
for transfection 
(μl) 
DNA (μg) 9;1 
(pOG44;pcDNA5) 
XtremeGENE 
reagent 3:1 (μl) 
HEK-FRT-Flp-In cells 500 4.5 ; 0.5 
 
15 
Table 2.10 Reactions for stable transfection of HEK-FRT-Flp-In cells 
 
24hrs post transfection, cells were given fresh medium. 48hrs post transfection cells 
were trysinised and seeded 1 in 4, 1 in 8, and neat in media containing 100μg/ml 
Hygromycin for selection. Selective media was changed every 3-4days. Single clones 
were picked using cloning discs or cylinder between 12-20days. Clones were 
expanded and confirmed positive by Western blot. 
2.9.8 Colony survival assay 
Media containing methylcellulose is used in this assay. Due to its viscous consistency, 
it provides an optimal semi solid matrix where in single cells producing colonies can 
form without easy disruption. Methylcellulose media is made up before cells are treated 
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and is used up to four weeks after preparation. The methylcellulose media is made as 
following: 
10g of methylcellulose is autoclaved in a 1L glass bottle with a magnetic stir bar. 
 200mls of MPW water, at 55°C, is added to the autoclaved methylcellulose and 
shaken vigorously until all the powder is mixed with the MPW and not stuck to 
the walls of the bottle. 
 500mls of DMEM containing sodium bicarbonate in filter sterilised and added to 
the methylcellulose mix and shaken vigorously. 
 DMEM media; 11.99g of DMEM plus 32.5mls of 7.5% sodium bicarbonate 
dissolved in 500mls of MPW.  
 Allow to stir overnight at 4°C. (Note; methylcellulose only becomes fully soluble  
when temperature is below 8°C) 
 100mls of FBS, 30mls of CS and 10 mls of penn/strep are added to the 
solution. MPW is then added to bring the final volume to 1L. The media is then 
stirred over night at 4°C and then stored at 4-8°C until use. (Note; The 
methylcellulose media is stirred at room temperature for a few hours before on 
the day of use.)  
5mls of methylcellulose media is added to each well in a 6 well plate. 
Treatment of cell lines with Olaparib was carried out in 24 well plates. 2x105 cells were 
seeded in a 24 well plate with media and treated with the following concentrations of 
Olaparib; 0µM, 0.25µM, 0.5µM, 1µM, 1.5µM and 3µM. Cells were treated in a final 
volume of 1ml per well for 24hrs. 24hrs following treatment cells were serially diluted 
1;10, 1;100 and 1;500 ( approximately 2x104, 2x103 and 4x102 cells/ml). 2x103, 2x102 
and 40 cells were dropped onto the prepared 6 well plates containing methylcellulose 
in technical duplicate for each drug concentration (ie 100µL of diluted cells). Once cells 
were plated, the 6 well plates were mixed gently in an 8-shape motion, 5 times 
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forwards and backwards. MPW was then added between the wells in a plate for 
humidity and the plates were placed undisturbed in a 37°C incubator for 10-14 days. 
Chronic treatment of cells with Hydroxy Urea (HU) was carried out much the same as 
with Olaparib. Cells were serially diluted as before and then added drop-wise to 
methylcellulose media containing the following concentrations of HU; 0µM, 100µM, 
150µM and 200µM. 
10-14 days after plating, colonies formed were counted and an average of the technical 
duplicates was taken and used as a single result. Colonies formed in each cell line 
were compared to untreated cell and percentage survival was plotted using a 
logarithmic scale. Each experiment was completed at least 3 times. The IC50 values 
were calculated from log dose response curves using GraphPad Prism 6 software. 
2.9.9 siRNA knockdown in human cells 
siRNA knockdown of proteins in cells was carried out using Thermo Scientific 
Dharmafect transfection reagent. 1 x 105 HeLa cells were plated in 6 well dishes in 
antibiotic free media and incubated o/n at at 37°C, 5% CO2. A 5µM stock solution of 
siRNAs was prepared in 1X siRNA buffer (Provided with Dharmafect). In one tube 10µl 
of the 5µM siRNA stock was diluted in 190µl of optimum. In the second tube 4µl of 
Dharmafect was added to 196µl optimum. Both tubes were incubated at RT for 5mins 
before adding the content of both tubes together and incubating the mixture for a 
further 20mins at RT. 1.6mls of complete media was added to the siRNA/Dharmafect 
solution after the incubation. The culture media was aspirated from the cells in 6-well 
plates and the transfection mixture was added to the cells. The final concentration of 
siRNA used was 25nM. Cells were incubated at 37°C, 5% CO2 for up to 72hrs before 
harvesting and analysis. When cells were required for further experiments the 
transfection media was removed after 24hrs and replaced with complete media after 
re-seeding. 
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2.9.10 Cell synchronisation; Double thymidine block 
In order to synchronize HEK cells in late G1/S phase for analysis of cell cycle 
progression via BrdU/PI FACScan analysis cells were seeded in 10cm dishes at 20% 
confluency in the morning of the start of the experiment. That evening cells were 
treated with 2.5mM thymidine and incubated at 37°C, 5% CO2 for 16hrs to arrest the 
majority of cells in early S-phase. The media containing thymidine was then aspirated 
from the cells and they were allowed to recover for 6hrs. After recovery, the cells were 
treated with a further 2.5mM thymidine for 16hrs at 37°C, 5% CO2. The thymidine 
containing media was then aspirated from the cells and fresh media was applied to 
release the cells from the arrest. Cells were harvested between 0 and 10hrs in 2hr 
intervals after the final release before fixation and analysis by PI/BrdU FACScan. Cells 
were pulse labelled with 10µM BrdU for 30 mins before harvesting to incorporate BrdU 
into replicating S-phase cells.  
2.10 Flow cytometry methods 
2.10.1 Flow cytometry and FACS 
Samples were analysed by Becton Dickinson FACScan using Cell quest. Post analysis was 
carried out using WinMDI 2.9 software. 
Propidium iodide/BrdUcell cycle assay 
6 X 106 HEK 293 cells were harvested from culture using trypsin. The cells were 
washed twice with PBS and resuspended in 200µL PBS. The cells were then fixed by 
adding 2mls of 70% ice cold ethanol dropwise to the cells while gently vortexing the 
cells.  Cells were fixed for at least 16hrs at -20°C. After fixation, the samples were 
washed twice with PBS and resuspended in 1ml 2M HCL/0.5% Triton X and incubated 
at RT for 30mins. The samples were then centrifuged at 300 x g and resuspended in 
1ml of 0.1M Sodiumtetraborate (pH8.5) and incubated for 1min at RT. The cells were 
washed a further two times in Blocking buffer before incubating the samples in 1;500 
anti-BrdU in 100µl blocking buffer. The cells were incubated with the BrdU antibody for 
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1hr30mins at RT. Following primary antibody incubation, the samples were washed 
with blocking buffer and then resuspended in 100µl of 1;100 FITC anti-BrdU 
conjugated secondary antibody in blocking buffer and incubated in the dark for 30mins. 
The samples were then washed in PBS and resuspended in 500µl PBS with 25 µg/ml 
propidium iodide (PI) and 1;400 RNAse roughly 15mins before FACS analysis. Flow 
cytometry was performed on a Becton Dickinson FACScan with excitation at 488 nm. 
Complete cells were gated by forward and side scatter, singlets were gated by PI area 
vs events and the percentage of cells at different stages of the cell cycle was deduced 
by plotting PI vs BrdU (FL2-A vs FL1-H). 10,000 gated cells were counted. 
2.10.2 Homologous recombination efficiency assay (HRE assay) 
3 x 106 DTDR17 DT40 cells were transiently transfected with 30µg of pIsce-I plasmid 
using the Amaxa nucleofection system. Programme B-23 was used. Directly after 
transfection, cells were incubated in 6 well plates containing 5mls of media and 
incubated at 37°C for 24 hours. Cells were then spun down at 300g for 5mins and 
washed twice with PBS before re-suspension in 500µL of PBS. The cells were 
analysed for green fluorescence using the FACScan fluorescence activated cell sorter. 
A live population of cells was gated for using forward and side scatter and the 
percentage of green fluorescent cells per 10,000 cells within this population were 
counted and compared to no DNA transfected cells and plotted on a bar chart.  
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2.11 Microscopy methods 
2.11.1 Immunocytochemistry  
Pre-extraction (Adherent cell) 
Before fixation cells growing on cover slips (70% confluent) or in dishes (70% 
confluent)  were washed twice with CSK buffer, incubated for 5mins with CSK buffer 
containing 0.5% Triton X, then washed a further two times with CSK buffer. All steps 
were carried out on ice. 
Fixation, permeabilisation and staining 
Cells were fixed with either 4% paraformaldehyde at RT or 100% cold methanol at -
20°C for 10mins. Cells fixed with paraformaldehyde were then permeabilised, 3 x 
3mins, with PBS and 0.5% triton X. there is no need to permeabilise methanol fixed 
cells.  
 The cells were then blocked in IF blocking buffer for 20mins to 1hour at 37°C. 
Blocking buffer was then removed and the primary antibody was added in blocking 
buffer to the cells. These were incubated at 37°C for 1 hour. The primary antibody was 
removed and the cells were washed 3 times with PBS. A solution containing a 1:1000 
dilution secondary Alexa antibody and 1µg/ml Dapi in blocking buffer was then added 
to the cells for 30 mins at 37°C. The cells were washed a further 3 times with PBS and 
mounted on slides with 15µl of prolong gold. 
 EdU staining was carried out using the Invitrogen Click-it EdU imaging Kit using 
alexa fluor 555 azide. This was carried out according to manufacturer’s guidelines. 
 The slides were kept in the dark o/n and the following day the coverslips were 
sealed with clear nail varnish. Slides were kept at 4°C in the dark until imaged.  
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Note for DT40 cells (suspension cells)  
Dt40 cells were pre-extracted in 15ml falcon tubes. 3x106 cells were used per slide. 
After pre-extraction the cells were resuspended in 200µl PBS and pipetted onto 
polylysine coated slides. They were left to settle and attach to the slides for 15mins 
before fixation, permeabilisation and staining. Silicone isolators were sealed onto the 
slides before cells were added, maintaining a sealed area to fix and stain the cells. 
All immunocytochemistry experiments were imaged using a DeltaVision Spectris 
Restoration Microscope built around an Olympus IX70 stand, with a 60 x/100 x/1.4NA 
lens (Applied Precision, LLC, WA). Optical sections were recorded every 0.2 µm, and 
3D data sets were deconvolved using the constrained iterative algorithm   implemented 
in SoftWoRx software (Applied Precision LLC). Image data were quantified using 
SoftWoRx software. 
2.11.2 Live cell monitoring and laser induced DNA damage 
HEK 293 and U2OS cells were plated in 35mm ibidi µ-Dishes with a Grid-500 at a 
density of 1-2 x 105 cells and incubated o/n at 37°C in 5% CO2. The following morning 
cells were pre-sensitized with 10µM BrdU (in complete DMEM) for 24hrs before laser 
striping. When required, cells were treated with 1µg/ml doxycycline/tetracycline to 
induce expression of proteins in a tetracycline inducible system. One hour before laser 
striping the culture media was aspirated from the cells and replaced with 1ml HEPES 
buffered DMEM in the absence of phenol red to prevent a potential interference of the 
phenol red in complete media with the laser absorption. The cells were then allowed to 
equilibrate with the temperature of the microscope platform for at least 20mins before 
the induction of a laser induced damage stripe. The microscope and platform was 
maintained at 37°C throughout the experiment. Before beginning, the laser focus was 
calibrated. All photoactivation experiments were conducted using a DeltaVision 
Spectris (as above) fitted with a 10 mW 405 nm solid-state laser. The laser was 
focused to diffraction-limited spots in the shape of a single line and spot bleaching 
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performed with a single 2sec stationary pulse at 100% laser power. A pattern spacing 
of 10 was adopted to create a line of spot bleaching. The cells were subsequently 
imaged every 30sec after laser induced damage to monitor the accumulation of the 
fluorescent tagged protein to the site of damage. The 60X lens was used to induce the 
photobleaching and to image the cells. 
2.11.3 Laser induced DNA damage 
In order to analyse the recruitment of non-fluorescently tagged proteins to laser 
induced damage stripes a different system was adopted in comparison to 2.5.2. Cells 
were prepared using the same mechanism as in 2.5.2. A Leica TCS SPSII was used to 
induce a laser stripe damage in the live cells. Using the FRAP Wizard, a 405nm laser 
was adopted to induce the stripe of damage. The laser was focused to a line (ROI) 
across the nucleus of two cells at a time and the width of the ROI rectangle used was 4 
pixels. Using the 60X lens, a stripe of damage was induced with 100% laser power and 
200 iterations. The position of the cells damaged within the grid system on the ibidi 
dishes was recorded and the cells were allowed to recover at 37°C in 5% CO2 for 1hr 
post damage to allow the recruitment of repair proteins of interest to the laser induced 
stripe of damage. After recovery, the cells were pre-extracted, fixed and stained using 
the desired immuno-fluorescent antibodies and imaged using the DeltaVision Spectris 
Restoration Microscope. 
Note; when HEK 293 cells were used for methods 2.5.2/2.5.3 The ibidi dishes were 
pretreated with polylysine for 24hrs at 4°C before seeding the cells. This was done to 
allow the cells to adhere more tightly to the dish and prevent the loss of the cells during 
striping and processing as HEK 293 cells are semi-adherent. 
2.11.4 γ-irradiation of DT40 cells and foci counting 
In order to quantify the number of RAD51, RPA and CtIP foci induced in different DT40 
cell lines after DNA damage, cells were γ-irradiated, fixed and stained and then the 
damage induced foci were counted. DT40 cells were seeded 2 x 105 cells/ml 24hrs 
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before irradiation. A cesium source of γ-irradiation was used to induce 4GY of damage 
to the cells. After irradiation the cells were allowed to recover at 37°C in 5% CO2 for 1-
4hrs. After recovery the cells were pre-extracted, fixed and stained with the appropriate 
antibodies as in 2.5.1. The cells were imaged using a 60X lens on the DeltaVision 
Spectris Restoration Microscope. The images were deconvoluted as previously 
described and the damage induced foci were counted using Imaris software. The foci 
were counted in relation to quality and foci of non-damaged cells were compared to 
damaged cells. The experiment was repeated in triplicate counting between 100-300 
cells per experiment. 
2.12 Statistics  
Standard deviation(S.D) 
Error bars were calculated using Standard deviation in all cases when the experiment 
was repeated at least three times. S.D was calculated as follows; 
 
 
 
Paired student t-test 
The paired student t-test was used to calculate the statistical significance between two 
data sets ie HRE assay. It was calculated as follows; 
 
S=SD 
X=each value in the data set 
X=mean of all values in data set 
N=number of data points 
M1/M2=data set 1 and 2 means 
SD1/SD2=Standard deviation of data 
set 1 and 2. 
N=number of data points 
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Once the t value was calculated the corresponding p value was elucidated from a 
maths table. The degrees of freedom were taken to be n-1. 
IC50 values 
In order to determine the inhibitory effect of Parp inhibitor Olaparib on the survival of 
DTDR17 cells using a colony survival assay, an IC50 value was calculated. IC50 value 
is defined as the concentration of a test compound required to achieve half maximal 
inhibition with Olaparib. The IC50 values were calculated from log dose response 
curves using GraphPad Prism 6 software. 
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Chapter 3 The role of the BARD1 BRCT domains in the stabilisation 
of the BRCA1 complexes. 
3.1 Introduction 
BARD1 was discovered in a yeast two-hybrid screen identifying BRCA1 interacting 
proteins [194]. The heterodimer formed between BRCA1 and BARD1 is obligatory for 
their function in the DNA damage response (DDR). Loss of either proteins leads to 
indistinguishable phenotypes. Both Brca1- and Bard1- null mice are embryonic lethal 
[207], and cell lines derived from these mice exhibit severe chromosomal abnormalities 
and defects in HR.  
 One of the main functions of BARD1 is to bind to BRCA1, stabilising and 
enhancing BRCA1 activity [169, 209, 347]. However more recently, it has become 
evident that the BRCT domains of BARD1 contribute to the maintenance of genome 
stability [266, 269]. The BARD1 BRCT domains are not required to bind BRCA1, 
revealing a novel role for BARD1 in HR independent of its requirements to stabilise and 
retain BRCA1 in the nucleus. The mechanism and function by which the BRCT 
domains of BARD1 contribute to the DDR remain unknown.  
 In this chapter, genetic and biochemical assays are deployed to investigate 
whether the BARD1 BRCT domains contribute to the stabilisation of the BRCA1-A, B 
and C complexes. 
3.2 Results 
3.2.1 The BARD1 BRCT domains are required for HR 
Current evidence supporting that the BARD1 BRCT domains are important for efficient 
HR has been carried out in model systems using transient expression or transient 
knockdown of BARD1 as opposed to stable expression or knockout [266] which would 
allow a more in-depth and long-term study of the functional importance of the BARD1 
BRCT domains in the DDR. In order to clarify the importance of the BARD1 BRCT 
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domains in HR, DT40 cell lines with a complete Bard1 knock-out status were used (gift 
from C. Vanderberg). DT40 have been shown to be a good model system to study the 
DDR and have been used in numerous studies of DNA repair.  Loss or mutation of 
DDR proteins in DT40 cells have a strong phenotypic resemblance to their murine 
counterpart [348]. DT40 show a high rate of targeted integration of transfected DNA 
[348, 349] allowing facile gene knockout and stable integration of a gene of interest. 
The Bard1 cells were stably reconstituted with either HsBARD1 or HsBARD1ΔBRCT. 
 DT40 cell lines used throughout chapters 3-5 are derived from a 
modified version of DT40 (known as DTDR17). DTDR17 cells are genetically modified 
to allow the measurement of homologous recombination efficiency in vivo. This cell line 
contains a single copy the pDR-GFP construct, previously described by Pierce et al 
[350]. The construct contains two inactive copies of the GFP gene. One GFP gene 
contains two stop codons at the 5’ end and a restriction site recognised by the 
restriction enzyme Isce-I. The second GFP gene only consists of an internal fragment 
of the gene, lacking both the 5’ and the 3’ end. Once the restriction enzyme Isce-I is 
introduced into the cell line it generates a staggered DSB. Efficient HR is measured by 
the relative expression of GFP by FACs. Once Isce-I creates a staggered DSB in the 
non-functional GFP, only cells which are proficient in HR can express a functional GFP 
thereby efficient HR can be measured by the relative GFP expression of mutant cell 
lines in comparison to WT cells. The repair of an Isce-I induced DSB by homologous 
recombination can be measured in the DTDR17 cell line.    
 In order to confirm that the BRCT domains of BARD1 are required for efficient 
HR the homologous recombination efficiency (HRE) assay was used. Bard1 cells 
reconstituted with either full length HsBARD1 or HsBARD1ΔBRCT were transfected 
with the Isce-I plasmid to generate a DSB. The level of GFP expression was analysed 
by FACs 24hrs after transfection. Consistent with previous studies, the loss of the 
BRCT domains of BARD1 greatly reduces the ability of the cells to carry out efficient 
HR (figure 3.1(b). Importantly the decrease in GFP expression, which correlates with a 
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decrease in HRE, seen in the absence of the BARD1 BRCT domains was fully 
corrected with the expression of full length HsBARD1. This suggests that the human 
and chicken BARD1 genes are interchangeable fully functional orthologues. The stable 
expression levels of reconstituted BARD1 cells with either HsBARD1 or 
HsBARD1ΔBRCT can be found in figure 3.14. 
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Figure 3.1 The BARD1 BRCT domains are required for efficient HR 
(a) Schematic representation of the pDR-GFP construct which is stably integrated into a single 
site of the DT40 genome in the DTDR17 cell line. The pDR-GFP contains a SceGFP gene 
which has two in frame stop codons and also an Isce-I restriction site. A functional GFP is only 
produced when the Isce-I induced DSB is repaired by short tract non-crossover gene 
conversion, using the internal GFP fragment as a template for repair.  
(b) HRE assay illustrating the percentage of cells expressing GFP 24hrs after transfection with 
the Isce-I expressing plasmid. Results were normalised to untransfected cells. Data shown are 
the mean of at least 3 independent experiments. Error bars, s.d. *** indicates a statistical 
significance p value of ≤ 0.001. P value derived from the student t-test. 
(c) Representive dot plot of raw data from figure (b) Cells expressing GFP were identified by 
FACS analysis. GFP positive cells were gated for relative to their GFP status and size (FSC-H) 
and seen in the box R2. 
 
 
DTDR17 cells lacking the BRCT domains of BARD1 showed a decrease in their 
ability to carry out efficient HR in comparison to WT cells according to the HRE assay 
in figure 3.1(b,c). Bard1 cells reconstituted with HsBARD1 appear to express double 
the level of GFP in comparison to WT, however this is commonly seen throughout this 
chapter in HRE assays. It is believed to be due to the overexpression of BARD1, 
however the endogenous level of BARD1 could not be analysed due to the lack of 
chicken BARD1 antibodies. The defects in HR seen in figure 3.1 in the absence of the 
BARD1 BRCT domains is not believed to be due to an expression difference between 
reconstituted   HsBARD1 and HsBARD1ΔBRCT as the expression of both proteins 
appear to be very similar as seen in figure 3.14(a). 
c 
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Bard1 cells reconstituted with HsBARD1ΔBRCT were also sensitive to the 
PARP inhibitor, Olaparib (figure3.2 (b). In comparison to WT cells, Bard1 cells and cells 
reconstituted with HsBARD1ΔBRCT showed a 10 to 20 fold decrease in the amount of 
colonies formed when treated with a PARP inhibitor at 3μM and around a four fold 
decrease in IC50 value. PARP is an important factor in the repair of single stranded 
breaks and it is generally accepted that cells lacking both PARP-dependent SSB repair 
and also key proteins required for the repair of DNA DSBs are inviable [219, 351, 352]. 
Brca1 null cells have been shown to be extremely sensitive to PARP inhibitors. 
Experimental studies suggest that in the absence of PARP, unrepaired SSB form DSB 
during replication and only cells which are competent in repairing DSB can survive.  
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Figure 3.2 Loss of the BRCT domains of BARD1 sensitises cells to Olaparib 
(a) Schematic representation of how PARP inhibitors sensitise HR deficient cells. Adapted from 
Joseph A. De Sot and  Chu-Xia Deng 2006. 
(b) Colony survival assay illustrating the sensitivity of Bard1 and HsBARD1ΔBRCT cells to 
PARP inhibitor, Olaparib. Wild type, Bard1 and mutant cells expressing either HsBARD1 or 
HsBARD1ΔBRCT were treated for 24hrs with 0-3µM Olaparib before being plated on 
methylcellulose cellulose media, as described in the Methods and materials section. Surviving 
colonies were counted 9-12 days after plating and plotted relative to untreated cells. Data 
shown are the mean of at least 3 independent experiments. The IC50 values were calculated 
from log dose response curves  from at least 3 independent experiments. 
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As shown in figures 3.1 and 3.2, Bard1 cells are extremely sensitive to PARP inhibitors 
and also have severely impeded HR according to the HRE assay in comparison to WT 
cells.  Bard1 cells expressing HsBARD1ΔBRCT also appear to be less efficient in 
repairing DNA DSBs. The loss of the BRCT domains alone doesn’t demonstrate the 
same level of sensitivity as a complete BARD1 Knock-out. The loss of the BARD1 
BRCT domains does not affect the formation of the BRCA1 BARD1 heterodimer 
allowing BRCA1 to play its role in repairing the DSB [194] whereas complete loss of 
BARD1 prevents the retention of BRCA1 in the nucleus where it has its DDR function. 
This may partly explain the difference in sensitivity to DNA DSBs, between BARD1 
knockout cells and those which lack the BARD1 BRCT domains. Results so far in this 
chapter suggest that the loss of the BARD1 BRCT domains decreases the efficiency of 
HR in cells and sensitises these cells to PARP inhibitors indicating that the BRCT 
domains of BARD1 contribute to the efficient repair of DNA DSBs. 
To confirm that the decrease in HR efficiency and sensitivity to PARP inhibitors 
shown in cells lacking the BARD1 BRCT domains cannot be accounted for by the 
potential mislocalisation of the protein, the localisation of HsBARD1 and 
HsBARD1ΔBRCT in Bard1 cells was analysed by Western blot. Lysates from Bard1 
cells reconstituted with either HsBARD1 or HsBARD1ΔBRCT were separated into their 
nuclear and cytoplasmic fractions and the localisation of BARD1 was investigated by 
Western blot. Fractionations of cell extracts confirm that HsBARD1 and 
HsBARD1ΔBRCT are proficient in localising to the nucleus (figure 3.3). The BARD1 
antibody used recognises only human BARD1 and does not recognise chicken BARD1, 
therefore a direct comparison between Wild type cells and mutant reconstituted cell 
lines was not possible. α-GAPDH was used as a cytoplasmic marker and α-P84 was 
used as a nuclear indicator to assure that the method of fractionation used was 
proficient in separating the nuclear and cytoplasmic fractions. It is important to note that 
figure 3.3 is not an accurate depiction of the overall expression of HsBARD1 and 
HsBARD1ΔBRCT as the “whole” expression of HsBARD1 is relatively low. A more 
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accurate representation of the total expression of BARD1 and HsBARD1ΔBRCT can 
be seen in figure 3.14(a) and figure 3.3 should only be referenced in relation to the 
cytoplasmic and nuclear localisations as the whole lysates appear to not have 
transferred correctly. 
 
 
 
  
 
 
 
                              
 
Figure 3.3 Fractionation of DTDR17 Bard1 reconstituted cells. 
Cell lysates were fractioned into their cytoplasmic and nuclear fractions as described in the 
Methods and Materials chapter. W(whole), C(cytoplasmic) and N(nuclear) Fractions were 
analysed by Western blotting. The majority of BARD1 is located in the nuclear fractions for both 
reconstituted mutant cell lines.  
 
 
During the analysis of the Homologous recombination efficiency of Bard1 cells and 
reconstituted cells in figures 3.1(b), 3.12(a) and 3.15(a) it became clear that the 
difference in the expression level of reconstituted proteins corresponded to a variation 
in the results of the assay. To investigate the impact this had on the results observed 
with the loss of the BRCT domains, a number of different unique clones from the same 
DTDR17 Bard1 cell line reconstituted with HsBARD1ΔBRCT were analysed using the 
HRE assay. As shown in figure 3.4(b) there is a variation in the expression of 
HsBARD1ΔBRCT. Consistent with the results in figure 3.1, all unique clones in figure 
HsBARD1 HsBARD1ΔBRCT 
W W C C N N 
GAPDH (cytoplasmic) 
P84 (nuclear) 
BARD1 
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3.4 show a decrease in efficient repair of DSBs by HR. It appears that the expression 
of level of HsBARD1ΔBRCT does impact the level of GFP expression in the HRE 
assay however the overall result remains clear in comparison to either Wild type cells 
or Bard1 cells reconstituted with full length HsBARD1. The difference of clonal 
expression was calculated by band density using ImageJ. The % expression of the 
HsBARD1ΔBRCT clones were normalised relative to the expression of GAPDH 
compared to the highest expressing clone (13).  
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Figure 3.4 HRE assay comparing DTDR17 BARD1-/- + HsBARD1ΔBRCT clones. 
(a) HRE assay illustrating the percentage of cells expressing GFP 24hrs after transfection with 
the Isce-I expressing plasmid. Results were normalised to untransfected cells. Data shown are 
the mean of at least 3 independent experiments. Error bars, s.d. 
(b) Western blot illustrating the expression of the different unique clones. % expressing 
compared to highest expressing clone and band density calculated using imageJ. 
(c) Representative dot plot of raw data from figure (a) Cells expressing GFP were identified by 
FACS analysis. GFP positive cells were gated for relative to their GFP status and size (FSC-H) 
and seen in the box R2. 
 
 
The results in figures 3.1(b), 3.2(b) and 3.4(a) strongly suggest that the BARD1 BRCT 
domains are important in the repair of DNA DSBs. Figures 3.1(b) and 3.4(a) shows that 
the loss of the BARD1 BRCT domains results in a decrease in efficient HR compared 
to WT cells and figure 3.2(b) indicates that the loss of the BRCT domains of BARD1 
sensitises the cells to PARP inhibitors. The defects seen in cell lines lacking the 
BARD1 BRCT domains appears not to be due to mislocalisation of the protein to the 
nucleus (figure 3.3). As sensitivity to PARP inhibitors is common in cells with aberrant 
HR, these results firmly implicate a functional role for the BARD1 BRCT in the repair of 
DNA DSBs.                                                                           
c 
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3.2.2 The BARD1 BRCT domains help stabilise CtIP in the BRCA1-C 
complex. 
Several years ago three different proteins were discovered to form complexes with the 
BRCA1 BARD1 heterodimer. These proteins were identified as Abraxas, FANCJ and 
CtIP and they form three different complexes referred to as the BRCA1-A, BRCA1-B 
and BRCA1-C respectively [133, 228, 346]. All three proteins bind to the BRCA1 BRCT 
domains in a phosphorylation dependent manner and are important in the DDR [353]. 
To date the main function of BARD1 in these complexes is to bind BRCA1, allowing its 
nuclear retention and greatly increasing BRCA1s E3 ligase activity. With the recent 
knowledge that the BRCT domains of BARD1 are also important for HR, it is possible 
that they contribute to the formation and/or stabilisation of the BRCA1 complexes. 
 As previously mentioned, Abraxas, FANCJ and CtIP bind to the BRCA1 BRCT 
domains in a phosphorylation dependent manner. The BARD1 BRCT domains have 
also been shown to be capable of binding a synthetic phospho-peptide containing a 
pSer-D/E-D/E-E motif, however there are no known phospho-proteins which 
specifically interact with the BARD1 BRCT domains [346]. Although BRCA1 is known 
to form the main phospho-dependent interaction with Abraxas, FANCJ and CtIP it has 
never been shown if BARD1 can contribute to these interactions. To determine if the 
BARD1 BRCT domains contribute to the formation of the BRCA1 complexes, Flp-In 
HEK 293 cells stably expressing either GFP-BARD1 or GFP-BARD1ΔBRCT were 
generated.  
Flp-In HEK 293 cells were used to generate stable cell lines expressing GFP-BARD1 
and GFP-BARD1ΔBRCT as they are designed to allow tetracycline inducible 
expression of the stably integrated gene. This cell line also allows facile targeted 
integration of a Flp-In expression vector containing your gene of interest into a single 
stably integrated FRT site at a transcriptionally active genomic locus within the cell line.  
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A pull down of GFP-BARD1ΔBRCT was compared to GFP-BARD1 in their ability to 
form the BRCA1 complexes. Using the same conditions. GFP-BARD1ΔBRCT and 
GFP-BARD1 were immunoprecipitated and the amount of Abraxas, CtIP and FANCJ 
pulled down with GFP-BARD1ΔBRCT and GFP-BARD1 was analysed by Western blot 
to determine any differences in their ability to form the BRCA1 complexes. 
BARD1ΔBRCT was not as efficient at forming the BRCA1-C complex which binds CtIP 
(figure 3.5). The decrease in the amount of CtIP found to co-immunoprecipitate with 
GFP-BARD1ΔBRCT in comparison to GFP-BARD1 was statistically significant 
according to the student t-test. This suggests that the BRCT domains of BARD1 may 
help stabilise the BRCA1-C complex and could potentially clarify their role in promoting 
genome stability. 
HEK 293 cells stably expressing GFP alone were used as a control.  As previously 
stated, the expression GFP-BARD1 and GFP-BARD1ΔBRCT was induced and 
regulated by tetracycline. For this experiment, it was important to keep the levels of 
expression of GFP-BARD1 and GFP-BARD1ΔBRCT as close to endogenous levels of 
BARD1 as possible to avoid potential dominant negative effects associated with 
overexpression of proteins. In order to maintain a 3 fold over endogenous BARD1 
expression GFP-BARD1 was induced with 2.5ng tetracycline and GFP-BARD1ΔBRCT 
was induced with 7.5ng tetracycline over night  before harvesting cells (figure 3.5(a).  
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Figure 3.5 The BRCT domains of BARD1 are important in stabilising the BRCA1-C 
complex 
(a) Western blot illustrating the concentration of tet required to induce the expression GFP-
BARD1 and GFP-BARD1ΔBRCT to 3 times the endogenous BARD1 level. Cells were induced 
o/n with different tet concentration and harvested the following morning before analysis by 
Western blot.  
(b)Licor quantification of a GFT-trap pull down. GFP-BARD1 and GFP-BARD1ΔBRCT were 
pulled down and immunopercipitated proteins were analysed by licor Western blotting. Each 
protein band was quantified by Licor software and figures were normalised to amount of BRCA1 
present. FL(GFP-BARD1), Δ (GFP-BARD1ΔBRCT). *** indicates a statistical significance p 
value of ≤ 0.001. P value derived from the student t-test. Data shown are the mean of at least 6 
independent experiments. Error bars, s.d. 
(c) A representative Licor Western blot from which the graph in figure (a) was generated. FL 
(GFP-BARD1), Δ (GFP-BARD1ΔBRCT), G(GFP) 
(d) Duplicate Western blot from experiment in figure (b) using a different CtIP (T-16) antibody. 
 
 
The pull downs were carried out under crosslinked conditions to ensure that all 
potential BRCA1 complex members could be co-immunoprecipitated with BARD1. The 
GFP-BARD1 and GFP-BARD1ΔBRCT lysates were crosslinked with DSP, an amine 
reactive crosslinker, before the pull down was carried out. The amount of Abraxas, 
c 
d 
Abraxas 
BRCA1 
CtIP 
BARD1 
FancJ 
FL Δ G FL Δ G 
Input GFP-trap 
FL G Δ G FL FL Δ Δ G 
GFP-beads Pre-clear Input 
CtIP (T16) 
BARD1 
113 
 
FANCJ and CtIP found to co-immunoprecipitate with GFP-BARD1 and GFP-
BARD1ΔBRCT was plotted in figure 3.5(b) relative to the amount of BRCA1 pulled 
down. As BRCA1 is known to be responsible for binding Abraxas, FANCJ and CtIP, the 
difference in the ability of either GFP-BARD1 or GFP-BARD1ΔBRCT to pull down the 
BRCA1 complex members is illustrated relative to the amount BRCA1 pulled down 
(figure 3.5(b). The CtIP antibody (T-16) normally used for traditional Western blotting 
was not compatible with the Licor system so another CtIP antibody (bethyl) was used, 
however the same result was observed with the T-16 antibody using a traditional 
Western blot method and X-ray film as seen in figure 3.5 (d). The CtIP antibody used in 
figure 3.5 (c) shows extremely high background signal, therefore no input was shown. 
This antibody was only suitable for use after imunnoprecipitation as the majority of 
unspecific bands are lost. There was very little variation in the levels of FANCJ pulled 
down with both GFP-BARD1 and GFP-BARD1ΔBRCT through each experiment and 
no difference was observed in the amount of FANCJ co-immunoprecipitated with GFP-
BARD1 in comparison to GFP-BARD1ΔBRCT. However on several occasions the 
amount of Abraxas pulled down appeared to be less in the case of GFP-
BARD1ΔBRCT in comparison to GFP-BARD1. This was not consistently reproducible 
to make any conclusive deductions. 
 Similar to DTDR17 cells, GFP-BARD1 and GFP-BARD1ΔBRCT expressed in 
the FLP-In HEK 293 cells are proficient at localising to the nucleus (figure 3.6 (a). GFP-
BARD1 and GFP-BARD1ΔBRCT and the control cell line containing just GFP also 
progress through the cell cycle at the same rate (figure 3.6 (b,c,). This evidence 
suggest that the decrease in the amount of CtIP bound to the BRCA1-C complex in the 
absence of the BARD1 BRCT domains is not due to defects in the progression through 
the cell cycle. BRCA1 is known to have important roles in the regulation of the cell 
cycle as a heterodimer with BARD1 [134]. Although the HEK 293 cell lines contain 
endogenous BARD1 it still important to rule out any possible dominant negative effects 
that the overexpression of GFP-BARD1 and GFP-BARD1ΔBRCT may have on the cell 
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cycle. The expression levels of Abraxas, FANCJ and CtIP do not change significantly 
between the different cell lines during the cell cycle (figure 3.6(d). 
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Figure 3.6 GFP-BARD1 and GFP-BARD1ΔBRCT cell lines are not hindered through the 
cell cycle. 
(a) Western blot of the localisation of HEK reconstituted cell lines. GFP (G), GFP-BARD1 (FL) 
and GFP-BARD1ΔBRCT (Δ) 
(b) Representative FACS analysis for cell cycle profiles of cells stained with propidium iodide 
(PI).Cells were arrested in late G1 phase by a double thymidine block and released. Samples 
were taken up to 10hrs after release. 
(c) Representative table of the amount of cells in the different stages of the cell cycle obtained 
from the FACS analysis of cell cycle profiles, as in (a), of cells stained with PI and BrdU .Cells 
were pulse labelled with BrdU 20 minutes before fixing and staining. 
(d) Western blot of the lysates collected at each time point after release from the double 
thymidine block. Unsynchronised (Un). 
 
The results shown in this chapter so far strongly suggest that the BARD1 BRCT 
domains have an important functional role in the repair of DNA DSBs as loss of the 
BRCT domains of BARD1 results in a decrease of HR efficiency and also sensitises 
cells to PARP inhibitors. Evidence from figure 3.5(b) shows that the loss of the BRCT 
domains of BARD1 may abrogate the formation of the BRCA1-C complex as less CtIP 
is found to co-immunoprecipitate with the BARD1 BRCA1 heterodimer in the absence 
of the BARD1 BRCT domains. This result potentially implicates a functional role for the 
BARD1 BRCT domains in the stabilisation of the BRCA1-C complex. 
3.2.3 Designing BARD1 BRCT point mutants to disrupt the potential 
binding of phosphorylated proteins. 
It has become evident that the BARD1 BRCT domains play an important role in the 
DNA damage response and, according to figure 3.5(b), may help stabilise CtIP to the 
BRCA1-C complex. The BRCT domain is an evolutionary conserved module which is 
found in many prokaryotic and eukaryotic proteins. BRCT domains have been shown to 
bind proteins in a phosphorylation dependent manner. Several BRCT domain 
containing proteins have been associated with processes that are essential for cell 
cycle regulation and DNA repair [290]. It is possible that the DDR function of the 
BARD1 BRCT domains may depend on their potential interaction with a phospho-
protein. In order to investigate this hypothesis, single point mutations, which are 
predicted to disrupt potential phospho-protein binding, were generated in the BARD1 
BRCT domains. 
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 BRCT domains were first discovered in the C-terminus of the BRCA1 protein 
which contains two tandem repeat BRCT domains [193]. Although several BRCT 
domain containing proteins commonly have two copies of a BRCT sequence, however 
proteins containing between one and eight units have been identified [193, 289, 290, 
304]. The method by which the BRCT domains of BRCA1 bind phosphorylated proteins 
has been described by three independent crystallographic studies [314, 315, 354]. The 
BRCA1 BRCT domains recognise pSer-X-X-Phe motifs such as those found in 
Abraxas, FANCJ and CtIP and BRCA1 has been shown to interact with these three 
proteins in a phosphorylation dependent manner. Mutations in the pSer-X-X-Phe motifs 
of Abraxas, FANCJ and CtIP prevent their binding to BRCA1 (figure 3.7(a). The 
phospho-peptide binds in a groove which involves both the BRCT domains. The crystal 
structure of the BRCA1 BRCT domains revealed that there is a phospho-binding 
pocket in the N-terminal BRCT domain which binds the phosphate oxygen atom. The 
phenylalanine residue is recognised by a hydrophobic pocket found at the interface of 
the N- and C-terminal BRCT interface reviewed in [291].   
 BRCA1 and BARD1 are structurally very similar, especially in relation to the 
formation and location of their BRCT domains. Both proteins contain tandem BRCT 
domains in the C-terminus of the protein. However in contrast to the BRCA1 BRCT 
domains, there are no known phospho-binding proteins known to interact with the 
BARD1 BRCT domains. The recent elucidation of the crystal structure of the BARD1 
BRCT domains identified Ser575 and Lys619 as two key residues for binding pSer 
peptides. His686 was considered to be favoured as the main residue responsible for 
forming the hydrophobic groove according to the BARD1 BRCT crystal structure, 
similar to M1775R in BRCA1 [311]. Consistent with previous studies, point mutations in 
the BRCT domains of BRCA1, equivalent to Ser575 and Lys619 in BARD1, prevent 
phosphorylated Abraxas, FANCJ and CtIP binding to the BRCA1 BRCT domains 
(figure 3.7(b) Taking into consideration the crystal structure of BARD1 BRCT domains 
and comparing them to known point mutations affecting the binding of phospho-
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proteins to the BRCA1 BRCT domains (figure 3.8(a), three separate point mutation 
were generated in the BARD1 BRCT domains which are predicted to abrogate the 
binding of a potential phospho-peptide. As an extra measure of assurance, the BRCT 
domains of BARD1 were compared in different species revealing highly conserved 
regions where the phospho-protein interactions are thought to occur (figure 3.8(d). 
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Figure 3.7 BRCA1 binds Abraxas, FANCJ and CtIP is a phospho-dependent manner. 
(a) Mammalian two-Hybrid assay between BRCA1 and its binding partners. The intensity of the 
luciferase read out (ALU) indicated binding between the bait and prey proteins. PM and PV are 
the empty vectors used as a binding control..The BRCA1 BRCT domains interact with Abraxas, 
FANCJ and CtIP but not with their mutant counterparts which prevent phosphorylation. . Data 
shown are the mean of at least 3 independent experiments. Error bars, s.d. 
(b) Mammalian two-Hybrid analysis indicating that BRCA1S1665F, BRCA1K1702M, 
BRCA1M1775R and the triple mutant prevent interaction with the known phoshpo-binding 
protein interactors. FANCJ (888-1249) was used as full length FANCJ does not interact with 
BRCA1 in this Mammalian two-hybrid. Data shown are the mean of at least 3 independent 
experiments. Error bars, s.d. 
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Figure 3.8 BARD1 BRCT point mutants 
(a) Amino acid sequence alignment of the BRCT domains of BARD1, BRCA1, MDC1 and 
MCPH1. Mutated sites are circled in red, regions highlighted blue are highly conserved and 
responsible for the phosho-serine binding pocket. Figure adapted from Williams et al 2004 
(b) Stick model of the phospho-binding pocket of BRCA1(green) and binding of CtIP ligand 
(pink) BARD1 phosho binding pocket is superimposed onto BRCA1s in grey. Figure adapted 
from Birrane et al. 2007 
(c) Illustration of the BRCT binding pockets. Figure adapted from Williams et al 2004. 
(d) Sequence alignment of BARD1 BRCT from a variety of species. 
 
 
The point mutants generated in the BRCT domains of BARD1 were, S575F, K619M 
and H686R. The S575F and K619M mutation are predicted to disrupt the phospho-
binding groove whereas the H686R is predicted to disrupt the hydrophobic binding 
pocket. A triple mutant was also generated as there has been evidence suggesting that 
a single point mutation in the BRCT domain of another protein (XRCC1) is not enough 
to prevent binding of a phospho-protein to the BRCT domains (correspondence with 
Keith Caldecott).  
 
3.2.4 BARD1 binds CtIP and potentially Abraxas not in a 
phosphorylation dependent manner. 
Previous results in this chapter indicated that BARD1 potentially stabilises CtIP to the 
BRCA1-C complex. Full length BARD1 interacts with CtIP and to a lesser extent 
Abraxas in a Mammalian two-Hybrid system (figure 3.9(a). This interaction appears to 
be dependent on the phosphorylation of CtIP and Abraxas as their phospho-mutant 
counterparts do not interact with BARD1 in the Mammalian two-hybrid (figure 3.9). The 
BRCT domains of BARD1 alone are not sufficient to form these interactions. The 
BARD1 BRCT domains do not interact with Abraxas and CtIP (figure 3.9(a). However, 
it has often been observed in the lab that large full length proteins such as BRCA1 and 
FANCJ do not interact in a Mammalian two-Hybrid. In a mammalian two-Hybrid system 
the prey and bait proteins are fused to an activating domain and a binding domain. 
Only when the activation domain and binding domain are brought into close contact, by 
the interaction of the bait and prey proteins, do they form a functional transcription 
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factor. This leads to the significant increase of the expression of a reporter gene, which 
is GFP in this case, which is measured and relates to the interaction between the bait 
and prey proteins. In the case of full length BRCA1 and FANCJ, it is possible that the 
lack of interaction seen in a mammalian two-hybrid is due to the structural confirmation 
of the proteins preventing the interaction between their fused binding and activation 
domains. In the case of BRCA1, only the BRCT domains are used and similarly only 
the region around the pSer-X-X-Phe of FANCJ can be used in this system.  
 Figure 3.9(b) reveals that the BARD1 BRCT domains containing point 
mutations also interact with CtIP and Abraxas suggesting that the interaction is not 
dependent on the phospho-binding potential of BARD1 BRCT domains. Loss of the 
BARD1 BRCT domains shows a greater interaction with CtIP than observed with the 
full length protein. Figure 3.9 illustrates that BARD1 interacts with CtIP and to a lesser 
extent Abraxas even in the absence of its BRCT domains. In both figures the relative 
signal obtained is a lot lower than those seen with BRCA1 interactions, this may 
indicate that the BARD1 binding seen is of a weaker or more transient nature. 
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Figure 3.9 BARD1 interacts with CtIP and to a lesser extent Abraxas. 
(a) Mammalian two-Hybrid assay between BARD1 and the BRCA1 binding partners. The 
intensity of the luciferase read out (ALU) indicated binding between the bait and prey proteins. 
PM and PV are the empty vectors used as a binding control.BARD1 interact CtIP and to a 
lesser extent Abraxas but not with their mutant counterparts which prevent phosphorylation. . 
Data shown are the mean of at least 3 independent experiments. Error bars, s.d. 
(b) Mammalian two-Hybrid analysis indicating that BARD1S575F, BARD1K619M, 
BARD1H686R and the triple mutant do not prevent interaction with the known BRCA1 
interacters. Data shown are the mean of at least 3 independent experiments. Error bars, s.d. 
 
3.2.5 The binding of BARD1 to CtIP it dependent on BRCA1. 
To determine whether BARD1 can directly bind to CtIP, a point mutant in the ring 
domain of BARD1 (BARD1L107P) was generated to prevent the formation of the 
BRCA1 BARD1 heterodimer. BRCA1 and BARD1 bind via α-helices flanking their 
RING domains [206]. BARD1L107P has been previously shown to abrogate the 
binding of BRCA1 to BARD1 by disrupting one of the α-helices at the interface of 
binding [269]. BARD1L107P does indeed prevent BRCA1 binding (figure 3.10(b). In the 
absence of BRCA1, BARD1 cannot bind to CtIP as shown in figure 3.10(a). To confirm 
this result the interaction between BARD1 and the BRCA1 interacting partners were 
examined in cells treated with a BRCA1 siRNA. As expected similar results were seen 
in both experiments when BRCA1 was knocked down or prevented from binding to 
BARD1. 
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Figure 3.10 BARD1 and CtIP binding it dependent on BRCA1 
(a) Mammalian two-Hybrid assay between BARD1L107P and the BRCA1 binding partners. The 
intensity of the luciferase read out (ALU) indicated binding between the bait and prey proteins. 
PM and PV are the empty vectors used as a binding control.BARD1L107P does not form any 
interactions. Data shown are the mean of at least 3 independent experiments. Error bars, s.d. 
(b) Mammalian two-Hybrid analysis indicating that BARD1 can interact with both the large and 
small ring domains of BRCA1. Data shown are the mean of at least 3 independent experiments. 
Error bars, s.d. 
(c) Mammalian two-Hybrid analysis indicating that BARD1L107P prevents the Ring domain of 
BRCA1 binding. Data shown are the mean of at least 3 independent experiments. Error bars, 
s.d. 
(d) Mammalian two-Hybrid analysis showing that in the absence of BRCA1 BARD1 cannot 
interact with Abraxas, FANCJ or CtIP. Experiment was carried out 48 hrs after siRNA 
transfection. Data shown are the mean of at least 3 independent experiments. Error bars, s.d. 
(e) Western blot of lysates harvested between 24 and 72hrs after siRNA treatment. BRCA1 
knockdown is clearly present after 24 and 48hrs. Whereas the non-specific control (NSC) does 
not appear to affect the levels of BRCA1 expression. 
 
The results in figure 3.10 indicate that the interaction between BARD1 and CtIP, shown 
earlier in a Mammalian two-Hybrid assay, depends on BRCA1.  The Mammalian two-
Hybrid assay can indicate a direct or an indirect interaction between a bait and a prey 
protein. It appears that for this experiment the formation of the BRCA1 BARD1 
heterodimer is necessary for CtIP to bind. With this result in mind, the overall weaker 
signals observed in figure 3.9 of BARD1 and the BRCA1 complex members in 
comparison to the signal obtained with BRCA1 and its interacting partners may be 
partially explained by an indirect interaction between BARD1 and CtIP. It appears that 
the interaction between BARD1 and CtIP seen in a Mammalian two-hybrid may be 
completely dependent on the presence of BRCA1 as BARD1 BRCT domains alone 
cannot bind CtIP (figure 3.9a). It is possible that the interaction seen between BARD1 
and CtIP in the Mammalian two-hybrid is in fact an interaction between BRCA1 and 
CtIP. 
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3.2.6 The predicted Phospho-binding residues within the BARD1 
BRCT domains are not responsible for stabilising CtIP to the 
BRCA1-C complex. 
The BARD1 BRCT domains appear to play a role in the stabilisation of CtIP to the 
BRCA1-C complex (figure 3.5b). As discussed previously, the best characterised 
function of BRCT domains are their ability to bind phosphorylated proteins. In order to 
elucidate whether the potential phospho-binding function of the BARD1 BRCT domains 
are responsible for this stabilisation, stable inducible HEK Flp-In cell lines containing 
GFP-BARD1S575F, GFP-BARD1K619M, GFP-BARD1H686R and GFP-BARD1 triple 
mutant were generated. Tetracycline was used to induce the expression of the BARD1 
mutants to near endogenous levels (figure 3.11(a). Using a GFP-trap pull down system 
as previously described, it became clear that point mutations in the BRCT domains of 
BARD1 disrupting potential phospho-protein interaction domains, had no effect on 
stabilising the BRCA1 complexes as the same levels of Abraxas, FANCJ and CtIP 
were co-immunoprecipitated with GFP-BARD1 and the BARD1 point mutants (figure 
3.11(b) As shown previously by a Mammalian two-Hybrid analysis, the presence of 
BRCA1 is not only vital to the formation of the BRCA1 complexes but also necessary to 
see any interaction between BARD1 and CtIP. This is evident in figure 3.11(d) as no 
Abraxas, FANCJ or CtIP can be pulled down with BARD1 in the absence of BRCA1. 
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Figure 3.11 BARD1 phospho-mutants to not contribute to the stabilisation of the BRCA1 
complexes 
(a) Tet induced expression of the BARD1 mutant HEK cell lines. Concentration of tet used for 
each cell line is circled in red. 
(b) Licor quantification of a GFT-trap pull down. GFP-BARD1 and mutant forms were pulled 
down and immunopercipitated proteins were anylised by licor Western blot. Each protein band 
was quantified by Licor software and protein values were normalised to amount of BRCA1 
present. Data shown are the mean of at least 3 independent experiments. Error bars, s.d. 
(c) A representative Licor Western blot from which the graph in figure (a) was generated. 
FL(GFP-BARD1), Δ (GFP-BARD1ΔBRCT) A (GFP-BARD1 triple mutant), S(GFP-
BARD1S575F), K (GFP-BARD1K619M), H(GFP-BARD1H686R) 
(d) Pull down comparing GFP-BARD1 to GFP-BARD1L107P, Analysed by Western blot. GFP-
BARD1L107P does not co-immunopercipitate with BRCA1, Abraxas, FANCJ or CtIP. 
 
 
 
 
 
3.2.7 BRCA1 BRCT point mutants have a HR defect 
The BRCT domains of BRCA1 are crucial in the repair of DNA DSBs. Loss of the 
BRCT domains of BRCA1 impairs the efficient repair of DNA DSB, leading to a HR 
phenotype. There are several conflicting findings in the literature regarding the HR 
status of cells containing point mutations in the phospho-binding regions of BRCA1. 
Valerie et al see an increase in HR while Baer et al see a reduction [298, 321]. 
However these experiments were carried out in cell lines transiently expressing 
BRCA1. In order to compare the effects of the point mutations generated in BARD1 
BRCT domains to those in the BRCA1 BRCT domains on a biological level, DTDR17 
BRCA1-/- cells were reconstituted with either a complete HsBRCA1 BRCT delete 
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mutant or with the BRCA1 point mutants previously discussed. Brca1 cells 
reconstituted with BRCA1 BRCT domain point mutants, known to disrupt the binding of 
phosphoproteins, showed a decrease in HR efficiency by the HRE assay (figure 
3.12(a). Consistent with this result, BRCA1 mutant cell lines were also sensitive to 
PARP inhibitors demonstrated in the colony survival assay in figure 3.12(c).  
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Cell Line IC50 Value(µM) IC50 Fold increase over DTDR17 
DTDR17 5.268 1 
DTDR17 -BRCA1 1.066 4.9 
DTDR17 +BRCA1 4.21 1.25 
DTDR17 +BRCA1ΔBRCT 1.418 3.56 
DTDR17 +BRCA1 A 0.939 5.61 
DTDR17 +BRCA1 S 1.346 3.9 
DTDR17 +BRCA1 K 1.702 3.1 
DTDR17 +BRCA1 M 1.737 3.04 
Figure 3.12 Point mutations in the BRCA1 BRCT domains abrogates HR efficiency 
 
(a) HRE assay illustrating the percentage of cells expressing GFP 24hrs after transfection with 
the Isce-I expressing plasmid. Results were normalised to untransfected cells. 
*** indicates a statistical significance p value of ≤ 0.001 and * represents a p value of ≤ 0.05 P 
value derived from the student t-test Data shown are the mean of at least 3 independent 
experiments. Error bars, s.d.  
(b) Western blot illustrating the expression of the different reconstituted Brca1 cell lines. % 
expression compared to the expression of reconstituted Brca1 cell line expressing full length 
BRCA1. Band density calculated using imageJ. 
(c) Representive dot plot of raw data from figure (a) Cells expressing GFP were identified by 
FACS analysis. GFP positive cells were gated for relative to their GFP status and size (FSC-H) 
and seen in the box R2. 
(d) Colony survival assay illustrating the sensitivity of Brca1 and reconstituted mutant cell lines 
to PARP inhibitor, Olaparib. Cells were treated for 24hrs with 0-3µM Olaparib before being 
plated on methylcellulose cellulose media, as described in the Methods and materials section. 
Surviving colonies were counted 9-12 days after plating and plotted relative to untreated cells. 
Data shown are the mean of at least 3 independent experiments. Error bars, s.d. The 
IC50 values were calculated from log dose response curves of at least 3 independent 
experiments. 
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It is evident from the results in figure 3.12(a), that in comparison to Brca1 cells 
reconstituted with full length human BRCA1, reconstituted mutant BRCA1 variants 
show defects in HR. The BRCA1 antibody used to detect the expression of 
reconstituted BRCA1 in figure 3.12(b) only detects human BRCA1 hence endogenous 
chicken BRCA1 cannot be detected. The same cell lines are also significantly more 
sensitive to PARP inhibitors in comparison to Wild type cells. The phenotype of these 
cells cannot be explained by a localisation failure as BRCA1 in all the reconstituted  cell 
lines localises to the nucleus (figure 3.13). 
 
 
 
 
 
 
 
 
 
 
Figure 3.13 Fractionation of DTDR17 Brca1 reconstituted cells. 
Cell lysates were fractioned into their cytoplasmic and nuclear fractions as described in the 
Methods and Materials chapter. W(whole), C(cytoplasmic) and N(nuclear) Fractions were 
analysed by Western blotting. The majority of BRCA1 is located in the nuclear fractions for both 
reconstituted mutant cell lines.  
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3.2.8 BARD1 BRCT point mutants do not have a HR phenotype. 
Point mutations in the BRCT domains of BARD1 which are predicted to disrupt 
potential phosphorylated proteins binding appear not to be important in the formation of 
the BRCA1 complexes. The loss of the BRCT domains of BARD1 greatly impairs the 
cells ability to carry out efficient repair of DNA DSBs. In order to elucidate whether 
these particular point mutants also show defects in the HRE assay and are sensitive to 
PARP inhibitors, the DTDR17 Bard1 cell line was stably reconstituted with the 
respective BARD1 point mutants. The expression of reconstituted BARD1 and the 
BARD1 point mutants are illustrated in figure 3.14,  
 Interestingly, although the equivalent point mutants in BRCA1 show clear 
defects in HR, the point mutations in the BARD1 BRCT domains appear to behave like 
Wild type cells. In both the HRE assay (figure 3.15(a), and the colony survival assay 
with PARP inhibitors (figure 3.15(b), the mutant cell lines do not seem to have any 
complications in faithfully repairing DNA DSBs. 
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Figure 3.14 Generation of DTDR17 Bard1 mutant cell lines 
(a) Western blot of reconstituted DTDR17 Bard1 cell lines. Upper band seen is unspecific in 
DT40 cells. % expression above blot was calculated using imageJ densitometry and is relative 
to the expression of reconstituted full length hsBARD1. 
(b) PCR of cDNA extracted from the respective cell lines. Human and chicken BARD1 primers 
were used to amplify a small internal region of BARD1.  
a 
b 
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The reconstituted cell lines generated in figure 3.14(a) show a variation in expression 
which may contribute to a variation in the HRE assay results as previously discussed. It 
is clear from the PCR analysis in figure 3.14(b) that the cell lines have indeed been 
reconstituted correctly as the human BARD1 primers only detect reconstituted human 
BARD1. The BARD1 chicken primers fail to detect any template cDNA in either the 
parental or reconstituted cell lines as wild type BARD1 is completely absent. The 
primers were designed to be exclusive to either human or chicken BARD1. 
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Figure 3.15 BARD1 point mutant do not have a HR phenotype 
(a) HRE assay illustrating the percentage of cells expressing GFP 24hrs after transfection with 
the Isce-I expressing plasmid. Results were normalised to untransfected cells. Data shown are 
the mean of at least 3 independent experiments. Error bars, s.d.  
(b) Representive dot plot of raw data from figure (a) Cells expressing GFP were identified by 
FACS analysis. GFP positive cells were gated for relative to their GFP status and size (FSC-H) 
and seen in the box R2. 
(c) Colony survival assay illustrating the sensitivity of Bard1 and reconstituted mutant cell lines 
to PARP inhibitor, Olaparib. Cells were treated for 24hrs with 0-3µM Olaparib before being 
plated on methylcellulose cellulose media, as described in the Methods and materials section. 
Surviving colonies were counted 9-12 days after plating and plotted relative to untreated cells. 
Data shown are the mean of at least 3 independent experiments. Error bars, s.d. 
 
As previously mentioned, point mutants in the BRCT domains of BARD1 do not show 
any defects in HR. Although the levels of HRE are not as high in BARD1S575F and 
BARD1K619M compared to the other mutant cell lines, they are still higher than Wild 
type levels. This may also be partly due to their expression levels as demonstrated in 
figure 3.4. All the point mutants show almost no sensitivity to PARP inhibitors unlike 
cells without the BRCT domains of BARD1. These results clearly indicate that the HR 
phenotype seen with the loss of the BARD1 BRCT domains is not due to the potential 
phospho-binding ability of the BRCT domains. 
 As expected the point mutations generated in BARD1 do not affect the 
localisation of BARD1 as it localises to the nucleus as seen in figure 3.16. 
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Figure 3.16 Localisation of Bard1 reconstituted cell lines 
Cell lysates were fractioned into their cytoplasmic and nuclear fractions as described in the 
Methods and Materials chapter. W(whole), C(cytoplasmic) and N(nuclear) Fractions were 
analysed by Western blot. The majority of BARD1 is located in the nuclear fractions for both 
reconstituted mutant cell lines.  
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3.3 Summary 
The BARD1 BRCT domains are important for HR and potentially help stabilise the 
BRCA1-C complex.  
BARD1 interacts with CtIP in a BRCA1 dependent manner. 
Potential phospho-binding sites of the BARD1 BRCT domains do not contribute to the 
stabilisation of the BRCA1 complexes. 
Potential phospho-binding sites of the BARD1 BRCT domains appear not to be 
important for HR, whereas disruption of the phospho-binding sites of the BRCA1 BRCT 
domains impedes the efficient repair of DNA DSBs. 
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Chapter 4 The role of the BARD1 BRCT domains in recruitment 
to DNA Damage 
4.1 Introduction 
The localisation of the BRCA1 BARD1 heterodimer to sites of DNA damage is vital for 
the repair of DNA lesions, specifically DNA DSBs. Using molecular biology techniques 
it has become evident that the BARD1 BRCT domains play an important role in HR. In 
order to gain a more functional understanding of the role of the BARD1 BRCT domains 
in HR, this chapter will attempt to address the relevance of the BARD1 BRCT domains 
in terms of localisation and recruitment to sites of Damage. 
4.2 Results 
4.2.1 Localisation of BARD1ΔBRCT is different to BARD1. 
The BRCA1 BARD1 heterodimer has long been known to localise to sites of damage 
[208] and this recruitment is fundamental to the repair of damaged DNA. The 
recruitment of BRCA1 to lesions is mediated by γH2AX and MDC1[323]. More recently 
a complex ubiquitylation signalling pathway initiated by the phosphorylation of H2AX is 
thought to ultimately recruit BRCA1 via the RAP80 complex and Abraxas [128, 130, 
133].  
 Yu et al published a paper recently which highlighted the importance of the 
BARD1 BRCT domains as they localise BRCA1 to sites of damage very shortly after 
damage in a PAR dependent manner [287]. In order to further investigate the functional 
role the BARD1 BRCT domains have in recruitment to DSBs, Tet inducible HEK 293 
cell lines were used as described in chapter 3. As previously mentioned, these cell 
lines stably express either GFP-BARD1 or GFP-BARD1ΔBRCT. A HEK cell line 
expressing just GFP alone was used a control for most experiments. 
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 During the initial characterisation of the cell line, there was a striking difference 
between the localisation of GFP-BARD1 and GFP-BARD1ΔBRCT (figure 4.1). GFP 
protein on its own appears to localise to both the cytoplasm and the nucleus whereas 
GFP-BARD1 and GFP-BARD1ΔBRCT can be found mainly in the nucleus. 
Interestingly GFP-BARD1 appears to form discrete nuclear foci unlike GFP-
BARD1ΔBRCT whose nuclear localisation is more scattered. 
 
 
 
 
 
 
 
 
Figure 4.1 Localisation of GFP-BARD1 and GFP-BARD1ΔBRCT 
Immunofluorescent microscopy illustrating the localisation of GFP-BARD1, GFP-BARD1ΔBRCT 
and GFP alone. X-axis indicated the cell lines used and Y-axis shows nuclear stain (DAPI) and 
GFP. Images were taken by DeltaVision Spectris Restoration Microscope using a 60X objective. 
A similar supplementary figure (S1) can be seen in the supplementary data on disc at the end of 
the appendix. 
 
4.2.2 GFP-BARD1ΔBRCT cannot efficiently form S-phase foci. 
Figure 4.1 illustrates that BARD1 forms discrete nuclear foci however these foci are 
absent in the cell line expressing BARD1ΔBRCT. Baer et al described similar discrete 
nuclear foci termed “BRCA1 nuclear dots” [355]. These foci are S-phase dependent, 
and both BRCA1 and BARD1 have been shown to localise to these foci. According to 
figure 4.2 it appears that the foci seen in figure 4.1 are also S-phase related. The 
number of cells with more than 10 foci/cell is equivalent to the amount of cells in S-
DAPI 
GFP 
GFP GFP-BARD1 GFP-BARD1ΔBRCT 
15µm 
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phase according to EDU and PCNA staining. Interestingly even the predicted phospho-
binding point mutants of the BARD1 BRCT domains, described in the previous chapter, 
also form these nuclear foci. GFP-BARD1L107P, which cannot interact with BRCA1, 
also forms nuclear foci indicating that the recruitment of BARD1 to these S-phase 
associated foci is not dependent on its interaction with BRCA1. Only the complete loss 
of the BRCT domains appear to disrupt the ability of BARD1 to localise to the “BRCA1 
Nuclear dots”  
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Figure 4,2 Ability of BARD1 and mutants to form S-phase foci. 
(a) Graph illustrating the percentage of cells containing GFP-BARD1 foci. N represents the 
amount of cells counted. 
(b) Representative microscopy images from figure (a). Supplementary image S2(a).  
(c) Graph illustrating the percentage of GFP-BARD1 cells in S-phase according to PCNA and 
EDU positive cells. 
(d) Representative microscopy images from figure (c). Supplementary image S2(b). Images 
were taken by DeltaVision Spectris Restoration Microscope using a 60X objective. 
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The presence of both EDU and PCNA are considered to be good indicators of cells in 
S-phase. Unfortunately colocalisation of EDU/PCNA with GFP-BARD1 was not 
possible as GFP-BARD1 bleaches during the staining process. Several different 
techniques were adapted, however no clear images could be taken. In relation to the 
EDU and PCNA staining, GFP-BARD1 and GFP-BARD1ΔBRCT were used as 
representative cell lines to indicate the average amount of HEK cells in S-phase. As 
seen in chapter 3, the number of cells in each stage of the cell cycle is not affected by 
the overexpression of GFP-BARD1. 
 
4.2.3 GFP-BARD1 and GFP-BARD1ΔBRCT localise to DSBs 
The BRCA1 BARD1 heterodimer localises to sites containing acute DNA damage and 
this localisation it believed to coordinate repair events [208]. The BARD1 BRCT 
domains are extremely important for the efficient repair of DNA DSBs as loss of the 
BRCT domains substantially reduces the ability of the cell to faithfully repair DSBs by 
HR. Loss of the BRCT domains of BARD1 also sensitises the cell to PARP inhibitors as 
shown in the previous chapter. As seen in figure 4.2, GFP-BARD1ΔBRCT appears to 
show defects in localising to S-phase foci under normal conditions. This phenomenon 
along with the knowledge that the BARD1 BRCT domains are important for HR begs 
the question of whether the BARD1 BRCT domains are required to localise BARD1 to 
DSBs. 
 To address this question, the localisation of GFP-BARD1 and GFP-
BARD1ΔBRCT was visualised by microscopy after the induction of a laser DSB stripe. 
The use of a UV laser to generate a linear subnuclear DNA DSB stripe has been 
extensively used to investigate the DSB recruitment process [356-358]. Intriguingly 
both GFP-BARD1 and GFP-BARD1ΔBRCT localised to laser damage stripes (figure 
4.3). Both BARD1 and BARD1ΔBRCT colocalised with the DNA damage marker 
γH2AX, whereas the GFP control did not localise to the site of damage. The laser 
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striped cells were fixed and stained with γH2AX 1hr after laser treatment to allow 
BARD1 and other repair proteins to accumulate to sites of damage. 
 
 
 
 
 
 
 
 
 
 
Figure 4.3 Localisation of GFP-BARD1 and GFP-BARD1ΔBRCT to DSBs 
Representative images illustrating the localisation of GFP-BARD1 and GFP-BARD1ΔBRCT to 
γH2AX positive laser induced DSB stripes. Laser stripe was generated using a 405nm Leica UV 
laser and imaged by DeltaVision Spectris Restoration Microscope using a 100X objective. Cells 
were fixed and stained with α-γH2AX antibody 1hr after laser stripe. Experiment was repeated 
at least 3 times using 6 cells each time. Supplementary image S3. 
 
 
It is evident from the images in figure 4.3 that although GFP-BARD1ΔBRCT does 
indeed localise to the stripe of damage, the amount of protein present appears to be 
less in comparison to GFP-BARD1. This may be due to the expression of GFP-
BARD1ΔBRCT as all HEK BARD1 cell lines were induced with the maximum 
concentration of tetracycline for microscopy (10µg/ml) which could reflect different 
expression with different cell lines. It is also possible that GFP-BARD1ΔBRCT is less 
efficient at localising to damage stripes. 
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In order to confirm this result and to study the ability of the BARD1 BRCT point 
mutants, discussed in chapter 3, to localise to DSBs a U2OS cell line which allows the 
visualisation of a DSB by microscopy was utilised. The U2OS cell line contains a stably 
integrated reporter containing several hundred lac operator repeats upstream of a 
transgene [359]. As described by Greenberg et al. the expression of an mCherry 
tagged Fok1 nuclease domain fused to a Lac repressor results in the binding of this 
construct to the Lac operator repeats where the Fok1 nuclease creates a DSB in vivo 
[360]. The DSB is represented by a single mCherry foci within the cell. Transient co-
transfection of GFP-BARD1 constructs with the mCherry-Fok1-LacI revealed that 
BARD1 containing point mutations in the BRCT domains appear to localise to DSB 
similar to full length BARD1. In agreement with figure 4.3, GFP-BARD1ΔBRCT also 
appears to efficiently localise to the DSB (figure 4.4 (b,c). As a control mCherry-Fok1-
LacI containing a point mutation in the Fok1 nuclease (Fok1D450A) which renders the 
enzyme nuclease dead was used (both plasmids were a kind gift from Roger 
Greenberg).  
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Figure 4.4 Localisation of BARD1 and mutants to Fok1 induced DSBs. 
(a) Illustration of the Fok1 mCherry LacI binding to the Lac operator repeats. Adapted from 
Greenberg et al, 2010. 
(b) Graph of the percentage of cells in which mCherry-Fok1-LacI colocalise with GFP-tagged 
BARD1. Blue bars represent cells transfected with the mCherry-Fok1-LacI, red bars indicate 
transfection with mCherry-Fok1d450a-LacI. Experiment was repeated 3 times, each time 
analysing 100 cells per transfection. 
(c) Representative microscopy images from (b). Cells were pre-extracted, fixed and stained 
24hrs after co-transfection. Images were taken by DeltaVision Spectris Restoration Microscope 
using a 60X objective. Supplementary image S4. 
 
It is important to note that the high background level of GFP foci formed with the 
nuclease dead Fok1 (20-30%) is unlikely to be due to the nuclease activity of the 
Fok1D450A mutant and more likely to be due to naturally occurring DSB in the highly 
repetitive lac operator sequence. Extremely repetitive sequences are known to be very 
fragile and breaks are often associated with them. 
4.2.4 BARD1ΔBRCT shows delayed kinetics in localising to DSB. 
It has become clear that the loss of the BARD1 BRCT domains do not affect the ability 
of BARD1 to localise to DNA DSBs. However in a recent study, Yu et al. show that the 
loss of the BRCT domains of BARD1 appears to have a more subtle kinetic problem in 
localising to sites of damage. The BARD1 BRCT domains are important in the very 
early recruitment of BRCA1 to DSBs independent of γH2AX. This paper suggests that 
BARD1 is recruited to PAR at DSB via its BRCT domains in the first 20seconds after a 
break occurs. In the presence of PARP inhibitors GFP-BARD1 is only recruited later 
on. Functionally this does not affect the overall recruitment of BRCA1 to sites of 
damage, as in the absence of the BARD1 BRCT domains, BRCA1 is later recruited in a 
γH2AX dependent manner. The biological and functional relevance of this early 
recruitment remains unclear as BARD1ΔBRCT can also localise to DSB tethered to 
BRCA1 in the later recruitment stage involving γH2AX [287]. 
 In the aforementioned paper, U2OS cells were transiently transfected with 
different GFP BARD1 constructs. To investigate whether the same results were 
observed in cell lines stably expressing GFP-BARD1 and GFP-BARD1ΔBRCT, the 
HEK cell lines ,previously described, were laser striped and the recruitment of GFP-
BARD1 and GFP-BARD1ΔBRCT were monitored in real time in the presence or 
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absence of a PARP inhibitor. In agreement with Yu et al, GFP-BARD1 recruited to the 
damage stripes in under a minute whereas GFP-BARD1ΔBRCT only recruited to the 
DSB after well over 2 minutes (figure 4.5). The delayed kinetics of GFP-BARD1ΔBRCT 
appeared to be due to the inability of BARD1 to bind PAR at DSB as the presence of a 
PARP inhibitor showed the same delayed kinetics with the full length GFP-BARD1 
protein. The inhibition of PARP only affected the kinetics of GFP-BARD1, as there is no 
PARP present for the BRCT domains to bind to and initiate the very early recruitment 
of BARD1 to sites of damage. PARP inhibitors had no effect on the recruitment of GFP-
BARD1ΔBRCT.  
 As described earlier in the chapter, HEK GFP-BARD1 cells contain two 
distinctly different types of cells, in relation to the expression of GFP-BARD1. 50% of 
the population contain discrete S-phase associated nuclear foci, whereas the other half 
have a more uniform distribution of GFP-BARD1. Cells containing S-phase foci 
required over 5 minutes before any recruitment could be seen to stripes. Intriguingly 
there was no difference seen in recruitment of “S-phase foci” cells when treated with a 
PARP inhibitors. GFP-BARD1ΔBRCT only have one type of cell morphology as they 
appear not to form S-phase foci. 
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Figure 4.5 Real time localisation of GFP-BARD1 and GFP-BARD1ΔBRCT to DSBs. 
(a) Graph illustrating the time difference between GFP-BARD1 and GFP-BARD1ΔBRCT in 
localising to laser induced DSB stripes with and without PARP inhibitors. The experiment was 
repeated up to 6 times, each time with at least 6 cells. 
(b,c,d) Representative images for the graph in figure (a). (b) GFP-BARD1, (c) GFP-
BARD1ΔBRCT and (d) GFP-BARD1 cells containing S-phase foci. Live stripes and imaging was 
generated using a 405nm laser on a DeltaVision Spectris Restoration Microscope using a 60X 
objective. Supplementary figures S5(a,b,c) 
 
4.2.5 Delayed recruitment kinetics of GFP-BARD1ΔBRCT does not 
appear to affect HR. 
According to Yu et al the early recruitment of BARD1 to laser induced stripes is due to 
the BRCT domains binding PAR which is found at DSBs. Specifically the potential 
phospho-interacting amino acid K619. BARD1K619A was shown not to interact with 
PAR and to have the same delayed recruitment kinetics as the complete loss of the 
BRCT domains [287]. 
 To address whether there is any functional relevance in the delayed recruitment 
of BARD1ΔBRCT in terms of faithful repair of DSBs, a HRE assay was used to 
determine the homologous recombination efficiency of cells treated with a PARP 
inhibitor.  In chapter 3, DTDR17 cells containing point mutations in the BARD1 BRCT 
domains which are predicted to prevent the binding of a phospho-protein, were HR 
competent and showed no sensitivity to PARP inhibitors. As the role of PAR appears 
important for the early recruitment of BARD1, Bard1 DTDR17 cells reconstituted with 
either HsBARD1, HsBARD1ΔBRCT or BARD1 BRCT point mutants (as described in 
chapter3) were treated with a low dose of a PARP inhibitor before measuring the HR 
efficiency of the cells via the HRE assay. The BARD1 point mutations suggested to be 
responsible for the early recruitment of BARD1 at DSB showed no defects in HR (figure 
4.6) These results indicated that the early recruitment of BARD1 to sites of damage 
does not affect the ability of the cell to carry out faithful repair of DNA DSBs.  
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Figure 4.6 BARD1 BRCT point mutant are HR proficient in the presence of a PARP 
inhibitor 
(a) HRE assay illustrating the percentage of cells expressing GFP 24hrs after transfection with 
the Isce-I expressing plasmid and treatment with 100nM olaparib. Results were normalised to 
untransfected cells. Data shown are the mean of at least 3 independent experiments. Error 
bars, s.d.  
(b) Representive dot plot of raw data from figure (a) Cells expressing GFP were identified by 
FACS analysis. GFP positive cells were gated for relative to their GFP status and size (FSC-H) 
and seen in the box R2. 
 
 
4.2.6 The BRCT domains of BARD1 are important in the recruitment 
of RAD51 to DSBs. 
The BRCT domains of BARD1 are important for the early recruitment of BARD1 and 
BRCA1 to DSBs. This early recruitment depends on the phospho-binding amino acids 
within the BARD1 BRCT domains according to Li et al [287]. However, as shown 
earlier and in chapter 3, the corresponding point mutations in the BARD1 BRCT 
domains do not appear to affect the ability of the cell to carry out HR. BARD1ΔBRCT 
cells retain the ability to localise to DNA DSBs more than likely due to the γH2AX 
dependent recruitment of the BRCA1 BARD1 heterodimer. The functional relevance of 
the BARD1 BRCT domains in recruitment to DSBs may lie in their ability to recruit 
downstream proteins involved in the repair of DSBs. In order to investigate this theory, 
the DTDR17 Bard1 cell lines reconstituted with either full length HsBARD1 or 
HsBARD1ΔBRCT were treated with γ-irradiation and the recruitment of downstream 
repair proteins was analysed. 
RAD51 has been shown to be vital for the repair of DSBs by HR. RAD51 is the 
main protein responsible for strand invasion of a homologous sister chromatid, the 
main event during HR repair [226]. Once a DSB occurs the DNA is first resected 
allowing RPA to bind, RPA is then displaced by RAD51 allowing repair to take place 
[361]. The recruitment of RAD51 to a DSB is dependent on the BRCA1 BARD1 
heterodimer and loss of BRCA1 results in failure of RAD51 to localise to the DSB [362]. 
In order to assess whether the BRCT domains of BARD1 are important for the 
recruitment of RAD51 and RPA to DSBs, the aforementioned DTDR17 cell lines were 
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treated with 4GY γ-irradiation and stained for either RAD51 or RPA 4hrs after 
irradiation, allowing enough time to see the recruitment. Γ-irradiation is commonly used 
to study the recruitment of repair proteins to DSB. 
Interestingly complete loss of BARD1 or just the BRCT domains of BARD1 
resulted in a severe decrease in the amount of RAD51 foci detected after γ-irradiation, 
suggesting that the BRCT domains are indeed important for the ultimate recruitment of 
RAD51 (figure 4.7(a,b). Recruitment of RPA, however, was not hindered in the Bard1 
cells and only reduced by 2 fold in the Bard1 cells reconstituted with either HsBARD1 
or HsBARD1ΔBRCT (figure 4.7(c,d)  
.  
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Figure 4.7 Recruitment of RAD51 and RPA to DSB after γ-irradiation. 
(a) Bar chart reflecting the fold increase of RAD51 after 4 GY γ-irradiation in comparison to 
undamaged in DTDR17 cells with different BARD1 status. Data shown are the mean of at least 
3 independent experiments. Error bars, s.d 
(b) Representative microscopy images from figure (a). Cells were pre-extracted, stained and 
fixed with α-RAD51 4hrs after irradiation. Images were taken using a DeltaVision Spectris 
Restoration Microscope using a 60X objective. Supplementary image S6(a). 
(c) Bar chart reflecting the fold increase of RPA  after 4 GY γ-irradiation in comparison to 
undamaged in DTDR17 cells with different BARD1 status. Data shown are the mean of at least 
3 independent experiments. Error bars, s.d.  
(d) Representative microscopy images from figure (c). Cells were pre-extracted, stained and 
fixed with α-RPA 4hrs after irradiation. Images were taken using a DeltaVision Spectris 
Restoration Microscope using a 60X objective. Supplementary image S6(b) 
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Although the results obtained for the recruitment of RAD51 to DSB induced foci appear 
to be consistent for each experimental replica, the consistency of the RPA data is not 
as clear. The RAD51 antibody used has been previously used for similar experiments 
in DT40 [345, 363], indicating that this particular antibody does recognise chicken 
RAD51. Whereas there have been no similar studies carried out using the RPA 
antibody that was used in this experiment in DT40 cells.  
4.2.7 Loss of the BRCT domains of BARD1 shows a slight decrease 
in CtIP recruitment to IR induced DSBs 
From studies carried out in the previous chapter, the BARD1 BRCT domains appear to 
help stabilise the BRCA1-C complex involving CtIP.  CtIP collaborates with the MRN 
complex to promote DNA end resection which is important for the initiation of repair of 
DSB by HR [55, 87]. CtIP is also required for the recruitment of RAD51 to DSB [345]. 
As RAD51 IR foci are reduced in the absence of the BARD1 BRCT domains, it is 
possible that it results from a defect in the ability of CtIP to recruit to sites of damage.  
 DTDR17 Bard1 cells reconstituted with either HsBARD1 or HsBARD1ΔBRCT 
were treated with IR and the number of CtIP IR induced foci were analysed to study the 
effect that the BRCT domains of BARD1 has on the recruitment of CtIP to DSBs. There 
appears to be a slight reduction in the amount of IR induced CtIP foci formed in the 
absence of the BARD1 BRCT domains (figure 4.8). Cells were pre-extracted, fixed and 
stained 1hr after γ-irradiation. A shorter recovery time was used in this experiment in 
comparison to the RAD51 experiment as CtIP is recruited to DSBs much earlier than 
RAD51. 
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Figure 4.8 Recruitment of CtIP to DSB after γ-irradiation. 
(a) Bar chart reflecting the fold increase of CtIP after 4 GY γ-irradiation in comparison to 
undamaged in DTDR17 cells with different BARD1 status. Foci were counted using the Imaris 
software. Data shown are the mean of at least 3 independent experiments. Error bars, s.d 
(b) Representative microscopy images from figure (a). Cells were pre-extracted, stained and 
fixed with α-CtIP 1hrs after irradiation. Images were taken using a DeltaVision Spectris 
Restoration Microscope using a 60X objective. Supplementary image S7. 
 
 
Interestingly Bard1 cells showed the same slight increase in IR induced CtIP foci as 
Wild type and reconstituted full length BARD1. However the results in figure 4.8 remain 
difficult to interpret as the fold increase of IR induced CtIP foci is very small compared 
to undamaged. 
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4.3 Summary 
BARD1ΔBRCT cells do not form S-phase associated foci whereas full length BARD1 
and the respective point mutants do. 
The recruitment of BARD1 to the S-phase foci is not dependent on BRCA1.  
BARD1ΔBRCT can localise to laser induced DSBs, however with slightly delayed 
kinetics in comparison to BARD1. 
Point mutations in the BRCT domains do not prevent BARD1 from localising to DSBs. 
Early recruitment of BARD1 via its BRCT domains appears not to have a functional role 
in HR. 
Loss of the BRCT domains of BARD1 hinders the formation of IR induced RAD51 foci 
and potentially CtIP. 
 
Note; Due to the potential poor quality of printed microscopy images, an electronic 
copy of the microscopy images can be found on the supplementary disc at the end of 
the appendix
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Chapter 5 Novel interacters of the BARD1 BRCT domains. 
5.1 Introduction 
BARD1 plays an important role in maintaining genome stability. This is mainly through 
its binding with BRCA1. BARD1 is responsible for retaining BRCA1 in the nucleus, 
where it has its function, by masking the nuclear export signal of BRCA1. BRCA1 
ubiquitin ligase activity is also greatly enhanced in the presence of BARD1. 
 The BARD1 BRCT domains are also important for HR. Along with its binding to 
BRCA1, BARD1 has also been shown to interact with CstF-50, a polyadenylation factor 
that is involved in specifying the processing site of mRNA [364]. This interaction is 
thought to inhibit polyadenylation and prevent inappropriate RNA processing during 
transcription at sites of DNA repair. 
BARD1 has also been described as a NF-kB interactor and is thought to regulate its 
transcriptional activity [365]. To date there are no known BARD1 BRCT interactors 
apart from its ability to bind PAR [287], which is important for very early recruitment to 
DNA damage.  
This chapter describes attempts to identify potential BARD1 BRCT interactors as well 
as novel BARD1 interactors which may contribute to the DNA Damage response. 
5.2 Results 
5.2.1 Optimisation of GFP-BARD1 pull down. 
 BRCT domains are highly conserved protein regions which bind phosphorylated 
proteins and are found in many DNA damage response proteins [300, 301, 346]. With 
the recent knowledge that the BARD1 BRCT domains are important for HR, it is 
plausible that the HR function of the BARD1 BRCT domains may depend on their 
interaction with another protein involved in DNA repair. In order to investigate this 
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possibility Mass Spectrometry was used to identify potential new BARD1 BRCT 
interactors. 
 HEK Flp In cells stably expressing either GFP-BARD1 or GFP-BARD1ΔBRCT, 
previously used in chapters 3 and 4, were used to analyse potential BARD1 and 
BARD1ΔBRCT interactors. By comparing the BARD1 interactors or complex members 
with the BARD1ΔBRCT interactors via Mass Spectrometry, it was possible to identify 
proteins which were dependent on the BARD1 BRCT domains. Pulling down the 
BARD1 BRCT domains alone was decided against as proteins which may indirectly 
interact with BARD1 or its BRCT domains, as part of a complex, may have been 
missed. 
 Before analysing the potential BARD1 interactors via Mass Spectrometry, the 
GFP pull down was optimised to assure it would have the capacity to pull down the 
majority of BARD1 complexes or interactors. GFP-trap beads were used for the pull 
down as the beads are covalently coated in a Camelidae VHH domain which binds 
GFP. These VHH domains are the smallest intact antigen binding fragments available 
and avoids the use of large conventional antibodies. GFP-trap beads are also 
extremely specific and do not require long incubation for binding. For this experiment it 
was important to maintain the expression of GFP-BARD1 and GFP-BARD1ΔBRCT as 
close to endogenous levels of BARD1 as possible. Expression levels greatly exceeding 
endogenous levels of BARD1 may have unwanted dominant negative effects. A variety 
of different tetracycline concentrations were used to induce BARD1 expression and it 
appeared that 2.5ng/ml was optimal for GFP-BARD1 expression whereas 7.5ng/ml was 
need to induce GFP-BARD1ΔBRCT to the same level. Using 2.5ng and 7.5ng 
tetracycline, GFP-BARD1 and GFP-BARD1ΔBRCT expression was maintained at 
around 3 fold over endogenous (figure 3.5(a). All tetracycline inducible cell lines were 
maintained in Tet-free media as normal media can contain different levels of 
Tetracycline. 
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In order to assess whether the conditions for pulling down GFP-BARD1 and 
GFP-BARD1ΔBRCT were optimal, a GFP-trap pull down was carried out and analysed 
by Western blot. Under the conditions used, as described in the materials and methods 
chapter, GFP-BARD1 was clearly pulled down. The BRCA1/BARD1 complex members 
such as Abraxas, FANCJ and CtIP also co-immunoprecipitated with both GFP-BARD1 
and GFP-BARD1ΔBRCT (figure 5.1). The ability to pull down BRCA1 and the BRCA1 
complex members clearly demonstrates the potential ability of this technique to identify 
BARD1 interactors, direct or indirect.  
 Mass Spectrometry analysis was carried out with lysates from both crosslinked 
and non-crosslinked pull down conditions. DSP was used as a crosslinking agent. DSP 
contains two reactive amine N-hydroxysuccinimide esters, one at each end of an 8-
carbon linker arm, These reactive esters form a stable amine bond with primary 
amines. DSP is a reversible crosslinker, allowing the separation of complex proteins 
after immunoprecipitation. Using DSP, less stable interactions formed between BARD1 
and potential interactors may be found. It is clear from figure 5.1 that the use of DSP 
does not affect the efficacy of the GFP-trap pull down as BRCA1 and the BRCA1 A, B 
and C complex members are still co-immunoprecipitated with both GFP-BARD1 and 
GFP-BARD1ΔBRCT. 
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Figure 5.1 Crosslinking does not interfere with the efficacy of GFP-trap pull downs. 
(a) Representative Western blot from a non-crosslinked GFP-BARD1 and GFP-BARD1ΔBRCT 
pull down. Input is 50µg of lysate. HEK-GFP (G), GFP-BARD1 (FL), GFP-BARD1ΔBRCT (Δ).  
(b) Representative Western blot from a non-crosslinked GFP-BARD1 and GFP-BARD1ΔBRCT 
pull down. Lysates were quenched with 200mM Tris before adding to beads. Input is 50µg of 
lysate. 
(c) Representative Western blot from a crosslinked GFP-BARD1 and GFP-BARD1ΔBRCT pull 
down. Lysates were quenched with 200mM Tris before adding to beads. Input is 50µg of lysate. 
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A HEK cell lines containing only GFP was used as a negative control for this 
experiment, and as seen in figure 5.1, GFP alone fails to pull down any of the proteins 
associated with the BRCA1 BARD1 complexes. As observed in chapter 3, loss of the 
BRCT domains of BARD1 does not prevent the binding of the BRCA1 complexes, 
however a decrease is often seen with CtIP and on occasion with Abraxas. Tris was 
used in figure 5.1 (b) as a control because after DSP treatment the reaction must be 
quenched with Tris. The addition of 200mM Tris also has no effect on the efficiency of 
the pull down. 
5.2.2 Mass Spectrometry analysis of proteins co-
immunoprecipitated with GFP-BARD1 and GFP-BARD1ΔBRCT. 
Mass Spectrometry was initially used to identify proteins co-immunoprecipitated with 
both GFP-BARD1 and GFP-BARD1ΔBRCT under non-crosslinked conditions (figure 
5.2). GFP-trap pull down was carried out using 40mg of either GFP-BARD1 or GFP-
BARD1ΔBRCT cell lysates. The cells were treated with tetracycline to induce BARD1 
expression over night before harvesting and lysis. The concentration of tetracycline 
used is described in figure 3.5(a). Immunoprecipitated proteins were then run on a pre-
cast 4-12% Bis-Tris gel to minimise contamination. Once the proteins had run around 
1cm into the gel, the gel was stained and the proteins were excised and digested with 
trypsin before Mass Spectrometry analysis, as described in the methods and materials 
chapter. This initial Mass Spectrometry was carried out using a Thermo Scientific LTQ 
Orbitrap and sample preparation was carried out in lab. 
 Mass Spectrometry analysis was carried out using PEAKs. In order to 
confidently identify proteins and peptides bound to either BARD1 or BARD1ΔBRCT, a 
stringent validation cut off was used. Only proteins containing at least two identified 
peptides with over 95% homology were taken as positive results. Non-specific or 
contaminating proteins were taken into account by deducting any proteins found in the 
GFP-only control sample. The higher the coverage and the number of unique peptides 
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associated with a protein, the more reliable the result is. There is also a direct 
correlation with the amount of that particular protein identified. 
 As expected, BRCA1 and BARD1 were the most common proteins identified by 
Mass Spectrometry. Both have over 30% coverage and large number of unique 
peptides. Interestingly FANCJ was also identified with high confidence. FANCJ is the 
only BRCA1 complex protein identified however both Abraxas and CtIP are known to 
be difficult to detect via Mass Spectrometry. Although Abraxas itself was not identified, 
other members of the BRCA1-A complex such as RAP80 and Merit40 were. 
 The following tables show a selection of Mass Spectrometry hits, found in both 
GFP-BARD1 and GFP-BARD1ΔBRCT samples or either one or the other. Several of 
the proteins identified have a function in DNA repair, stress response, transcription 
regulation and post-translational modification which will be discussed later. As seen in 
the Venn diagram in figure 5.3, 202 proteins were associated with only GFP-BARD1 
and 239 with GFP-BARD1ΔBRCT. Only 35 proteins were identified in both samples.  
 
 
 
Figure 5.2 GFP-trap pull down and Mass Spectrometry 
Illustration of the method used to identify potential BARD1 and BARD1ΔBRCT interactors. 
Cropssslinking was used in this diagram, however Mass Spectrometry was also permormed 
under non-crosslinkling conditions. 
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Accession 
Number 
Protein Name Coverage (%) #Peptides 
(unique) 
 
IPI00017746 BARD1 59/44 45 (45)/ 31 (31) 
IPI00218982 BRCA1 28/38 33 (33)/ 48 (48) 
IPI00012500 FANCJ 9/22 5 (5)/ 18 (18) 
IPI01022339 DDX17 27/ 34 14 (8)/ 16 (10) 
IPI01015591 DHX15 9/ 4 4 (4)/ 2 (1) 
IPI00642944 PABPC4 17/ 24 7 (4)/ 8 (3) 
IPI00003886 SNORD19B 7/ 5 3 (3)/ 1 (1) 
IPI01013544 HSPA1B 32/ 47 15 (0)/ 24 (1) 
IPI00006702 PELP1 6/ 2 3 (3)/ 2 (2) 
IPI01022950 SLC25A3 4/ 4 1 (1)/ 1 (1) 
 
Accession 
Number 
Protein Name Coverage (%) #Peptides 
(unique) 
 
IPI00910607 BAT2D1 6 4 (1) 
IPI00646886 MOV10 14 5 (5) 
IPI00880119 PHF8 6 2 (2) 
IPI00941219 PRRC2C 3 5 (2) 
IPI00438230 TRIM28 20 8 (8) 
IPI00967719 RAP80 10 1 (1) 
IPI00893035 CAD 11 1 (1) 
IPI00006442 COIL Coilin 11 5 (5) 
IPI00894449 KIF3C 4 1 (1) 
IPI00292387 NOLC1 13 8 (8) 
 
1 
2 
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Accession 
Number 
Protein Name Coverage (%) #Peptides 
(unique) 
 
IPI00101987 MERIT40 6 1 (1) 
IPI00979099 BCLAF1 2 1 (1) 
IPI00005711 HDAC6 3 1 (1) 
IPI00172559 PALB2 1 1 (1) 
IPI00749013 UBCH5C 14 1 (1) 
IPI00008524 PABPC1 29 13 (8) 
IPI01010638 PHGDH 5 2 (2) 
IPI00009104 RUVBL2 5 2 (2) 
 
Table 5.1 Mass Spectrometry protein hits under normal conditions 
(1) Proteins identified by Mass Spectrometry common to both GFP-BARD1 and GFP-
BARD1ΔBRCT. Coverage represents the % coverage of peptides found in relation to the 
protein. 
(2) Table of Mass Spectrometry hits associated with only GFP-BARD1. 
(3) Table of identified protein only found in the GFP-BARD1ΔBRCT sample. 
PINK; DNA Damage and repair  
GREEN; Transcription regulation 
PURPLE; Stress response 
BLUE; Post-translational modifying enzymes (demethylases, Sumo-conjugating enzymes etc) 
ORANGE; Associated or part of the NuRD complex.  
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Figure 5.3 Venn Diagram of Mass Spectrometry hits 
Venn diagram indicating the number of proteins found in either GFP-BARD1 or GFP-
BARD1ΔBRCT. The overlap of the two spheres shows number of protein common in both 
samples. 
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5.2.3 Mass Spectrometry analysis of cross-linked proteins co-
immunoprecipitated with GFP-BARD1 and GFP-BARD1ΔBRCT. 
In order to identify more transient or indirect BARD1 interactors and more specifically 
proteins which interact with the BARD1 BRCT domains, a second Mass Spectrometry 
was carried out using a crosslinker. During the lysis of GFP-BARD1 and GFP-
BARD1ΔBRCT cells, DSP was added to crosslink proteins, stabilising complexes and 
weaker more transient interactions. As stated previously, DSP is a reversible 
crosslinker containing two reactive NHS esters at either side of a spacer arm. These 
NHS esters stably bind primary amine groups often found in the side chain lysine 
residues of most proteins. DSP contains a disulphide bond in the spacer arm which can 
be easily cleaved in the presence of a reducing agent such as DTT. The reversibility of 
DSP made it an optimal crosslinker for this experiment as proteins which form 
complexes with BARD1 can be easily separated after immunoprecipitation and 
analysed by Mass Spectrometry.   
 GFP-trap pull down of GFP-BARD1 and GFP-BARD1ΔBRCT for analysis by 
Mass Spectrometry was carried out in the same way as in 5.2.2 apart from the addition 
of DSP. After immunoprecipitation the samples were processed and analysed by the 
Mass Spectrometry facility in the College of Life Sciences, Dundee whereas previously 
the Mass Spectrometry facility in Ninewells was used. Trypsin digestion and 
preparation of the samples was carried out as part of the service. Mass Spectrometry 
was accomplished using an Orbitrap. Analysis of Mass Spectrometry targets was 
performed using Scaffold software. The validation of results was achieved using the 
same exclusion principals used for the previous Mass Spectrometry and GFP-alone 
proteins were also subtracted from the GFP-BARD1 and GFP-BARD1ΔBRCT hits. 
 As in 5.2.2, BRCA1 and BARD1 were identified with the highest confidence 
from the list of potential Mass Spectrometry hits. As expected, the number of potentially 
interesting protein hits were dramatically increased in the presence of a crosslinker. 
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Several more proteins known to be involved in DNA damage repair were identified in 
this screen compared to the non-crosslinked pull down Mass Spectrometry. Intriguingly 
the number of proteins common to both GFP-BARD1 and GFP-BARD1ΔBRCT that 
were identified was far greater when crosslinked (figure 5.5). 
 
 
 
 
 
 
 
 
Figure 5.4 GFP-trap pull down samples for Mass Spectrometry 
(a) Illustration of the DSP crosslinker, image adapted from Piercenet.com 
Image of a coomassie stained gel containing the GFP GFP-BARD1 and GFP-BARD1ΔBRCT 
samples after immunoprecipitation. The proteins were then cut from the gel, digested and 
identified by Mass Spectrometry. 
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Accession 
Number 
Protein Name Coverage (%) 
FL/Δ 
#Peptides 
unique FL/Δ 
 
IPI00017746 BARD1 59/46 45/42 
IPI00218982 BRCA1 38/48 51/69 
IPI00029754 MLH1 11/16 5/8 
IPI00396071 RAP80 11/14 6/5 
IPI00000846 CHD4 3.4/6 4/7 
IPI00017297 MATRIN3 9.7/5.4 4/2 
IPI00164724 BRE 7.3/7.3 3/3 
IPI00008531 CoREST 8.7/8.7 3/3 
IPI00171798 MTA2 5.4/12 1/4 
IPI00871617 BRCC36 8.9/12 2/3 
IPI00746337 PMS2 4.6/5.1 3/3 
IPI00101987 MERIT40 13/20 1/2 
IPI00012773 MTA1 7/7 4/4 
IPI00412408 BRCA2 .5/1 1/2 
IPI00017303 MSH2 4.1/1.5 2/1 
IPI00184330 MCM2 1.4/2.8 1/2 
IPI00172559 PALB2 1.3/3.4 1/2 
IPI00012500 FANCJ 40/49 34/48 
IPI00217540 LSD1 13/14 7/8 
IPI00445401 HUWE1 1.6/2.5 4/5 
IPI00395865 RBBP7 17/13 3/2 
IPI00013774 HDAC1 12/15 3/2 
 
 
1 
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Accession 
Number 
Protein Name Coverage (%) #Peptides 
unique 
 
IPI00032957 UBC9 28 9 
IPI00646779 TUBB6 27 2 
IPI00007927 SMC2 2 2 
IPI00219446 PEBP1 20 2 
IPI00215914 ARF1 22 2 
IPI00003309 RPABC3 13 2 
IPI00029159 MRE11 6.8 4 
 
 
Accession 
Number 
Protein Name Coverage (%) #Peptides 
unique 
 
IPI00947285 Suprabasin 9.2 3 
IPI00009342 IQGAP1 1.9 2 
IPI00396015 ACC1 1.2 2 
 
Table 5.2 Crosslinked Mass Spectrometry protein hits. 
(1) Proteins identified by Mass Spectrometry common to both GFP-BARD1 and GFP-
BARD1ΔBRCT. Coverage represents the % coverage of peptides found in relation to the 
protein. 
(2) Table of Mass Spectrometry hits associated with only GFP-BARD1. 
(3) Table of identified protein only found in the GFP-BARD1ΔBRCT sample. 
PINK; DNA Damage and repair  
GREEN; Transcription regulation 
BLUE; Post-translational modifying enzymes (demethylases, Sumo-conjugating enzymes etc) 
ORANGE; Associated or part of the NuRD complex.  
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Figure 5.5 Venn Diagram of Crosslinked Mass Spectrometry hits 
Venn diagram indicating the number of proteins found in either GFP-BARD1 or GFP-
BARD1ΔBRCT. The overlap of the two spheres shows number of protein common in both 
samples. 
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5.2.4 Identification and validation of potential BARD1 and BARD1 
BRCT domain interacting proteins. 
After data analysis, six proteins, identified by Mass Spectrometry which potentially 
interact with either full length BARD1 or the BARD1 BRCT domains, were chosen for 
further validation and analysis. The following proteins were chosen for further analysis 
as they are known to localise to sites of damage. CHD4, HUWEI. LSD1, MTA2, RBBP7 
and UBC9 have all been either shown to be involved in DNA repair or form complexes 
with proteins associated with the DDR. Interestingly several protein identified as 
potential BARD1 interactors are part of the NuRD complex, a chromatin remodelling 
complex. The involvement of chromatin remodelling factors in the repair of DNA 
damage is now beginning to emerge and the potential involvement of BARD1 would be 
very interesting in terms of the its function in the DDR. 
 CHD4 (chromodomain-helicase-DNA-binding 4) was first identified as an 
autoantigen in dermatitis often leading to malignancy [366-368]. CHD4 contains an 
ATPase/helicase domain which allows it to bind and mobilise nucleosomes on DNA 
[369]. CHD4 is also a core member of the NuRD complex which is a key chromatin 
remodelling complex. It is believed that the CHD4 PHD fingers preferentially bind 
unmodified lysine residue 4 on histone 3 and also to trimethylated lysine 9 on the same 
histone [370]. Chromatin remodelling proteins have long been known to be involved in 
the DDR. Interestingly CHD4 has been shown to be recruited to sites of DNA damage 
in two independent mechanisms. Firstly it has been shown to be recruited by binding to 
poly(ADP-ribosyl)ated proteins, including PARP1 [371] and secondly by the ubiquitin 
ligase RNF8 [372]. It is believed that CHD4, as part of the NuRD complex, creates a 
chromatin environment which allows the amplification of the DNA damage signal 
ultimately leading to the recruitment of repair proteins such as BRCA1. CHD4s 
involvement in DNA damage repair and its binding to poly(ADP-ribosyl)ated proteins 
makes it a very interesting potential BARD1 interactor. However it was only found in 
the crosslinked Mass Spectrometry pull down in both GFP-BARD1 and GFP-
183 
 
BARD1ΔBRCT suggesting that the interaction is not dependent on the BRCT domains 
and may be transient or indirect. 
 MTA1 and MTA2 are also integral components of the NuRD complex [373] and 
were identified in the crosslinked pull down by Mass Spectrometry. Both MTA1 and 
MTA2 were common to both GFP-BARD1 and GFP-BARD1ΔBRCT. MTA1 has been 
suggested to be important in the efficient repair of DSBs as depletion of MAT1 renders 
cells sensitive to IR [374] and re-expression of MTA1 rectifies this defect. 
 HUWEI is a large HECT domain containing ubiquitin ligase protein. Several 
HUWEI substrates are involved in DNA damage responses and repair [375-378]. 
HuweI adds lysine 48 (k48) chains to its substrates targeting them for proteasomal 
degradation, however it has also been shown to add lysine 63 (k63) ubiquitin chains to 
C-Myc suggesting a signalling role [379]. Interestingly UBC9, a SUMO conjugating 
enzyme, was also identified as a potential BARD1 interactor.  
It has become evident that SUMO modification plays an important role in DNA 
repair [380-385]. UBC9 is the only known SUMO conjugating enzyme in mammalian 
cells and it has been shown, along with other SUMO proteins, to localise to DSB [380, 
382, 386]. SUMOylation is also important for recruitment of repair proteins to sites of 
damage [181]. 
Signalling involving posttranslational modifications such as ubiquitylation and 
sumoylation plays a fundamental role in the repair of DNA DSBs making a potential 
interaction between BARD1 and HUWEI and UBC9 very interesting. As with CHD4, 
HUWEI was only identified in the crosslinked pull down in both GFP-BARD1 and GFP-
BARD1ΔBRCT. Intriguingly UBC9 was identified with high confidence in the 
crosslinked GFP-BARD1 sample only suggesting that if BARD1 and UBC9 interact it 
may be through the BARD1 BRCT domains.  
 RBBP7 was identified in both GFP-BARD1 and GFP-BARD1ΔBRCT 
crosslinked pull down samples. RBBP7 was highlighted as an interesting Mass 
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Spectrometry candidate as it is also suggested to be involved in the NuRD complex 
and interacts with BRCA1 [387]  
 LSD1 was the first human lysine specific demethylase discovered in 2004 [388, 
389]. LSD1 removes one or two methyl groups from lysine 4 on histone 4. Work in 
Mosammaparast lab, suggests a direct role for LSD1 in DNA repair as LSD1 is directly 
recruited to laser induced DNA damage stripes [390]. As methylation plays an 
important role in recruiting some of the major DDR proteins such as 53BP1 to sites of 
damage, a potential interaction between LSD1 and BARD1 may shed some light on 
alternative functions of BARD1 in DNA damage repair. LSD1 was identified in both 
GFP-BARD1 and GFP-BARD1ΔBRCT pull down samples, however only when a 
crosslinker was used. 
 In order to confirm the selected Mass Spectrometry hits, a GFP-trap pull down 
was used. The pull down was carried out under the same conditions as used to identify 
BARD1 interactors by Mass Spectrometry. GFP-BARD1 and GFP-BARD1ΔBRCT were 
pulled down under crosslinking conditions and the respective Mass Spectrometry hit 
proteins were blotted for by Western blot. Unfortunately the proteins of interest were 
not detected by Western blot after co-immunoprecipitation with GFP-BARD1 and GFP-
BARD1ΔBRCT (figure 5.6).  BRCA1 and FANCJ were used as positive controls for the 
pull down. 
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Figure 5.6 Confirming potential BARD1 interactors 
Representative Western blot of Mass Spectrometry identified BARD1 interactors. HEK GFP-
BARD1 and GFP-BARD1ΔBRCT cells were induced with tetracycline o/n before lysis and 
crosslinking. GFP-BARD1 and GFP-BARD1ΔBRCT lysates were pulled down and co-
immunoprecipitated proteins were blotted for. Experiment was carried out at least 3 times.  
 
 
It is clear from figure 5.6 that the antibodies used do indeed recognise their target 
proteins as a representative band can be seen in the input lane. It is possible that a 
Western blot is not sensitive enough to detect the amount of protein identified by Mass 
Spectrometry as less than 10 peptides from each protein were detected. It remains 
unclear if the chosen Mass Spectrometry candidates are indeed true BARD1 or BARD1 
BRCT interactors. It is also important to keep in mind that these potential hits may not 
directly bind with BARD1 as BARD1 and BRCA1 form several complexes of which 
these proteins may interact with. 
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5.2.5 CHD4 localises to laser induced DNA DSBs. 
Although the Mass Spectrometry target proteins could not be confirmed by Western 
blot, it is still possible that they are indeed true interactors. As BARD1 localises to laser 
induced DNA DSBs, the localisation of the potential BARD1 interactors to the same 
laser induced damage stripes, along with the Mass Spectrometry data, might indicate a 
possible function at DSB with BARD1.   
 This hypothesis was tested by inducing a laser stripe of damage in U2OS cells 
and evaluating whether the proteins of interest co-localised with γH2AX using the same 
antibodies as in figure 5.6. Surprisingly none of the Mass Spectrometry hits co-
localised with γH2AX (figure 5.7 (a). However preliminary results suggest that CHD4 
can localise to a laser induced damage stripe (figure 5.7 (b). The antibodies used to 
confirm the Mass Spectrometry targets were chosen specifically for their compatibility 
for Western blots but also for their suggested potential to be used for 
immunofluorescence. The negative results seen in figure 5.7(a) may be partly due to 
the antibodies not being suitable for immunofluorescence or in-vivo studies.  
All the potential protein interactors chosen are known to be involved directly or 
indirectly with DNA damage repair and CHD4 in particular has been shown to localise 
to laser stripe induced damage [371, 391]. The results seen in figure 5.7 (b) suggest 
that CHD4 does localise to sites of damage, however this may be due to the fact that 
HEK cells were transiently transfected with a GFP-tagged HsCHD4 construct with no 
reliance on antibodies. This leads to the speculation that the other Mass Spectrometry 
hits may also localise to DNA damage under the correct experimental settings. Due to 
lack of time, no further evaluation could be carried out. 
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Figure 5.7 CHD4 localises to laser induced DNA damage stripe. 
(a) Representative images illustrating the failure of the Mass Spectrometry target proteins to 
localise to γH2AX positive laser induced DSB stripes. Laser stripe was generated using a 
405nm Leica UV laser and imaged by DeltaVision Spectris Restoration Microscope using a 
100X objective. Cells were fixed and stained with antibodies against the respective proteins 
(green) and γH2AX (red) 1hr after laser stripe. Experiment was repeated at least 3 times using 
6 cells each time. Supplementary figure S8(a) 
(b) Preliminary results showing live imaging localisation of a transiently expressed GFP-CHD4 
to Laser induced DNA damage stripe. HEK cells were transiently transfected with GFP-CHD4 
24 hrs before laser striping. Cells were laser damaged using a 405nm laser on the DeltaVision 
Spectris Restoration Microscope. A 60X objective was used to capture the image. Images were 
taken before laser stripe and 5mins after. Supplementary figure S8(b) 
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5.3 Summary 
2.5ng/ml and 7.5ng/ml tetracycline is needed to induce the expression of GFP-BARD1 
and GFP-BARD1ΔBRCT to around 3 fold endogenous BARD1 levels in HEK inducible 
cell lines. 
Abraxas, FANCJ and CtIP co-immunoprecipitate with both GFP-BARD1 and GFP-
BARD1ΔBRCT under the conditions used with GFP-trap beads. 
Mass Spectrometry analysis of proteins co-immunoprecipitated with both GFP-BARD1 
and GFP-BARD1ΔBRCT revealed that the majority of proteins which may bind BARD1 
are part of a complex or weak interactors as crosslinking is required. 
Several proteins identified as potential BARD1 interactors have a role in transcription 
regulation, post-translational modification and DNA repair. 
CHD4, HuweI, LSD1, MTA1 and RBBP7 were found to interact with both BARD1 and 
BARD1ΔBRCT via Mass Spectrometry, however none of them could be confirmed. 
UBC9 was found to interact only with BARD1, suggesting that it potentially requires the 
BARD1 BRCT domains for interaction, however this result was also not confirmed. 
CHD4 localises to laser induced DNA damage stripes. 
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Chapter 6 Ubiquitin ligases and signalling at DNA DSBs. 
The results in Chapter 6 are unrelated to the other results chapters and include the 
main findings of the original project of my PhD. Due to experimental difficulties in 
generating certain cell lines within this chapter and the publication of similar results by 
other groups on RNF8 and RNF168, a second project was initiated. This second 
project involved the investigation of the importance of the BARD1 BRCT domains in 
HR and the majority of the results in this thesis arise from this second project. Chapter 
6 was included as a representation of a small piece of work carried out at the beginning 
of my PhD before the aims of the project changed.  
6.1 Introduction 
Signalling at DSBs is an early event in DSB repair that depends on protein 
ubiquitylation [136] along with various other posttranslational modifications. Signalling 
at DSBs ultimately leads to the recruitment of proteins involved in the repair of DSBs. 
Early on in the DSB response, phosphorylation-dependant protein-protein interactions 
are vital to coordinate both damage recognition and also signal amplification. The 
signalling cascade becomes highly dependent on the ubiquitin ligase activity of RNF8 
and RNF168 which recruits other DDR proteins and also amplifies the damage signal. 
 Although there has been great advances in determining the mechanism and 
signalling involved at DSBs there are still many important questions that have yet to be 
answered. Some of the main questions that have yet to be addressed involve the 
interplay between different posttranslational modification within DNA damage signalling 
and their effects on chromatin structure. This chapter will address the function and 
biological relevance of RNF8 and RNF168 in the repair of DNA DSBs using 
biochemical and molecular biology techniques,  
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6.2 Results 
6.2.1 Generation of ubiquitin ligase dead RNF8 and RNF168. 
Signalling at DSB employs a variety of DDR proteins and various posttranslational 
modifications which form a subnuclear foci at the DSB site known as ionizing radiation 
induced foci (IRIF) [105]. The IRIF arise due to an accumulation of DDR proteins, 
which are paramount for mediating not only the signalling and repair of damaged DNA 
but also to activate cell cycle checkpoints or apoptosis.  
 Signalling at DNA DSBs ultimately serves to recruit repair proteins such as 
BRCA1 and 53BP1 to sites of damage. It has become evident that both RNF8 and 
RNF168 ubiquitin ligases are important mediators of DNA repair at DSBs, as shown in 
studies carried out with knock-out mice [178, 179, 392]. In order to investigate the 
effect that the ubiquitin ligase activity of RNF8 and RNF168 has on the repair of DNA 
damage, point mutations were generated in the RING domains of both proteins which 
rendered them ubiquitin ligase dead.  
 The RING finger motif is a cysteine rich sequence which adopts a 3D structure 
coordinating two zinc ions. Eight conserved amino acids, seven cysteines and one 
histidine, are responsible for binding the two zinc ions [393]. The RING domain E3 
ubiquitin ligases function as a substrate adapter linking the ubiquitin charged E2 
enzyme to the substrate. 
 The RING domains of RNF8 and RNF168 are very similar to those of BRCA1, 
another ubiquitin ligase important in DNA repair. Mutation of I26 in the BRCA1 RING 
domain has been shown to abrogate its ubiquitin ligase activity by preventing its 
binding to an E2 enzyme [170]. In order to generate point mutation in the RNF8 and 
RNF168 RING domains which would abrogate their ubiquitin ligase activity, they were 
compared to the BRCA1 RING domain (figure 6.1(a).  
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 RNF8I405A and RNF168I18A plasmids were generated in order to assess the 
contribution of the RING domains and ubiquitin ligase activity of these proteins in DNA 
repair. By creating a point mutation in the RING domain of RNF8 and RNF168 which is 
predicted to render the proteins ubiquitin ligase dead, cells harbouring these mutated 
proteins could be analysed in relation to their sensitivity to DNA damaging agents. Both 
WT and mutant counterparts were tagged with His in order to facilitate purification of 
these proteins. 
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Figure 6.1 Generation of RNF8 and RNF168 ubiquitin ligase dead point mutant. 
(a) Schematic representation of the BRCA1 BARD1 RING domains. The residue responsible for 
binding E2 enzymes in BRCA1 is circled in green. Mutation of i26 results in loss of ubiquitin 
ligase function. Sequence alignment of the BRCA1 RING domain with the RNF8 and RNF168 
RING domain. BRCA1 i26 is circled in red and the corresponding lysine residues in the RNF 
proteins are also circled. Figure adapted from Brzovic et al. (2003) 
(b) Illustration of RNF plasmids generated. Both WT and point mutant RNF proteins have been 
tagged with His to allow for His tag protein purification.  
 
6.2.2 Optimising the expression and solubility of His tagged RNF8, 
RNF168 and mutant proteins. 
RNF8I405A and RNF168I18A are predicted to lack their E3 ubiquitin ligase activity. In 
order to confirm that these point mutations do indeed disrupt the enzymatic ability of 
the RING domain, RNF8, RNF168 and their respective RING mutants were purified 
and biochemically analysed for ubiquitin ligase activity.  
 Before purification, the expression and solubility of the proteins were optimised. 
The mutant and WT RNF8 and RNF168 gene sequences were cloned into the pOPTH 
vector in order to tag them with 6xHis. His tags combine the advantages of small size 
and relatively high binding affinity. In addition, elution conditions for His-tagged proteins 
are mild allowing recovery of native proteins. However a His-tag does not enhance the 
solubility of the recombinant protein. 
 BL21(DE3) Lys competent E-coli cells were used as a host cells for the 
expression of the recombinant RNF8 and RNF168 proteins as they have two important 
attributes which makes them ideal for protein expression. BL21(DE3) Lys have key 
genetic markers which allows recombinant protein to be expressed with minimal basal 
expression  and they are also inducible which can help minimise the toxic effect of 
certain proteins. The expression of the recombinant protein is induced by adding IPTG. 
 Initially His-RNF8, His-RNF8I405A, His-RNF168 and His-RNF168I18A 
BL21(DE3) Lys cells were induced with 1mM IPTG and the cells were harvested 
between 30mins and 3hrs after induction to identify the optimal time to induce 
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expression.  His-RNF8 and His-RNF8I405A appeared to be maximally induced after 
1hr whereas His-RNF168 and His-RNF168I18A required 2-3hrs (figure 6.2) 
 Although the expression of His-RNF8 and His-RNF8I405A is clearly visible via 
coomasie stained gels, His-RNF168 and His-RNF168I18A expression required a 
Western blot using an α-His antibody for detection. From this point on, optimisation of 
His-RNF168 and His-RNF168I18A will be analysed by Western blot as opposed to 
coomasie staining. 
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Figure 6.2 Timed induction of RNF proteins. 
(a) Coomasie stained gel of BL21(DE3) Lys bacterial pellet after IPTG induction. Bacteria 
expressing either His-RNF8 or His-RNF8I405A were harvested before induction and up to 3hrs 
after 1mM induction with IPTG. Bacterial pellets were boiled in sample buffer and run on a 4-
12% Bis-Tris gel before staining with simply Blue coomasie stain.  
(b) Coomasie stained gel of BL21 bacterial pellet after IPTG induction of His-RNF168 and His-
RNF168I18A. Experiment was carried out in the same way as in (a). 
(c) Western blot of samples from figure (b). Bacterial pellets were boiled in sample buffer and 
run on a 4-12% Bis-Tris gel before Western blotting. α-His antibody was used to detect His-
RNF168 and His-RNF168I18A. 
 
 
 Once the correct amount of time needed to induce the expression of the RNF 
proteins was defined (2hrs), the solubility of the protein was optimised. The solubility 
of His-RNF8, His-RNF8I405A, His-RNF168 and His-RNF168I18A was carefully 
evaluated by comparing the supernatant (soluble) and pellet (insoluble) fractions of 
IPTG induced BL21(DE3) Lys cells after lysis. 
 BL21(DE3) Lys cells were induced with 0.4mM or 1mM IPTG and harvested 
2hrs after induction. The cells were then lysed, as described in the methods and 
materials section, and the soluble and insoluble fractions were separated by 
centrifugation before analysis by either coomasie stained gels or Western blot. Both 
His-RNF8 and His-RNF8I405A showed reasonable solubility after induction with both 
0.4mM and 1mM IPTG (figure 6.3 (a,b),  although the amount of insoluble His-RNF8 
and  His-RNF8I405A was greater when induced with 1mM IPTG, the overall soluble 
fraction remained the same with both concentrations of IPTG. This indicates that the 
use of 0.4mM IPTG is sufficient as higher concentrations do not increase the solubility. 
 The soluble fraction of both His-RNF168 and His-RNF168I18A was poor after 
induction with either 0.4mM and 1mM IPTG (figure 6.3 (c). The yield and solubility of 
0 30min 1hr 2hr 3hr 
RNF168 I18A 
RNF168 
c 
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proteins can be greatly affected by the concentration and time of induction as well as 
the incubation temperature. In order to optimise the solubility of His-RNF168 and His-
RNF168I18A, a longer induction time as well as a lower incubation temperature was 
used. Inducing His-RNF168 and His-RNF168I18A with 0.4mM IPTG overnight at 18°C 
appeared to increase the solubility of both proteins (figure 6.3 (d). 
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Figure 6.3 Solubility of RNF proteins 
(a) Coomasie stained gel of BL21(DE3) Lys His-RNF8 bacterial pellet after IPTG induction. 
Bacteria were harvested before induction and 2hrs after 0.4mM/1mM induction with IPTG. 
Bacterial pellets were lysed and separated into soluable and insoluable fractions via 
centrifugation and run on a 4-12% Bis-Tris gel before staining with simply Blue coomasie stain. 
(b) Coomasie stained gel of induced His-RNF8I405A. Sample prepared as in figure (a)  
(c) Western blot of IPTG induced His-RNF168 and His-RNF168I18A. Samples were prepared 
as if figure (a) and blotted for using α-His antibody. 
(d) Western blot of His-RNF168 and His-RNF168I18A induced with 0.4mM IPTG either for 2hrs 
at 37°C or o/n at 18°C.  Bacterial pellets were lysed and separated into soluable and insoluable 
fractions via centrifugation and run on a 4-12% Bis-Tris gel before blotting with α-His antibody. 
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6.2.3 Purification of His-RNF8, His-RNF8I405A, His-RNF168 and His-
RNF168I18A. 
Once the expression and solubility of the His-tagged RNF proteins was optimised, the 
system was scaled up and the proteins were purified. The purification of the ubiquitin 
ligases involved in the DDR allowed the biochemical characterisation of RNF8 and 
RNF168.  
 The expression of His-RNF8 and His-RNF8I405A was induced with 0.4mM 
IPTG at 37°C for 2hrs before lysis and purification whereas His-RNF168 and His-
RNF168I18A was induced with 0.4mM IPTG overnight at 18°C to increase the solubility 
of the protein. After lysis and sonication the soluble sample fractions were loaded onto 
the HisTrap FF column to allow the His-tagged proteins to bind to the Ni2+ charged 
sepharose. A low concentration of imidazole (40mM) was included in the binding/wash 
buffer to prevent unspecific His-cluster binding to the column. A higher concentration of 
imidazole (500mM) was used to elute the His-tagged RNF8 and RNF168 proteins. 
Imidazole is a competitive binder of Ni and displaces the His-tagged proteins from the 
column.  
 Eluted samples were collected and dialysed to reduce the concentration of 
imidazole and other potentially contaminating molecules. Using Dialysis, the 
concentration of NaCl was also lowered, as high salt may interfere with the biochemical 
assay in which the purified proteins will be used for. It is evident from figure 6.4, that 
the His-tagged proteins have been purified. Although there are some non-specific 
proteins contaminating the sample, this is unlikely to interfere with the biochemical 
assays as the E-coli bacterial host do not contain any ubiquitin ligases indicating that 
any ubiquitin ligase activity seen is completely due to the activity of RNF8 and RNF168. 
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Figure 6.4 Purification of His-RNF8, His-RNF8I405A, His-RNF168 and His-RNF168I18A. 
(a) Coomasie stained gel of purified His-RNF8 and His-RNF8I405A. Input represents sample 
prior to HisTrap FF column purification. Purified sample concentration was increased to highlight 
purity of sample. 
(b) Coomasie stained gel of purified His-RNF168 and His-RNF168I18A. Input represents 
sample prior to HisTrap FF column purification. Purified sample concentration was increased to 
highlight purity of sample. Input and purified samples contain only soluable fraction. 
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6.2.4 Purified His-RNF8I405A and His-RNF168I18A are inactive 
ubiquitin ligases. 
 To assess the ubiquitin ligase activity of purified His-tagged RNF8 and RNF168 
proteins an in vitro ubiquitin ligase activity assay was carried out. The ubiquitin ligase 
activity assay using BRCA1/BARD1 as the E3 ubiquitin ligase has been previously 
described by our laboratory [394]. Details of this assay can be found in the methods 
and materials chapter.  
This assay relies on the principle that in the presence of ubiquitin, ATP, an E1 
and E2 enzyme, an active E3 ubiquitin ligase enzyme monoubiquitylates free Histone 
H2A. Using both free ubiquitin and radioactive 125I labelled ubiquitin, ubiquitylation of 
H2A can be clearly seen by PAGE analysis.  
Mel18 is part of the PRC1-like polycomb repressor complexes and a 
heterodimer containing Mel18 and RING1B has been shown to be an efficient E3 
ligase, ubiquitylating free histones in vitro and specifically H2A in a nucleosomal 
context [395]. Mel18/RING1B (b) was used as a positive control for the ubiquitin ligase 
activity assays as it appeared to be the most competent at ubiquitylating H2A in vitro 
(figure6.5 (a). Mel18/RING1B (b) seemed to have increased E3 activity in comparison 
to other batches (a,c) of the purified protein and also in comparison to different 
BRCA1/BARD1 RING domain purified proteins.  
By optimizing the in vitro ubiquitin ligase activity assay the correct 
concentrations of all the components was elucidated (figure 6.5 (b). Maximal H2A 
ubiquitylation was observed in lane 4, containing 1µl of all the reagents used at the 
indicated concentration. The concentrations of the reagents highlighted in figure 6.5 (b) 
were then used in all subsequent assays. Reassuringly no ubiquitylation was seen in 
the absence of the E3 ligase (lane 9) and only autoubiquitylation of Mel18 can be seen 
in the absence of H2A (lane 8). The large lowest band seen in all the gels is 
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unconjugated 125I labelled ubiquitin as, more often than not, the majority of 125I labelled 
ubiquitin is not fully used up in the reaction. 
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Figure 6.5 Optimisation of the in vitro ubiquitin ligase activity assay 
(a) Ubiquitin ligase activity assay showing Mel18/RING1B and BRCA1/BARD1 ring domains 
display E3 ligase activity in the presence of H2A and UBCH5a E2 enzyme. Reagent were pre-
incubated for 1hr with ubiquitin before incubation for a further hour with I125 labelled ubiquitin 
and H2A at 37°C. 
125
I labelled products were analysed by PAGE and visualised using X-ray film 
or a phosphoimager. Ubiquitylated H2A and free 
125
I labelled ubiquitin are labelled. 
(b) Ubiquitin ligase activity assay illustrating the optimal conditions for the activity of 
Mel18/RING1B seen in the highlighted lane 4. Lane 8 contains no H2A substrate. Reagent were 
pre-incubated for 1hr with ubiquitin before incubation for a further hour with I125 labelled ubiquitin 
and H2A at 37°C. 
125
I labelled products were analysed by PAGE and visualised using X-ray film 
or a phosphoimager. Ubiquitylated substrates and free 
125
I labelled ubiquitin are labelled. 
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Both purified His-RNF8 and His-RNF168 show E3 ligase activity in vitro by 
ubiquitylating free histone H2A whereas the RING mutants do not appear to have any 
E3 activity (figure 6.6). The lack of ubiquitylated products formed by either His-
RNF8I405A or His-RNF168I18A suggests that the point mutations generated in the 
RING domains does prevent the E3 ligase activity of the proteins. Both His-RNF8 and 
His-RNF168 appear to be autoubiquitylated and seem to be involved in the formation of 
polyubiquitylated products. 
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Figure 6.6 His-RNF8 and His-RNF168 are active E3 ligases, His-RNF8i405a or His-
RNF168i18a show no E3 ligase activity. 
(a) Ubiquitin ligase activity assay showing His-RNF8 displays E3 ligase activity in the presence 
of H2A and UBCH5a E2 enzyme. His-RNF8i405a shows no E3 ligase activity. Reagent were 
pre-incubated for 1hr with ubiquitin before incubation for a further hour with 
125
I labelled ubiquitin 
and H2A at 37°C.
 125
I labelled products were analysed by PAGE and visualised using X-ray film 
or a phosphoimager. Ubiquitylated products and free 
125
I labelled ubiquitin are labelled. 
(b) Ubiquitin ligase activity assay showing His-RNF168 displays E3 ligase activity in the 
presence of H2A and UBCH5a E2 enzyme. His-RNF168i18a shows no E3 ligase activity. 
Experimental procedure carried out as in (a). 
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6.2.5 His-RNF8 and His-RNF168 ubiquitylate all free histones in vitro. 
 Very little is known about the ubiquitylation substrates of both RNF8 and 
RNF168, so far the main targets are H2A and H2AX where the ubiquitin ligases are 
proposed to form K63 linked-ubiquitin chains [119-122, 125, 126]. In order to assess 
the ubiquitin ligase capabilities of RNF8 and RNF168 on a variety of free histone 
substrates, a ubiquitin ligase activity assay was carried out. Both RNF8 and RNF168 
appear to be able to ubiquitylate all free tested histones in vitro whereas their mutant 
counterparts are not (figure 6.7).  
   The ability of RNF168 to ubiquitylate H2AX in comparison to RNF8 appears to 
be weaker in figure 6.7 (b). This is believed to be due to an overall weaker signal 
obtained with purified RNF168 in comparison to the activity of RNF8, overexposure of 
the same PAGE gel indicate that RNF168 can also ubiquitylate H2AX. It is important to 
note that although RNF8 and RNF168 were able to ubiquitylate all free histones tested, 
this does not directly implicate that RNF8 and RNF168 can ubiquitylate all histones in a 
nucleosomal context.  
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Figure 6.7 RNF8 and RNF168 ubiquitylate free histones in vitro 
(a) His-RNF8 but not His-RNF8i405a can ubiquitylate all tested free histones in vitro. Reagents 
were pre-incubated for 1hr with ubiquitin before incubation for a further hour with 
125
I labelled 
ubiquitin and indicated histones at 37°C. 
125
I labelled products were analysed by PAGE and 
visualised using X-ray film or a phosphoimager.Lysozyme was used as a positive control.  
(b) Ubiquitin ligase activity assay illustrating that His-RNF168 but not His-RNFi18a can 
ubiquitylate the majority of free histones. Experimental procedure carried out as in (a). 
 
 
 
 The higher intensity of the signal on the right hand side in the RNF8 figure 
6.7(a) is due to the use of an older batch of 125I labelled ubiquitin in the first four 
samples in the figure whereas a newer batch was used in the second half of the gel. 
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6.2.6 Rnf8 DT40 cells are sensitive to Parp inhibitors while Rnf168 
DT40 cells show sensitivity to HU. 
Both RNF8 and RNF168 localise to DNA damage foci after IR treatment [119]. A 
reduction in the level of RNF8 protein has been shown to decrease cell survival after IR 
and sensitise cells to UV and CPT [121, 177, 396]. Rnf168 cells are also sensitive to 
CTP and mutations in RNF168 are associated with the RIDDLE syndrome disease 
which is characterised by defects in DSB repair [126, 177]. Collectively this evidence 
suggests that both RNF 8 and RNF168 play an important role in the repair of DNA 
damage. 
To understand the contribution of RNF8 and RNF168 in repairing DNA damage 
in our systems, colony survival assays were carried out to assess the sensitivity of 
DT40 Rnf8 and Rnf168 knockout cells lines to DNA damaging agents (HU and Parp 
inhibitors). Rnf8 and Rnf168 knockout cells lines were treated with HU and PARP 
inhibitors and the percentage of surviving colonies were counted 10 days after 
treatment. Cells sensitive to either HU or PARP Inhibitors indicate defects in their ability 
to repair DNA damage (replication errors and DNA DSBs). Rnf8 cells showed a slight 
sensitivity to PARP inhibitors while Rnf168 cells showed a decrease in survival when 
treated with HU (Figure 6.9). 
The DT40 Rnf8 and Rnf168 cell lines were a kind gift from Vibe H. Oestergaard 
and details regarding the generation of the cell lines can be found in Oestergaard et al. 
2012 [177].  Before assessing the biological relevance of RNF8 and RNF168 in the 
repair of DNA damage, the knockout cell lines were first confirmed as true knockouts. 
Using primers, designed by Oestergaard et al, specific to the genomic region knocked 
out in either the RNF8 or RNF168 cell lines, a PCR was carried out confirming the 
knock out status of the RNF8 and RNF168 cell lines (figure 6.8). Knock out had to be 
confirmed by genomic PCR as there are no commercial antibodies available which 
recognise chicken RNF8  or RNF168. 
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Figure 6.8 Confirmation of the RNF8 and RNF168 knockout status of DT40 cell lines. 
(a) Confirmation of the knockout status of RNF8 and RNF168 cell lines. A PCR using the 
indicated primers shows a positive product band for RNF8 and RNF168 only in the WT genomic 
DNA  and not in the Knock out cell lines. The RNF8 PCR product is expected to be around 
250bp and >250bp for RNF168. 
(b) Illustration of the design of the PCR primers used to amplify a region of the RNF8 and 
RNF168 gene, subsequently knocked out. The PURO gene replaced the area of the RNF genes 
above it. VO232 and VO233 primers were designed to amplify the region of the RNF8 gene 
replaced by PURO whereas VO230 and VO231 was designed similarly for the RNF168 gene. 
Figures adapted from Oestergaard et al. 2012. 
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Figure 6.9 Sensitivity of Rnf8 and Rnf168 cells to DNA damaging agent. 
(a) Colony survival assay illustrating the sensitivity of Rnf8 cells to PARP inhibitor, Olaparib. 
Cells were treated for 24hrs with 0-3µM Olaparib before being plated on methylcellulose 
cellulose media, as described in the Methods and materials section. Surviving colonies were 
counted 9-12 days after plating and plotted relative to untreated cells. Data shown are the mean 
of at least 3 independent experiments. Error bars, s.d. 
(b) Colony survival assay illustrating the sensitivity of Rnf168 cells to HU. Cells chronically 
treated with 0-200µM HU as described in the Methods and materials section. Surviving colonies 
were counted 9-12 days after plating and plotted relative to untreated cells. Data shown are the 
mean of at least 3 independent experiments. Error bars, s.d. 
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Brca1 DT40 cells were used a positive control in figure 6.9 (a). Although Rnf8 cells 
showed an 8 fold lower survival percentage in comparison to WT cells when treated 
with a PARP inhibitor, Rnf168 cells showed negligible sensitivity. On the other hand, 
the survival of Rnf168 cells was greatly impaired after treatment with HU whereas Rnf8 
cells similar sensitivity to HU as Brca1 cells. Collectively these results indicate a 
potential function of the RNF8 and RNF168 proteins in the repair of damaged DNA. 
 
6.2.7 RNF8I405A cells are not sensitive to PARP inhibitors. The 
survival of RNF168I18A cells are compromised in the presence of 
HU. 
Results shown in figure 6.9 indicate a functional role for RNF8 and RNF168 in the 
repair of DNA damage. In order to elucidate whether the ubiquitin ligase activity of the 
RNF8 and RNF168 proteins are responsible for their functional role in DNA repair, Rnf8 
and Rnf168 DT40 cells were reconstituted with ubiquitin ligase dead RNF8 and 
RNF168 and analysed for their sensitivity to DNA damaging agents. According to data 
previously shown in this chapter, the point mutations generated in the RING domains of 
RNF8 and RNF168 prevents their ubiquitin ligase activity in vitro. Rnf8 DT40 cells were 
reconstituted with either HsGFP-RNF8 or HsGFP-RNF8I405A. Rnf168 cells were 
reconstituted with either GgYFP-RNF168 or GgYFP-RNF168I18A. 
 Rnf8 cells reconstituted with HsGFP-RNF8I405A were not sensitive to PARP 
inhibitors whereas complete knockout of RNF8 was sensitive. The expression of full 
length GFP-HsRNF8 in Rnf8 cells fully restored their resistance to PARP inhibitors. 
This may suggest that the function of RNF8 in DNA repair is not dependent on it E3 
ligase activity, at least not the type of damage created by PARP inhibitors. 
 Rnf168 cells reconstituted with YFP-GgRNF168I18A appeared to be more 
sensitive than complete Rnf168 knockout cells. Reconstitution of Rnf168 cells with full 
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length YFP-GgRNF168 only partially rescued the cell line from HU sensitivity. As the 
endogenous expression of the RNF8 and RNF168 proteins could not be analysed due 
to a lack of chicken antibodies against these proteins, it is difficult to conclude if the 
expression of the reconstituted proteins may interfere with the outcome of these 
results. However it seems that the ubiquitin ligase activity of RNF168 is indeed required 
for its function in DNA repair when treated with HU. 
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Figure 6.10 Sensitivity of RNF8i405A and RNF168i18A cells to DNA damaging agent. 
(a) Western blot of the expression of reconstituted RNF8 and RNF168 cell line. Α-GFP antibody 
was used to detect the expression of all reconstituted RNF proteins and α-GAPDH was used a 
loading control. 
(b) Colony survival assay illustrating that Rnf8 cells reconstituted with GFP_hsRNF8i405A does 
not appear to be sensitive to PARP inhibitor, Olaparib. Cells were treated for 24hrs with 0-3µM 
Olaparib before being plated on methylcellulose cellulose media, as described in the Methods 
and materials section. Surviving colonies were counted 9-12 days after plating and plotted 
relative to untreated cells. Data shown are the mean of at least 3 independent experiments. 
Error bars, s.d. 
(c) Colony survival assay illustrating the sensitivity of Rnf168 cells reconstituted with YFP-
GgRNF168i18A to HU. Cells chronically treated with 0-200µM HU as described in the Methods 
and materials section. Surviving colonies were counted 9-12 days after plating and plotted 
relative to untreated cells. Data shown are the mean of at least 3 independent experiments. 
Error bars, s.d. 
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Any sensitivity seen to either PARP inhibitors or HU seems to be independent of 
localisation of the reconstituted RNF proteins as they all localise to the nucleus as seen 
in figure 6.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.11 Nuclear localisation of reconstituted RNF proteins 
Cell lysates were fractioned into their cytoplasmic and nuclear fractions as described in the 
Methods and Materials chapter. W(whole), C(cytoplasmic) and N(nuclear) Fractions were 
analysed by Western blotting. The majority of all the RNF proteins, full length and mutant, are 
located in the nuclear fractions.  
 
 
 
Both RNF8 and RNF168 are believed to contribute to the ubiquitylation of histone H2A 
and H2AX in response to DNA damage, H2A and ubH2A was blotted for by Western 
blot using lysates from reconstituted Rnf8 and Rnf168 cells. Intriguingly an increase in 
ubH2A was seen in the Rnf8 cell line reconstituted with full length GFP-HsRNF8 and 
not with YFP-GgRNF168. Neither of the ubiquitin ligase dead reconstituted cells 
showed an increase in ubH2A levels by Western blot. This result suggests that RNF8 is 
necessary for mono-ubiquitylation of H2A which is in agreement with the literature. 
Interestingly RNF168 cells reconstituted with YFP-GgRNF168 and also WT cells did 
not show an increase in mono-ubiquitylated H2A. As RNF168 is proposed to be 
responsible for mono-ubiquitylation of H2A [123] you would expect to see an increase 
of mono-ubiquitylated H2A in the presence of RNF168 in comparison to its ubiquitin 
ligase dead counterpart. It is possible that RNF8 is the limiting factor involved in this 
W W C C N N W C N 
RNF 8 RNF 8 i405A RNF 168 
W C N 
RNF 168 i18A 
GAPDH 
(cytoplasmic) 
P84 (nuclear) 
GFP 
215 
 
process and only with the overexpression of RNF8 is an increase of ubiquitylated H2A 
observed. 
 
 
Figure 6.12 ub-H2A levels in the RNF reconstituted cell lines. 
Western blot of the H2A and ub-H2A levels from the indicated cell lines. Cells were harvested 
and a histone extraction was carried out as described in the methods and materials. Samples 
were analysed by PAGE and Western blotting. A H2A antibody was used to detect both H2A 
and ub-H2A. 
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6.3 Summary 
RNF8 and RNF168 are active ubiquitin ligases and ubiquitylate free histone substrates 
in vitro. 
RNF8I405A and RNF168I18A are ubiquitin ligase dead mutants unable to ubiquitylate 
free histone substrates in vitro. 
Rnf8 DT40 cells are sensitive to PARP inhibitors suggesting that RNF8 is important in 
repairing DSB. This function of RNF8 is not dependent on its ubiquitin ligase activity. 
Rnf168 DT40 cells are not sensitive to PARP inhibitors but show sensitivity to DNA 
damaging agent HU. The ubiquitin ligase function of RNF168 is required to overcome 
HU sensitivity. 
Overexpression of RNF8 increases the amount of mono-ubiquitylated H2A in vivo 
whereas its ubiquitin ligase dead mutant does not. Whereas no increase of mono-
ubiquitylated H2A was observed with the re-expression of RNF168 or RNF168I18A.
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Chapter 7 Discussion 
The work carried out in this dissertation highlights the contribution of the BARD1 BRCT 
domains to the repair of DNA DSBs by HR. My results suggest that the BARD1 BRCT 
domains promote the stability of the BRCA1-C complex and that this is not dependent 
on the potential phospho-peptide binding ability of the BARD1 BRCT domains. My 
results indicate that the BRCT domains of BARD1 are important in the localisation of 
BARD1 to sites of damage and also to S-phase “BRCA1 nuclear dots”. These findings 
together with the identification of potential interactions of BARD1 with proteins 
identified with Mass Spectrometry, lead to a model whereby the BARD1 BRCT 
domains contribute to the DDR by stabilising CtIP to the BRCA1-C complex and 
potentially ensure correct localisation of BARD1 at sites of damage. These roles of the 
BARD1 BRCT domains may function independently of other proteins or more likely, 
involve the interaction with another protein important for repair. 
BARD1 is known to play an important role in DNA repair as a regulator of BRCA1 
function and tumour suppressor activity. BARD1 and BRCA1 form a heterodimer 
through α-helices adjacent to their RING domains. BARD1 masks a nuclear export 
signal in BRCA1, promoting retention of BRCA1 in the nucleus where it carries out its 
functions in the DDR [397]. The binding of BARD1 to BRCA1 also greatly enhances the 
ubiquitin ligase activity of BRCA1 [169, 233]. Initial clues that BARD1 is important in 
genome stability came from the study of Bard1 null mice which are embryonic lethal 
and cells from these mice exhibited genetic instability [194, 207]. More recently, there 
has been evidence that the BRCT domains of BARD1 are important in DSB repair. 
Loss of the BRCT domains severely impaired the ability of the cells to carry out HR 
repair of DSBs according to Westermark et al. and Baer et al.[266, 269]. Interestingly a 
frame shift mutation in the BARD1 gene has also recently been identified in hereditary 
breast cancer patients. The frame shift mutation in BARD1 results in the loss of the 
second BRCT domain of BARD1 [213]. These patients do not carry either Brca1 or 
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Brca2 mutations which are more frequently associated with inherited breast and 
ovarian cancers. A similar study carried out by Ratajska et al. identified a novel 
truncation mutation in non-BRCA1/BRCA2 breast cancer patients resulting in the loss 
of both BRCT domains of BARD1 [214]. The work described in this thesis confirms the 
importance of the BARD1 BRCT domains in DNA DSB repair by HR. Spectrometry 
ifically, DT40 Bard1 cells expressing human BARD1ΔBRCT showed a marked 
decrease in their ability to carry out homology directed repair of DSB and were also 
sensitive to PARP inhibitors in comparison to WT cells.  
 The domain structure of BARD1 and BRCA1 are very similar. Both proteins 
contain RING finger domains in their N-terminus and tandem BRCT domain repeats in 
their C-terminus. The BRCA1 BRCT domains serve as phospho-protein interaction 
domains and interact with Abraxas, FANCJ and CtIP. The interaction of BRCA1 with 
these proteins is important for the maintenance of genome stability. The mechanism 
and function of the BARD1 BRCT domains in the DDR is still unclear, however as the 
BRCA1 BRCT domains mediate important interactions required for DNA damage repair 
it is possible that the BARD1 BRCT domains also carry out similar functions in the 
DDR. The three main questions which will be addressed in this thesis, regarding how 
the BRCT domains of BARD1 may contribute to the DDR, are as follows; Do the BRCT 
domains of BARD1 contribute to the stabilisation of the BRCA1 complexes? Do the 
BRCT domains affect the localisation of BARD1? And do the BRCT domains potentially 
interact with any proteins that may be important for DNA repair? These questions will 
be addressed in relation to how they might explain the importance of the BARD1 BRCT 
in genome stability and prevention of cancer. 
7.1 The importance of BRCT domains in the DDR. 
BRCT domains are versatile protein interacting domains first discovered in the C-
terminus of the tumour suppressor gene, BRCA1 [193]. BRCT domains are found in 
over 20 proteins in the human genome and can be found as a single unit or in multiple 
copies [193, 289, 290, 304]. The majority of BRCT domain containing proteins are 
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involved in the DNA damage response and DNA repair [289, 290, 300, 301, 346]. The 
importance of BRCT domains in DNA repair and maintenance of genome integrity is 
demonstrated by the fact that mutations in the BRCT domains of proteins such as 
BRCA1, NBN and MCPH1 lead to an increase susceptibility to cancer [183, 184, 398]. 
In agreement with this, Shakya et al. has shown that mutations in the BRCT domains of 
BRCA1 results in a decrease in efficient HR [298]. I have also shown that point 
mutations in the BRCA1 BRCT domains, responsible for binding phosphorylated 
peptides, results in decreased efficiency in HR. In contrast to these studies, Dever et al 
proposed that mutations in the BRCT binding site of BRCA1 results in hyper-
recombination [321], however analysis of breast cancers which often contain mutation 
in the BRCA1 BRCT domains suggest that the BRCT domains are indeed important in 
the DDR. Interestingly, as previously mentioned, mutations in the BARD1 BRCT 
domains have been associated with a small number of breast cancers further 
strengthening the hypothesis that the BRCT domains play a vital role in the repair of 
damaged DNA.  
 The DDR involves the recognition of damaged DNA which initiates a complex 
signalling pathway that has several functional consequences. Signalling at DNA 
damage sites marks the damage site for repair, recruits proteins involved in the repair 
and also creates a chromatin environment whereby repair can take place before the 
cell progresses through the cell cycle [399]. Phosphorylation plays a major role in the 
signalling at sites of DNA damage [400-402] and BRCT domains have been shown to 
bind phospho-proteins important for DNA repair [291, 300, 301, 314, 315, 346, 354]. 
The general fold of a BRCT domain involves a central 4-stranded β-sheet with a single 
α-helix on one side and a pair of α-helices on the other [299]. Phospho-peptides have 
been shown to bind tandem BRCT domains via conserved bipartite recognition of two 
distinct binding pockets. The first binding pocket recognises pSer in the N-terminal 
BRCT domain whereas a hydrophobic pocket found in the interface of the two BRCT 
domains binds the amino acid of the phospho-peptide at residue +3 from the pSer  
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[291]. Analysis of several BRCT domains indicate that both the hydrophobic core and 
residues involved in the binding of phosphorylated peptides are well conserved and the 
majority of variation in structure and sequence between different BRCT domains is 
found in connecting loops between BRCT domains [291, 305]. 
 Crystallography analysis of  BARD1 BRCT domains revealed that they share a 
very similar structural formation to other tandem BRCT domain containing proteins 
involved in the DDR such as those found in BRCA1 and MDC1 [311]. The BARD1 
BRCT domains also have a pSer binding pocket and a hydrophobic pocket which are 
believed to be involved in the binding of phospho-peptides. It has been suggested that 
the hydrophobic pocket responsible for binding the ligand at the +3 position determines 
the Spectrometry ificity of the ligand [304]. Intriguingly Birrane et al. found that the 
interaction between His686, which is responsible for potential ligand binding at the +3 
position, and a ligand may be dynamically regulated by its protonation in response to a 
change in pH. This suggests that an interaction between the BARD1 BRCT domains 
and a phospho-peptide may be dependent on a shift in the cellular microenvironment 
[311]. Although the BARD1 BRCT domains appear to be important in the repair of DNA 
DSBs via HR, the mechanism and exact function of the BARD1 BRCT domains in HR 
remain unclear and there are no known proteins which interact with the BARD1 BRCT 
domains. 
7.1.1 Do the BRCT domains contribute to the formation of the 
BRCA1-A, -B or -C complexes. 
Although there is no evidence that the BARD1 BRCT domains interact with Abraxas, 
CtIP or FANCJ it is still possible that they directly or indirectly help stabilise the 
BRCA1-A ,-B and -C complexes. The results in this dissertation suggest that the 
BARD1 BRCT domains help stabilise CtIP but not Abraxas or FANCJ in the BRCA-A, -
B and -C complexes. The BRCA1 complexes have been shown to be important in the 
repair of damaged DNA (reviewed in [353]) and the role that the BARD1 BRCT 
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domains play in the repair of DSBs may be attributed to their ability to stabilise CtIP to 
the BRCA1-C complex. 
 Germ line mutations of BRCA1 are associated with familiar breast and ovarian 
cancer [185, 403] and several of these mutations are found in the BRCT domains of 
BRCA1 disrupting their ability to bind phospho-peptides [404]. Although it remains 
largely unknown how the BRCA1 complexes contribute to cancer prevention, it is 
evident that the formation of these complexes are essential for BRCA1 tumour 
suppressor function. 
 The BRCA1-A complex contains at least five different components; RAP80, 
Abraxas, MERIT40, BRE and BRCC36 [128-130, 132, 133, 303]. Abraxas serves as a 
central adapter protein in this complex binding to the BRCA1 BRCT domains. RAP80 
binds to ubiquitylated H2A surrounding the DNA break via its ubiquitin interacting 
motifs. This tethers the BRCA1-A complex to the site of damage and is mainly 
responsible for the recruitment of BRCA1 and other key repair proteins to damaged 
DNA. The signalling and recruitment of the BRCA1-A complex at DNA damage sites is 
believed to have a repressive role in homology directed repair as the loss of Abraxas or 
RAP80 leads to a hyper-recombination phenotype in cells [224]. Interestingly the 
BARD1 BRCT domains did not appear to contribute to the stabilisation of the BRCA1-A 
complex and loss of the BARD1 BRCT domains showed a decrease in HR efficiency 
which would not correlate with the hyper-recombination phenotype seen by Hu et al. 
[224] if the BARD1 BRCT domains are involved in the stabilisation of the BRCA1-A 
complex.  
 According to evidence in this dissertation, the BARD1 BRCT domains do not 
contribute to the stabilisation of the BRCA1-B complex involving FANCJ. FANCJ is a 
DEAH helicase domain containing protein that binds to the BRCA1 BRCT domains 
[294]. FANCJ is required for progression through S phase [332] and it has also been 
shown to be required after DNA damage for the checkpoint that accumulates cells in 
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the G2 phase of the cell cycle [86, 301]. FANCJ is also known as a Fanconi anemia 
group J protein. Patients with Fanconi anemia (FA) develop several malignancies and 
also suffer with various developmental defects [334, 335]. As FA patients are extremely 
sensitive to DNA interstrand crosslinking agents [334, 335], FANCJ is considered to 
play a role in DNA interstrand crosslink repair. Similar to BRCA1, FANCJ mutations are 
also associated with hereditary breast cancer [294, 405] and FANCJ has been shown 
to be important in the repair of DSB by HR [406]. Evidence suggests that repair of DSB 
by HR is critical if interstrand crosslinks are not repaired correctly by the Fanconi 
anemia proteins hence the interaction of BRCA1 and FANCJ is essential for DNA DSB 
repair. As expected Brca1 cells are extremely sensitive to crosslinking agents such as 
MMC and cisplatin [200], however loss of the C-terminus of BARD1 including the 
BRCT domains does not sensitise cells to MMC treatment to the same extent as Brca1 
cells [269]. According to Westermark et al. there is no statistical significance in the 
sensitivity of cells which do not have the BRCT domains of BARD1to MMC compared 
to WT cells at a concentration where BRCA1 cells are extremely sensitive. This 
evidence is in line with the results in this dissertation which show that the BARD1 
BRCT domains do not contribute to the formation or stabilisation of the BRCA1-B 
complex and although the BRCT domains of BARD1 appear to be crucial for HR, it is 
not due to a function in the BRCA1-B complex. 
 Results in this dissertations suggest that the BARD1 BRCT domains play a role 
in stabilising CtIP in the BRCA1-C complex and a model can been seen in figure 7.1. In 
the absence of the BARD1 BRCT domains the amount of CtIP co-immunoprecipitated 
with BARD1 is severely reduced in comparison to the level of CtIP pulled down with full 
length BARD1. The number of CtIP foci formed in the absence of the BARD1 BRCT 
after cells were treated with γ-irridation was also observed to be less compared with 
WT cells. However the result of this experiment may be questionable as complete loss 
of BARD1 did not illustrate the same decrease in the number of IR induced CtIP foci as 
the loss of the BARD1 BRCT domains demonstrated. The BRCA1-C complex is 
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composed of CtIP, the MRN complex and BRCA1/BARD1 heterodimer. It is believed 
that the formation BRCA1-C complex is cell cycle dependent and only forms during S 
and G2 phase when cells can carry out HR [87]. BRCA1 has been shown to interact 
with CtIP through its BRCT domains in a phosphorylation dependent manner [86]. CtIP 
is a DNA endonuclease and is required for DNA end resection at the very early stages 
of DSB repair by HR [55, 222]. The interaction of CtIP with the MRN complex is thought 
to stimulate the nuclease activity of the MRN complex and promote DNA end resection. 
It is worth noting that the tumour suppressor function of BRCA1 and its role in 
homology directed repair  depends on the BRCT domains of BRCA1 [298] and that all 
three phospho-proteins known to interact with BRCA1 via its BRCT domains are 
important in HR [353]. In agreement with these results, I have shown that point 
mutations in the BRCT domains of BRCA1 which abrogate phospho-protein binding, 
severely decrease the ability of the cell to carry out HR and shows sensitivity to PARP 
inhibitors. As BARD1 is an important regulator of BRCA1 function, and is almost 
always found bound to BRCA1 in the nucleus where BRCA1 forms the BRCA1-A, -B, 
and –C complexes, it is possible that BARD1 BRCT domains may also be important in 
the BRCA1 complexes. There have been several opposing studies regarding the 
importance of the BRCA1-CtIP interaction in the repair of DNA DSB by HR. However it 
remains clear that both BRCA1 and CtIP are required for efficient HR. The involvement 
of BRCA1 in DNA resection remains contradictory.  On one hand, Schlegel et al. show 
that cells treated with a BRCA1 siRNA abolished the formation of ssDNA focus in 
response to ionising radiation suggesting a role for BRCA1 in DNA end resection 
however they conclude that this is not dependent on the BRCT domains of BRCA1 
[407]. Chen et al also found that the assembly of nuclear ssDNA/RPA foci after ionising 
radiation was impaired in the HCC1937 cell line which contains a truncated version of 
BRCA1 lacking its BRCT domains [87]. On the other hand, Zhao et al. showed no 
reduction in IR induced RPA foci in siRNA BRCA1 depleted HeLa cell [166]. It remains 
unclear if BRCA1, Spectrometry ifically the BRCT domains, play a role in end 
resection.  
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 The importance of the BRCA1-CtIP interaction in DNA resection and HR repair 
of DNA DSB is also controversial. Previous studies in our lab suggested that the 
interaction between CtIP and BRCA1 is crucial for the repair of DNA DSB by HR. DT40 
CtIP-/-/- cells were reconstituted with either WT human CtIP or with a phospho-mutant 
CtIP (HsCtIPS372A), which prevents CtIP binding to BRCA1, and the CtIP cell line 
expressing HsCtIPS372A showed a marked defect in the ability to carry out HR [344]. 
The repair of DSB by HR requires extensive DNA end resection implicating the 
importance of the BRCA1-CtIP interaction in end resection prior to repair of DSB by 
HR. Contrary to this, Nakamura et al. reported that homology directed repair was 
proficient in DT40 (CtIPS332A/-/-) cells expressing endogenous chicken CtIP with the 
equivalent phospho-point mutant as used by our lab [345]. Very recently Reczek et al. 
showed that the BRCA1-CtIP interaction is not required for the major resection 
dependent pathways of DSB repair including HR in mouse ES cells [225]. Although the 
relevance of the BRCA1-CtIP interaction in the repair of DNA DSB by HR remains 
unclear, Nakamura et al. suggested that they function in the nuclease mediated 
removal of covalently bound oligonucleotides to peptides at DNA DSBs [345]. This 
would be consistent with the observed sensitivity seen to topoisomerase inhibitors in 
cell lines in which BRCA1 and CtIP cannot interact. 
 If the interaction between BRCA1 and CtIP is not essential for HR, what are the 
cellular functions of this conserved interaction and how might the potential function of 
the BARD1 BRCT domains in stabilising the BRCA1-C complex be important for HR 
and tumour suppression? Previous studies have implicated this interaction to be 
important for activation of the G2/M cell cycle checkpoint [86], and unpublished results 
in our lab show that the BARD1 BRCT domains are required for the progression of the 
cells through the cell cycle after cisplatin treatment. Although these potential activities 
are likely to facilitate cellular responses to DNA damage, it doesn’t explain the defects 
seen in HR with the loss of the BARD1 BRCT domains or indeed with the loss of the 
BRCA1 BRCT domains. Interestingly, what does remain clear is that according to my 
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results, the contribution of the BARD1 BRCT domains to the stabilisation of the 
BRCA1-C complex is independent of the potential phospho-binding ability of the 
BARD1 BRCT domains as point mutations predicted to abrogate potential phospho-
peptide interaction did not show a decrease in the amount of CtIP pulled down in 
comparison to full length BARD1. However the contribution of the BRCT domains of 
BARD1 to the stabilisation of the BRCA1-C complex is completely dependent on the 
interaction of BRCA1 and BARD1, as I have shown that the L107P BARD1 mutant 
which cannot interact with BRCA1, does not form part of the BRCA1-C complex. Also 
BARD1 fails to interact with CtIP in the absence of BRCA1 as shown by mammalian-
two hybrid. Extensive further work is required to assess the contribution of the BARD1 
BRCT domains in the stabilisation of the BRCA1-C complex. 
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Figure 7.1 Current and predicted model for the BRCA1-C complex. 
Previous evidence from the literature has suggested that the BRCA1 BRCT domains interact 
with CtIP and the MRN complex (A). My results suggest that the BARD1 BRCT domains 
contribute to the stabilisation of the BRCA1-C complex by directly or indirectly interacting with 
CtIP (B,C). BRCA1 and BARD1 interact via their RING domains. Potentially, an indirect 
interaction between BARD1 and CtIP may require an intermediate protein termed (?). 
 
7.1.2 Are the BARD1 BRCT domains involved in the localisation of 
BARD1/BRCA1 to sites of damage. 
The mechanism and function of BRCA1 in the repair of DNA DSB remains unclear 
however BRCA1 is a bona fide player in DNA DSB repair by HR as Brca1 cells show 
extreme sensitivity to ionizing radiation and drugs which induce DSB [208, 408]. 
BRCA1 is a mediator between the sensor of damage and repair and is required for the 
efficient repair of DSB by HR [217, 353]. My results confirm the requirement of BRCA1 
in HR as loss of BRCA1 results in defects in HR and also sensitises cells to PARP 
inhibitors. Localisation of BRCA1 to DNA DSB is required for repair by HR, as 
Greenberg et al. showed the loss of RAD51 to laser induced DNA DSB in the absence 
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of a fully functional BRCA1 [228]. RAD51 is important in strand exchange vital to HR 
and defects in RAD51 function severely impedes the repair of DSBs [409-411]. BRCA1 
is also required for the sub nuclear assembly of RAD51 following DNA damage by the 
crosslinking agent cisplatin [362]. 
 The interaction of BARD1 with BRCA1 is crucial to BRCA1 function in HR as 
BARD1 stabilises and allows nuclear retention of BRCA1. Due to the importance of this 
interaction it is possible that the BARD1 BRCT domains play a role in the localisation of 
BRCA1 to sites of damage. Loss of the BARD1 BRCT domains leads to defects in the 
repair of DNA DSBs by HR as shown in my results and by Westermark et al. and Baer 
et al. [266, 269]. It is possible that the BRCT domains of BARD1 may contribute to HR 
and genome stability by facilitating the correct localisation of BRCA1 to DNA damage.  
 Phosphorylation of H2AX (γH2AX), mediated by ATM and ATR, has been 
shown to facilitate the recruitment of BRCA1 to sites of DNA damage [323]. However 
BRCA1 can still be recruited to sites of damage in the absence of γH2AX but it cannot 
be stably retained suggesting that γH2AX is required for the sustained recruitment of 
BRCA1/BARD1 [357]. The phosphorylation of H2AX initiates a signalling cascade 
which ultimately recruits repair proteins such as BRCA1 and 53BP1 to sites of damage. 
The degree of H2AX phosphorylation correlates with the level of DNA DSBs [356]. 
Recently, studies have shown that ubiquitylation during the signalling cascade at DSBs 
is responsible for the recruitment of BRCA1 through its interaction with RAP80 [128, 
130, 133]. RAP80 is part of the BRCA1-A complex and binds to ubiquitin chains on 
H2AX after H2AX phosphorylation. RAP80 cannot be solely responsible for BRCA1 
recruitment as the loss of RAP80 does not completely abolish IR induced BRCA1 foci 
according to Hu et al  [224]. 
 Recently Li et al. made a substantial contribution to the understanding of how 
BRCA1/BARD1 is recruited to DSBs. They suggested that BRCA1 is recruited to DNA 
damage in two waves, the initial early recruitment is suggested to be dependent on the 
228 
 
BARD1 BRCT domains and independent of γH2AX, whereas the second wave of 
recruitment depends on γH2AX [287].  This piece of work demonstrated that the 
BARD1 BRCT domains are capable of localising to laser stripe induced DSB within 20 
seconds after damage in the absence of γH2AX and is responsible for the very early 
recruitment of BRCA1/BARD1 to DSBs. In the absence of the BARD1 BRCT domains, 
BRCA1 failed to recruit early to DSBs and only localised to the DNA damage stripe 
after 2 minutes. This later recruitment of BRCA1 in the absence of the BARD1 BRCT 
domains was dependent on γH2AX. Although BARD1 failed to recruit early to the site 
of damage in the absence of its BRCT domains, it localised with BRCA1 in a γH2AX 
dependent manner later. In agreement with my results, the early recruitment of 
BRCA/BARD1 to laser induced damage stripes is believed to be due to the binding of 
the BARD1 BRCT domains to PAR. Cells treated with PARP inhibitors failed to recruit 
BRCA1/BARD1 in the early recruitment phase to DNA damage. My results also 
indicate that in the absence of the BRCT domains of BARD1 or with the treatment of 
PARP inhibitors, BARD1 requires longer to localise to laser induced damage stripes 
indicating the importance of the BARD1 BRCT domains in the early recruitment of 
BARD1 to DSBs. Although the trends seen by Li et at are very similar to those I 
observed in the recruitment of BARD1 with the loss of the BRCT domains or with the 
treatment of PARP inhibitors, the exact timings were delayed in my experiments. Li et 
al. shows early recruitment after 20 seconds and γH2AX recruitment after 2minutes, 
whereas I observed early recruitment after 1min and the later recruitment after 
3minutes. This may be partially explained by the use of different wave length lasers to 
induce damage. A 405nm UV laser was used in my experiments to induce damage, 
whereas Li et al. availed of 337.1nm laser. Regardless of the slight time difference, the 
results indicate the same outcome suggesting a role for the BARD1 BRCT domains in 
the very early recruitment of the BARD1 to DSBs. 
 Li et al. extended their finding by demonstrating that it is the phospho-binding 
ability of the BARD1 BRCT domains that are responsible for the early recruitment of 
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BRCA1/BARD1. They generated a point mutation in the BARD1 BRCT domain 
predicted to bind phosphorylated proteins (BARD1K619A) and this protein showed the 
same delayed kinetics in localising to sites of damage as the complete loss of the 
BARD1 BRCT domains did. In this study, the BARD1 BRCT domains bind ADP-ribose, 
the basic unit of PAR [287]. This is believed to be in a phosphorylation dependent 
manner as there are two phosphate groups in ADP-ribose and BARD1K619A failed to 
interact with PAR. Although poly(ADP-ribose) polymerases (PARPs) have been shown 
to be important for SSB repair [412-414], recent structural analysis has also indicated 
that PARP1 recognises DSBs [286].  
 I have shown that loss of the BRCT domains of BARD1 does not prevent 
BARD1 recruitment to laser induced DNA DSBs, however in agreement with the work 
carried out by Li et al. the BARD1 BRCT domains appear to play a more intricate role 
in the timing of recruitment. The observation that the BRCT domains of BARD1, 
particularly the potential phospho-interacting amino acids in the BARD1 BRCT 
domains, are important in the early recruitment of BRCA1/BARD1 to DNA damage 
does not explain their biological relevance in HR or tumour suppression. My results 
suggest that although the BRCT domains of BARD1 are important for HR, as loss of 
the BRCT domains of BARD1 results in defects in HR and sensitises cells to PARP 
inhibitors, the potential phospho-binding ability of the BARD1 BRCT domains are 
dispensable in HR. Bard1 DT40 cells reconstituted with BARD1S575F, BARD1K619M 
and BARD1H686R and a triple mutant containing all three point mutations showed no 
defects in the repair of HR and were not sensitive to PARP inhibitors. These cells were 
also competent in HR even after treatment with PARP inhibitors. Laufer et al. also 
presented similar results indicating that the potential phospho-peptdide interaction of 
the BRCT domains of BARD1 was not required for its function in HR [266]. This 
evidence suggests that the early recruitment of BRCA1/BARD1 to DSBs by the BARD1 
BRCT domains does not appear to affect the cells ability to carry out efficient HR.     
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 An interesting observation was made in this dissertation which suggested that 
in the absence of the BARD1 BRCT domains, BARD1 localisation to “BRCA1 nuclear 
dots” is impaired. In 1996, Scully et al. reported the discrete localisation of BRCA1 into 
nuclear foci [415]. As suggested by Chen et al. [416] and confirmed by Scully et al. the 
“BRCA1 nuclear dots” appear in the S-phase of the cell cycle [208]. BRCA1 expression 
is cell cycle dependent and elevated levels of BRCA1 expression are seen in S-phase 
[416-419] which correlates with a hyper-phosphorylated form of the protein [416]. 
Subsequently both RAD51 and BARD1 were shown to co-localise with “BRCA1 nuclear 
dots” in a S-phase dependent manner in the absence of DNA damage [215, 355]. I 
have also shown that the accumulation of BARD1 at discrete nuclear foci is S-Phase 
related as the number of cells with BARD1 nuclear foci directly correlated to the 
amount of cells in S-phase according to both EDU and PCNA immunostaining and 
FACs analysis of BrdU and PI stained cells. This evidence strongly suggested a role for 
BRCA1/BARD1 heterodimer in the maintenance of genome stability and potentially in 
the processing of replicated DNA. To date, the exact function of the BRCA1 nuclear 
foci is still unknown, however it does appear to be important in the availability of 
BRCA1/BARD1 for recruitment to sites of damage. After DNA damage these BRCA1 
foci largely disperse and form larger foci containing repair proteins important in the 
repair of DNA damage [215, 356, 420]. Also after DNA damage the BRCA1 nuclear foci 
co-localise with PCNA replication structures, whereas prior to damage co-localisation 
was not observed [208]. 
 There is no evidence suggesting that these S-phase BRCA1 nuclear foci are 
important in the actual repair of DSBs, however it is intriguing that in the absence of the 
BARD1 BRCT domains, BARD1 shows defects in its ability to localise to these foci. It 
would be very interesting to study the effects of BRCA1 recruitment to these S-phase 
associated nuclear foci in the absence of the BARD1 BRCT domains. Jin et al. 
suggested that the formation of the BRCA1 nuclear foci may require BRCA1 [355] 
however my results suggest that at least the recruitment of BARD1 to these nuclear 
231 
 
foci does not require its interaction with BRCA1. BARD1L107P which cannot interact 
with BRCA1 was fully competent in forming discrete nuclear foci similar to WT BARD1. 
Interestingly although loss of the BRCT domains of BARD1 compromised BARD1 
localisation to S-phase nuclear foci, point mutation that are predicted to abrogate 
phospho-protein interaction were also competent in forming S-phase nuclear foci. 
 The contribution of the BARD1 BRCT domains to the formation of the BRCA1 
nuclear foci requires much more investigation, as does the function and biological 
relevance of these structures. The defects seen in the localisation of BARD1 to nuclear 
foci do not appear to impede on the recruitment of BARD1 to sites of damage as 
BARD1ΔBRCT is proficient in localising to laser stripe induced damage. However it is 
clear from my results that the interaction of BRCA1 with BARD1 is not required for the 
BARD1 localisation to these S-phase nuclear foci which leads to the Spectrometry 
ulation that potentially it is BARD1 that allows BRCA1 to be recruited to the BRCA1 
nuclear foci.  
 Another interesting observation I made in this dissertation was the extremely 
delayed kinetics of cells exhibiting BARD1 nuclear foci to recruit to laser induced DNA 
damage stripes. Cells which exhibited uniformly dispersed BARD1 in the nucleus 
localised to laser stripes within 1 minute of damage whereas S-phase cells which 
showed discrete nuclear foci formation of BARD1 required at least 4 to 5 minutes to 
accumulate at sites of damage. There were no observable nuclear foci formation in 
cells lacking the BARD1 BRCT domains and the slight delayed kinetics seen with the 
localisation of these cells is believed to be due to the inability of BARD1 to be recruited 
in the absence of the BRCT domains as discussed earlier. The importance of the 
increased delayed kinetics seen in cells expressing full length BARD1 which formed 
discrete nuclear foci, believed to be S-phase BRCA1 nuclear foci, remains unclear. 
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7.1.3 How do novel interactors of BARD1 and its BRCT domains 
contribute to its role in DNA DSB repair. 
Mass Spectrometry analysis of BARD1 interacting proteins in this dissertation revealed 
several proteins involved in the NuRD complex which may interact with BARD1. The 
NuRD complex is a nucleosome remodelling and histone deacetylation complex. Given 
that the role of chromatin remodelling in response to DNA DSBs is just beginning to 
emerge, the potential association of BARD1 with members of the NuRD complex is 
very intriguing. 
 In eukaryotic cells, the tight packaging of DNA into highly structured and 
condensed chromatin poses a significant impediment to DNA based processes such as 
transcription, replication and repair. To overcome these regulatory boundaries, cells 
have evolved two major processes to modify chromatin structure. The first is by post 
translational modification of histone tails and the second by ATP-dependent 
remodelling of chromatin. Emerging evidence suggests that DNA signalling and repair 
processes act in an integrated fashion with chromatin structures at sites of DNA 
damage [421-426]. While it appears intuitive that condensed chromatin protects the 
DNA from damage, a more open and relaxed chromatin state is required for loading 
repair proteins onto chromatin at sites of damage [424].  
CHD4, MTA1/2, HDAC1, LSD1 and RBBP7 are all core components of the 
NuRD complex [427, 428] and were found to co-immunoprecipitate with BARD1 by 
Mass Spectrometry in this dissertation. Although none of these proteins could be 
confirmed to interact with BARD1 by western blot, their identification by Mass 
Spectrometry remains very interesting and may provide an insight into the importance 
of BARD1 in the repair of DSB with future work. It is possible that these proteins could 
not be confirmed by western blot due to the small quantities that were identified by 
Mass Spectrometry. Only a small number of peptides were identified for each NuRD 
protein by Mass Spectrometry in comparison to BRCA1 which identified over 50 unique 
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peptides in the analysis and confirmation of BARD1 interacting proteins. It is also 
important to note that the NuRD complex members identified as potential BARD1 
interactors where only seen when a crosslinker was used to stabilise potential BARD1 
complex members. This suggests that any interaction between BARD1 and the NuRD 
complex may be very distant or transient making it more difficult to confirm. Further 
study is needed to confirm that the Mass Spectrometry candidates identified as BARD1 
interactors are indeed true interactors however the current evidence of the role of the  
NuRD complex in DSB repair is intriquiging and could potentially involve BARD1. 
 Smeenk et al. have proposed that the NuRD complex is a novel regulator of 
DSB repair as the NuRD complex is rapidly recruited to DSBs and promotes histone 
ubiquitylation via RNF8/RNF168. They have also reported that the NuRD complex is 
important for the ubiquitin dependent accumulation of RNF168 and BRCA1 to sites of 
damage. Consequently the loss of certain components of the NuRD complex is 
implicated in defects in DNA repair and checkpoint activation [429]. CHD4 localises to 
laser induced DNA damage stripes [429]. Preliminary data from my dissertation also 
suggests that CHD4 localises to DNA damage stripes. An increase in γH2AX, a marker 
for DNA damage, was observed by Pegoraro et al. in the absence of CHD4 [430] which 
is consistent with the idea that CHD4 and the NuRD complex play a role in DNA repair. 
Loss of CHD4 also sensitises cells to IR [371]. CHD4 has been shown to be recruited 
to DNA damage by two separate mechanisms, first of all by binding to poly(ADP-
ribosyl)ated proteins, including PARP1 [371], which then mediates the PARP-
dependent recruitment of NuRD proteins MTA2 and HDAC1. The second method is 
dependent on the ubiquitin ligase RNF8 [372]. Upon recruitment by RNF8, the 
chromatin remodelling activity of CHD4 is proposed to decondense the chromatin 
surrounding a DSB allowing the formation of ubiquitin conjugates by both RNF8 and 
RNF168 [372]. The amplification of the ubiquitin signal at DSB is prerequisite for the 
DNA damage repair signal and downstream recruitment of repair proteins such as 
BRCA1 and 53BP1 [429]. In agreement with these results, knockdown of CHD4 results 
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in a decrease of ubiquitylation at DSBs which corresponds to the reduced accumulation 
of BRCA1 and RNF168 at DSBs [372]. The potential interaction of BARD1 and CHD4 
is very interesting especially as both proteins are recruited to DSB very early after 
damage in a PARP dependent manner. It would be intriguing to explore the connection 
between BARD1 and CHD4 in relation to their PARP dependent recruitment to DSBs. 
Both proteins are recruited to DSB in a PARP-dependent manner independent of 
γH2AX [287, 371] As Li et al proposed that the BARD1 BRCT domains bind PAR 
directly, it is possible that BARD1 may play a role in recruiting CHD4. However both 
CHD4 and BARD1 can also be recruited to DSB by RNF8 and BRCA1 suggesting that 
the early recruitment may function as a failsafe rather than being pivotal to their 
recruitment.  
MTA1 is an integral component of the NuRD complex [373] and is one of the 
most commonly overexpressed gene products in human cancers. The levels of MTA1 
have been shown to be greatly increased in metastatic and aggressive cancers [431-
433]. Given MTA1s role in cancer it was not surprising to find that it also played a role 
in the DNA damage response to ionizing radiation [374]. Depletion of MTA1 renders 
cells extremely sensitive to ionizing radiation suggesting a role for MTA1 in DSB repair 
[374]. Similarly to CHD4, Chou et al. have shown that MTA1 is also recruited to sites of 
DNA damage in a PARP-dependent fashion [288]. MTA1 protein is stabilised in 
response to ionizing radiation [374]. Under normal conditions MTA1 is targeted for 
degradation by COP1 ubiquitin ligase, however after DNA damage ATM 
phosphorylates COP1 which promotes its auto-degradation and therefore stabilises 
MTA1 in response to DNA damage [374]. The exact role of MTA1 in the repair of DSBs 
remains unclear however it would appear from experimental evidence that MTA1 
contributes to the efficient repair of DSBs. 
Another NuRD complex protein shown to interact with BARD1 by Mass 
Spectrometry was MTA2. A biochemical study indicated that MTA2 is responsible for 
modulating the histone deactylation activity of the NuRD complex [434]. Initial 
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indications that MTA2 is important for DSB repair came from a study carried out in 
worms. van Haaften et al. showed that the loss of EGR1, the worm MTA2 homolog, 
sensitised cells to IR [435]. Since then, it has been shown that MTA2 is also recruited 
to DSB breaks and human cells lacking MTA2 are also sensitive to IR [429]. 
Histone deactylase 1 (HDAC1) is another core component of the NuRD 
complex and is believed to be involved in transcriptional repression by removing acetyl 
groups from histone tails, condensing chromatin [373]. Bhaskara et al. have suggested 
a role for HDAC1 in DNA replication fork progression as loss of HDAC1/2 results in a 
reduction of the replication fork velocity and also increases replication stress leading to 
DNA damage [436]. A connection between HDAC1 and the DNA damage response 
was seen in 2009 by Pegoraro et al. as loss of many NuRD complex members 
including HDAC1 resulted in an increase in γH2AX signal. HDAC1 has also been 
shown to be recruited to laser induced DNA damage stripes [437] in a manner that is 
dependent on CHD4 and PARP [371]. The function of HDAC1 in DSB repair remains 
unclear as very little research has been carried out in this field so far.  
As mentioned previously, BARD1 was shown to interact with many proteins 
associated with the NuRD complex by Mass Spectrometry in this dissertation. It has 
become evident from research carried out that the NuRD complex appears to have a 
functional role in the repair of DSBs. As this is a very novel area of research it is 
difficult to predict the potential role that the interaction of BARD1 may have with 
members of the NuRD complex. It is possible that BARD1 may be involved in the 
recruitment of CHD4 to sites of damage as CHD4 can be recruited in a PARP 
dependent manner and BARD1 has been shown to interact with PAR at DSBs. The 
functional and biological relevance of these potential interactions is uncertain and 
whether the NuRD complex functions mainly to remodel chromatin allowing access of 
repair proteins or whether it has a more involved role in the actual repair of damage 
has yet to be discovered. However a potential interaction between BARD1 and 
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components of the NuRD complex may contribute to our understanding of the 
importance of BARD1 in DSB repair in the future. 
RBBP7 is another component of the NuRD complex which was found to co-
immunoprecipitate with BARD1 by Mass Spectrometry. RBBP7 is an evolutionary 
conserved histone binding protein [438] proposed to be important for establishing 
heterochromatin. Very little is known about the function of this protein however RBBP7 
is believed to be a structural protein that provides an interactive interface for other 
components of the NuRD complex [427, 434]. RBBP7 is a subunit of the CAF1 
complex which assembles chromatin during DNA replication and repair [439]. It has 
also been shown that RBBP7 interacts with the BRCA1 BRCT domains and this 
interaction is disrupted in the presence of DNA damaging agents [262]. As RBBP7 has 
already been shown to interact with BRCA1, it is possible that it was pulled down with 
BARD1 as part of a larger complex with BRCA1. The functional role of RBBP7 in repair 
of DSB is unclear as is the relevance of a potential interaction with BARD1. 
The final NuRD complex protein which was seen to associate with BARD1 in 
this dissertation was LSD1. LSD1 is a histone demethylase that mediates H3K4me1/2 
demethylation involved in transcriptional repression [388]. It has also been shown to be 
part of the NuRD complex [428]. A very recent study carried out by Mosammaparast et 
al. has discovered a novel function of LSD1 in the repair of DNA DSBs. This study 
showed that LSD1 localises to laser induced DNA DSB stripes which coincided with 
H3K4me2 demethylation. The recruitment of LSD1 to DSB was dependent on its 
interaction with ubiquitin ligase RNF168 which is very reminiscent of the CHD4-RNF8 
recruitment [390]. Interestingly, Mosammaparast et al. suggested that LSD1 is 
important in the recruitment of 53BP1 to sites of damage as loss of LSD1 in cells 
results in a decrease in 53BP1 foci formation after damage. As HR efficiency is 
observed to increase slightly in the absence of LSD1 it is proposed that LSD1 may play 
an important role in repressing or limiting the amount of HR which occurs after a DSB 
is sensed. I have shown that BARD1 is important for HR and loss of BARD1 results in 
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a decrease in HR efficiency. The potential interaction between BARD1 and LSD1 may 
be involved in the repair choice of DSB, whether it be by HR or NHEJ and would allow 
a greater understanding of the functional relevance of BARD1 in the repair of DSBs. 
Post translational modifications such as phosphorylation, ubiquitylation, 
methylation and sumoylation are extremely important in the DDR and also for the 
recruitment of repair proteins to sites of damage. Not only do post translational 
modifications remodel chromatin allowing access of repair proteins to the site of 
damage and repress transcription they are also responsible for a complex signalling 
pathway at DSBs which serves to recruit repair proteins. Histones surrounding DNA 
DSB are vastly ubiquitylated and amplify the DNA damage signal. Ubiquitylation of 
histones is also responsible for the ultimate recruitment of BRCA1 to sites of damage. 
Methylation of H4K20 has been shown to recruit the repair protein 53BP1 to DSBs 
[440]. The importance of PTMs at DSBs makes the potential interaction between 
BARD1 and members of the NuRD complex, especially the lysine demethylase LSD1, 
very intriguing. It is also important to note that HUWE1, a ubiquitin ligase, was also 
identified as a potential BARD1 interactor. 
In relation to post translational modifying enzymes involved in DSB repair and 
signalling, UBC9, a SUMO E2 conjugating enzyme was the only DDR protein identified 
that interacted with the BARD1 BRCT domains Spectrometry ifically according to Mass 
Spectrometry data in this dissertation. In contrast to the ubiquitylation pathway which 
utilises several E2 conjugating enzymes, UBC9 is the only SUMO E2 enzyme hence a 
vital regulator of the sumoylation pathway. Interestingly UBC9 has been shown to 
interact with RAD51 [441-443], a key component of the HR machinery and loss of 
nuclear UBC9 correlated with a decrease in the RAD51 foci formation after DNA 
damage [444]. In correlation with this, I have also seen a reduction in the formation of 
IR induced RAD51 foci in the absence of both full length BARD1 and just the BARD1 
BRCT domains. An intriguing similarity between BARD1 BRCT domains and UBC9 is 
their ability to interact with PARP, UBC9 was discovered as a PARP interactor in a 
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yeast-two hybrid screen [445] however the function of this interaction in relation to DNA 
repair is still unknown. As further evidence of the importance of UBC9 in the repair of 
DNA DSBs, a study carried out on samples derived from breast cancer patients which 
contained a polymorphism in UBC9 showed a decrease in efficient HR in comparison 
to samples containing WT UBC9. This body of evidence highly suggests that UBC9 is 
an important player in the repair of DNA DSBs however much more work is needed to 
determine its function and the relevance of a potential interaction between UBC9 and 
the BARD1 BRCT domains. 
7.1.4 Conclusions and future work. 
The work presented in this dissertation suggests an important role for the BARD1 
BRCT domains in the repair of DNA DSB by HR. Proteins containing BRCT domains 
have been shown to be integral to the DDR and the importance of the BARD1 BRCT 
domains only strengthen this observation. Very little is understood about the function 
and relevance of the BARD1 BRCT domains in DNA repair however the work I have 
presented here suggests that they may contribute to the stabilisation of the BRCA1-C 
complex by directly or indirectly binding CtIP. Future research into the relevance of the 
stabilisation of the BRCA1-C complex by the BARD1 BRCT domains is needed to 
elucidate if this stabilisation does indeed contribute to the ability of the cell to carry out 
efficient HR. Results that indicate that BARD1 BRCT domains stabilise the BRCA1-C 
complex were carried out in normal non-damaging conditions. It would be very 
interesting to study the effect of this finding in a damage context. Also it is not clear if 
BARD1 stabilises CtIP in the BRCA1-C complex by interacting directly with CtIP or 
through a scaffold protein which may bind both BARD1 and CtIP. Further work will be 
required to analyse this theory. Although results from this thesis suggest that the 
potential phospho-interacting ability of the BARD1 BRCT domains do not contribute to 
the HR function of the BARD1 BRCT domains, Birrane et al. suggested that the 
interaction of BARD1 BRCT with a phospho-protein may depend on the pH of the 
surrounding environment [311]. A potential phosphorylation dependent interaction 
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between the BARD1 BRCT domains and a repair protein may be important for HR 
under certain microenvironmental conditions, therefore I believe that future work should 
also concentrate on investigating the conditions of the microenvironment surrounding a 
DSB. A change in the pH at DSBs may uncover BARD1 BRCT interactors which 
remain hidden under normal conditions.    
  The BARD1 BRCT domains also appear to be important for the localisation of 
BARD1 to BRCA1 nuclear foci during S-phase however the  functional importance of 
these foci remains unclear. The BARD1 BRCT domains are responsible for the early 
recruitment of BRCA1 to DSB however the ultimate recruitment of BARD1 to sites of 
damage is not perturbed in the absence of the BRCT domains. Interestingly the HR 
defects seen in the absence of the BARD1 BRCT domains is functionally unrelated to 
the predicted phospho-peptide interaction sites of the BARD1 BRCT domains. In future 
work, I believe it is important to investigate the functional role of “BRCA1 nuclear foci” 
and if they contribute to the DDR. It would also be interesting to assess if the BARD1 
BRCT domains are needed to recruit BRCA1 to the S-phase foci. Although the BARD1 
BRCT domains have been shown to be important for the early recruitment of 
BRCA1/BARD1 to sites of damage, it remains unclear how this may contribute to HR. 
Further work is needed to fully investigate the functional outcome and requirements of 
this early recruitment of proteins to DSB.  
 Mass Spectrometry analysis of BARD1 interactors highlighted a variety of 
potential BARD1 interactors that play a role in the DDR. Interestingly the majority of 
these proteins are associated with the chromatin remodelling complex NuRD. Although 
none of these protein targets were verified, further research into the potential 
involvement of BARD1 with the NuRD complex may prove very interesting in relation to 
the repair of DNA especially as the role of chromatin remodelling proteins in DNA 
repair is a novel and exciting field of research at the moment. Although not much is 
known about the function of sumoylation in the DDR, results indicating that BARD1 
may interact with the SUMO E2 conjugating enzyme UBC9 in a BRCT dependent 
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manner may provide a greater insight into the importance of the BARD1 BRCT 
domains in HR uncovering a novel role for BARD1 and potentially BRCA1 in the repair 
of DNA. 
 
7.2 The role of ubiquitin ligases RNF8 and RNF168 in DSB repair 
DNA DSBs are considered to be one of the most dangerous types of lesions a cell can 
incur [446], which can arise during normal cellular process such as metabolism or 
replication or by exogenous agents such as IR or mutagenic chemicals [2]. DNA DSBs 
are repaired by either NHEJ or HR as discussed in the introduction and if they are not 
repaired properly it can lead a Spectrometry trum of mutations which can in turn lead to 
cancer [446]. The cellular response to DSBs is defined by the rapid accumulation of 
proteins involved in repair and also signalling factors at the site of damage [2, 165, 
423]. An efficient response to DNA damage involves a complex signalling cascade 
which avails of PTM such as phosphorylation, actylation and ubiquitylation which leads 
to the ultimate recruitment of DNA repair proteins. Over the past few years an 
expanding view of the importance of ubiquitin signalling as a means to modulate the 
timing and efficient repair of DSBs has emerged. 
 Studies carried out in knockout mice illustrate the importance of RNF8 and 
RNF168 ubiquitin ligases in the DNA damage induced ubiquitylation cascade and DSB 
repair [178, 179, 392]. Mutations in RNF168 are also associated with the human 
RIDDLE syndrome which is characterised by radiosensitivity and immunodeficiency 
among other clinical features [126]. K63, non-degrading, ubiquitin chains are essential 
for the recruitment of repair proteins BRCA1 and 53BP1 to DSBs [2, 181, 182], Both 
RNF8 and RNF168 are required for ubiquitylation at sites of damage and loss of either 
proteins severely impedes the recruitment of BRCA1 and 53BP1 to DSBs [122, 124, 
126, 177]. I have shown that both RNF8 and RNF168 are active ubiquitin ligases and 
ubiquitylate most free histones in vitro. In agreement with the importance of RNF8/168 
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in DNA damage repair, I have shown that loss of either RNF8 or RNF168 in DT40 cells 
sensitises them to DNA damaging agents. Oestergaard et al, showed a similar 
sensitivity of Rnf8 and Rnf168 DT40 cells to DNA damaging agents IR and CPP [177]. 
Although it is evident that ubiquitin ligases RNF8 and RNF168 are important for the 
repair of DSB the mechanism and exact functions of these proteins are only now 
beginning to emerge. 
 One of the earliest events in DSB repair is the recruitment of ATM which is 
responsible for the phosphorylation of H2AX [220]. γH2AX is a common marker 
associated with DNA damage. Recent evidence suggests that the ubiquitin ligase 
RNF2 and its interacting partner BMI1 are involved in the recruitment of ATM, initiating 
the signalling cascade at damage sites. RNF2/BMI1 catalyses the monubiquitination of 
H2AX at K119 and K120 in response to DNA damage and is required for the formation 
of γH2AX [447-450]. Based on the observation that loss of either RNF2 or BMI1 leads 
to sensitization of cells to IR and delays the DDR response, RNF2/BMI1 are predicted 
to play an important role in DNA repair. Although mono-ubiquitylation is an important 
step early in the DDR, it is the formation of K63 linked ubiquitin chains that are most 
persistent at sites of damage and are vital to the downstream recruitment of repair 
proteins BRCA1 and 53BP1 [2, 181, 182]. Interestingly, it has been shown that the 
concerted action of RNF8 and RNF168 are responsible for catalysing the conjugation 
of K63 linked ubiquitin chains on H2AX at position K13 and K15 [123, 451]. Intriguingly, 
K63 polyubiquitin chain formation crucial to the recruitment of repair proteins is found 
on the opposite side of histone H2A in respect to the monoubiquitination of H2AX by 
RNF2/BMI1.  
 There has been a lot of research dedicated to investigating whether RNF8 or 
RNF168 is responsible for the initial priming monoubiquitylation of histone H2AX and 
its subsequent polyubiquitylation. RNF8 is recruited to DSBs in a λH2AX and MDC1 
dependent manner by its FHA domain [119, 121], whereas RNF168 is recruited to 
damage by its UIMs dependent on RNF8 [124, 126]. Due to the recruitment order, it 
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was suggested that RNF8 was responsible for the monoubiquitylation of histones and 
RNF168 amplified the DNA damage signal by extending the ubiquitin chains. Despite 
the initial in vitro analysis that RNF8 can monoubiquitylate H2A and that both the 
catalytic activity of RNF8 as well as the UIMs of RNF168 are required for RNF168 
recruitment, recent observation indicate that H2A is a substrate for RNF168 and cannot 
be modified by RNF8 [123, 124, 126, 451]. This evidence suggests that RNF168 
monoubiquitylates H2AX at K13 and K15 and RNF8 extends K63 linked ubiquitin 
chains [123]. Mattiroli et al. propose a model whereby RNF8 ubiquitylates non-
nucleosomal proteins at DSBs which in turn recruits RNF168 and may explain the 
necessity of its ligase activity for the recruitment of RNF168. In concurrence with the 
proposed model, my results also indicate that RNF168 is responsible for the 
monoubiquitylation of H2A as only DT40 Rnf8 cells overexpressing full length RNF8 
showed an increase in monoubiquitylated H2A whereas a ubiquitin ligase dead mutant 
RNF8 and RNF168 did not. However re-expression of RNF168 in a RNF168 DT40 
knockout cell line did not indicate an increase in H2A mono-ubiquitylation. This may be 
due to the fact that endogenous levels of RNF8 in the cell may not be sufficient to see 
an overall increase in H2A mono-ubiquitylation explaining why an increase is only seen 
when RNF8 is overexpressed. 
 The non-proteolytic polyubiquitin chains catalyzed by RNF8 and RNF168 DSBs 
in response to damage serve as docking sites which ultimately recruit BRCA1 and 
53BP1 [120-122, 124]. The relative dynamics with which these two proteins localise to 
DNA damage is believed to be very important in regulating the choice of repair of DNA 
DSBs. The two main pathways used in mammalian cells to repair DNA DSBs are 
NHEJ, which is considered to be error prone, and HR, a faithful method of repair [25, 
446]. BRCA1 and 53BP1 have collective roles in DSB repair, BRCA1 is required for 
efficient repair by HR while 53BP1 promotes NHEJ [344, 452-454]. Although both 
RNF8 and RNF168 are required to recruit both BRCA1 and 53BP1, the overall function 
of the signalling pathway at DSBs is believed to repress HR preventing over resection 
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at sites of damage which may prove deleterious to the cell. Recruitment of 53BP1 
antagonises HR, however the recruitment of BRCA1 by RNF8 and RNF168 also 
appears to suppress HR as loss of Abraxas or RAP80, which tethers BRCA1 to the 
DSB, results in an increase in HR (unpublished results in the lab)[224, 232]. Loss of 
RNF168 has also been shown to affect NHEJ while RNF8 appears to be important for 
both HR and NHEJ [455, 456]. These findings support a model in which RNF8 and 
RNF168 are vital to the delicate choice between HR and NHEJ which may ultimately 
decide the outcome of the cell after damage. 
 The recruitment of BRCA1 to DSBs directly involves the ubiquitin ligase activity 
of RNF8 and RNF168, however the mechanism of 53BP1 recruitment requires more 
study. 53BP1 is recruited to dimethylated histone H4 on K20 at DSBs via its tudor 
domains [457, 458]. Although it does not contain any ubiquitin recognising domains, it 
is suggested that RNF8 and RNF168 ubiquitylation is required to remove factors that 
bind to H4K20me2 sites thus unmasking the binding sites for 53BP1 [455, 459]. 
However the exact mechanism responsible for the recruitment of 53BP1 by RNF8 and 
RNF168 is still not fully understood. Keeping in mind that the main function of RNF8 
and RNF168 is to closely regulate the amount of HR at DSBs, it was interesting to 
discover that DT40 Rnf8 cells were sensitive to PARP inhibitors suggesting a direct 
role in HR and according to my results this defect was not due to the ubiquitin ligase 
activity of RNF8 as a ubiquitin ligase dead mutant RNF8 was able to fully complement 
the initial sensitivity to PARP inhibitors. DT40 Rnf168 cells showed sensitivity to HU 
which could not be corrected by the re-expression of a ubiquitin ligase dead mutant.  
These results suggest that RNF8 and RNF168 are required for efficient repair of DNA 
damage however only RNF168 ubiquitin ligase activity appears to be necessary for 
repair. Interestingly, as suggested previously by Oestergaard et al. it seems that RNF8 
and RNF168 may not act in a strictly linear manner [177] as both proteins are sensitive 
to different types of damaging agents which result in different types of damage. It would 
be very interesting to study the contribution of both RNF8 and RNF168 to the repair of 
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different types of damage to gain a greater understanding of the role they play in the 
DDR. 
7.2.1 Conclusions and Future Work 
It is evident from the literature that both RNF8 and RNF168 are extremely important for 
the signalling response to DNA damage and the recruitment of repair proteins 53BP1 
and BRCA1 to sites of damage. In the absence of either of the proteins, cells become 
sensitive to a variety of DNA damaging agents suggesting that they are important for 
repair. Recent evidence has demonstrated that RNF168 is required for mono-
ubiquitylation of histone H2A whereas RNF8 is required to extend the ubiquitin chains 
after damage. My results indicate that although RNF8 and RNF168 are both important 
for DNA damage repair, the RNF8 ubiquitin ligase activity is not required for the repair 
of DSBs generated by PARP inhibitor.  Whereas Rnf168 cells are not sensitive to 
PARP inhibitors in the first place and instead show sensitivity to HU which is dependent 
of the ubiquitin ligase activity of RNF168. This leads to some very interesting questions 
which I believe should be addressed in the future. If RNF8 is important for the repair of 
DSB predicted to be generated by PARP inhibitors but does not require the ubiquitin 
ligase function of the protein, then how does RNF8 contribute to the repair? It would 
also be interesting to identify the suspected non-nucleosomal protein ubiquitylation 
targets of RNF8 which are predicted to be important for the recruitment of RNF168. By 
investigating the different repair pathways which require either RNF8 or RNF168, I 
believe we may gain a greater understanding of the individual contributions of these 
proteins in the DDR. 
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Appendix 
All appendix documents can be found on a disc at the end of the thesis. 
A complete list of the non-crosslinked Mass Spectrometry results can be found in PDFs 
in the appendix. 
A complete list of the results of the crosslinked Mass Spectrometry can be found in the 
disc appendix at the rear of the thesis. The document is in a Scaffold format and it is 
called "Mass spec BARD1". in order to view this, a free version of Scaffold 3 must first 
be downloaded. 
The appendix disc also contains supplementary microscopy images mentioned within 
the results chapters. 
